Transcranial magnetic stimulation (TMS) for schizophrenia by Dougall, Nadine et al.
Transcranial magnetic stimulation (TMS) for schizophrenia
(Review)
Dougall N, Maayan N, Soares-Weiser K, McDermott LM, McIntosh A
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2015, Issue 8
http://www.thecochranelibrary.com
Transcranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
25ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
33DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
122DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 1 Global state: 1. Clinical
improvement (CGI). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Analysis 1.2. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 2 Global state: 2. Average score for
clinical improvement (CGI, high = poor). . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 1.3. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: a.
Clinical improvement (PANSS > 30% reduction). . . . . . . . . . . . . . . . . . . . . . 129
Analysis 1.4. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: b.
Average total score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Analysis 1.5. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 5 Mental state: 1. General: c. Average
general psychopathology score (PANSS general, high = poor). . . . . . . . . . . . . . . . . . 131
Analysis 1.6. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: a. Average
depression score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
Analysis 1.7. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: b.i.
Hallucinations - clinical improvement (various scales). . . . . . . . . . . . . . . . . . . . . 133
Analysis 1.8. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: b.ii.
Average hallucinations score (various scales). . . . . . . . . . . . . . . . . . . . . . . . 134
Analysis 1.9. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: c. Average
negative symptom score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . 136
Analysis 1.10. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: d.i.
Positive symptoms - clinical improvement (PANSS > 30% reduction). . . . . . . . . . . . . . . 137
Analysis 1.11. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 11 Mental state: 2. Specific: d.ii.
Average positive symptom score (various scales). . . . . . . . . . . . . . . . . . . . . . . 138
Analysis 1.12. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General: a.
Serious. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Analysis 1.13. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 1. General: b.
Leaving the study early. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Analysis 1.14. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific. 141
Analysis 1.15. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 15 Quality of life: Average score
(Q-LES-Q, low = poor). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
Analysis 2.1. Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 1 Global state:
Clinical improvement (CGI ≤ 2). . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
Analysis 2.2. Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 2 Adverse effects:
Leaving the study early. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
iTranscranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 1 Global state: Average score (various
scales). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Analysis 3.2. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 2 Mental state: 1. General: a. Clinical
improvement (> 20% decrease in total PANSS score). . . . . . . . . . . . . . . . . . . . . 147
Analysis 3.3. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: b. Average total
score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Analysis 3.4. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: c. Average general
psychopathology score (PANSS, high = poor). . . . . . . . . . . . . . . . . . . . . . . . 149
Analysis 3.5. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 5 Mental state: 2. Specific: a. Average
depression score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Analysis 3.6. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: b. Average
hallucinations score (PANSS, high = poor). . . . . . . . . . . . . . . . . . . . . . . . . 151
Analysis 3.7. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: c. i. Negative
symptoms - clinical improvement (> 20% decrease in PANSS negative). . . . . . . . . . . . . . . 151
Analysis 3.8. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: c. ii. Average
negative symptom score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . 152
Analysis 3.9. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: d. Average
positive symptom score (various scales). . . . . . . . . . . . . . . . . . . . . . . . . . 153
Analysis 3.10. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: e. Average
psychotism score (SCL-90 PSY, high = poor). . . . . . . . . . . . . . . . . . . . . . . . 154
Analysis 3.11. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 11 Adverse effects: 1. General: a. Adverse
events (UKU). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Analysis 3.12. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General: b. Leaving
the study early. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Analysis 3.13. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 2. Specific: a.
Various. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Analysis 3.14. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific: b. Average
score (CSSES, high = poor). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
Analysis 4.1. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 1 Global
state: Clinical improvement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Analysis 4.2. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 2
Mental state: 1. General: a. Average overall mental state score (PANSS total, high = poor). . . . . . . . 159
Analysis 4.3. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 3
Mental state: 1. General: b. Average general psychopathology score (PANSS, high = poor). . . . . . . . 160
Analysis 4.4. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 4
Mental state: 2. Specific: a. Average negative symptom score (various scales). . . . . . . . . . . . . 161
Analysis 4.5. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 5
Mental state: 2. Specific: b. Average positive symptom score (PANSS, high = poor). . . . . . . . . . . 162
Analysis 4.6. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 6
Cognitive state: Average score (various measures). . . . . . . . . . . . . . . . . . . . . . 163
Analysis 4.7. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 7
Adverse effects: 1. Leaving the study early. . . . . . . . . . . . . . . . . . . . . . . . . 164
Analysis 4.8. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 8
Adverse effects: 2. Specific. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
Analysis 5.1. Comparison 5 SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs
SHAM TMS, Outcome 1 Global state: Clinical improvement. . . . . . . . . . . . . . . . . . 166
166ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
174APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
176CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
176DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
176SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
176DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiTranscranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Transcranial magnetic stimulation (TMS) for schizophrenia
Nadine Dougall1 , Nicola Maayan2 , Karla Soares-Weiser2, Lisa M McDermott3, Andrew McIntosh4
1NMAHP Research Unit, University of Stirling, Stirling, UK. 2Enhance Reviews Ltd, Wantage, UK. 3Primary Care and Public Health
Sciences, King’s College London, London, UK. 4University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
Contact address: Nadine Dougall, NMAHP Research Unit, University of Stirling, Unit 13 Scion House, Stirling University Innovation
Park, Stirling, FK9 4NF, UK. Nadine.dougall@stir.ac.uk.
Editorial group: Cochrane Schizophrenia Group.
Publication status and date: New, published in Issue 8, 2015.
Review content assessed as up-to-date: 15 April 2013.
Citation: Dougall N, Maayan N, Soares-Weiser K, McDermott LM, McIntosh A. Transcranial magnetic stimula-
tion (TMS) for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No.: CD006081. DOI:
10.1002/14651858.CD006081.pub2.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
People with schizophrenia often experience symptoms which fail to fully respond to antipsychotic medication. Transcranial magnetic
stimulation (TMS) has been proposed as a new treatment for people with schizophrenia, especially those who experience persistent
auditory hallucinations.
Objectives
To estimate the effects of TMS alone, comparedwith shamTMSorwith ’standardmanagement’ and any other comparison interventions
in reducing psychotic symptoms associated with schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (June 2006, June 2008, April 2013). This register is compiled by me-
thodical searches of MEDLINE, EMBASE, BIOSIS, CINAHL, Dissertation abstracts, LILACS, PSYNDEX, PsycINFO, RUSSMED,
and Sociofile, and is supplemented with handsearching of relevant journals and numerous conference proceedings.
Selection criteria
We included all randomised controlled trials recruiting at least five participants and comparing TMS with sham TMS or any other
treatment for people with schizophrenia.
Data collection and analysis
We extracted data independently. For dichotomous data we calculated relative risks (RRs) and their 95% confidence intervals (CIs).
For continuous data, we calculated mean differences (MD) and 95% CI. We used a fixed-effect model. We assessed overall quality of
the evidence using the GRADE approach.
Main results
We included 41 studies with 1473 participants in the review. We found significant differences in favour of temporoparietal TMS
compared to sham TMS for global state measured on the CGI scale (7 RCTs, n = 224, MD -0.5, 95% CI -0.76 to -0.23, very low-
quality evidence) and positive symptoms measured on the PANSS scale (5 RCTs, n = 127, MD -6.09, 95% CI -10.95 to -1.22, very
low-quality evidence). Participants experienced significantly more headaches in the temporoparietal TMS group (10 RCTs, n = 392, RR
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2.65, 95% CI 1.56 to 4.50, very low-quality evidence). However, no more participants left the study early from the TMS group than
from the sham group (very low-quality evidence). Cognitive state was assessed using 39 different measures, and all were equivocal (very
low-quality evidence).
We included only two trials which compared temporoparietal TMS with standard treatment. In both trials the participants received
first- and second-generation antipsychotic medication in both treatment groups, therefore TMS was used an adjunctive therapy to
medication. We found no significant differences in the number of participants that showed clinical improvement in global state (1
RCT, n = 100, RR 1.19, 95% CI 0.91 to 1.57) or left the study early (2 RCTs, n = 140, RR 0.33, 95% CI 0.08 to 1.46) (both very
low-quality evidence). No studies reported on global state score, mental state, cognitive state and adverse effects.
For prefrontal TMS compared to sham TMS, global state was measured on three different scales, all of which presented equivocal
results (very low quality evidence). We could not pool data for mental state on the PANSS scale due to high heterogeneity. Cognitive
state was assessed using 19 different measures, with 15/19 being equivocal (very low-quality evidence). Prefrontal TMS caused more
headaches (6 RCTs, n = 164, RR 2.77, 95% CI 1.22 to 6.26, very low-quality evidence) but there was no difference in the number of
participants leaving the study early (very low-quality evidence). No studies reported data for clinical improvement.
We found a significant difference in favour of prefrontal theta burst stimulation TMS compared to sham TMS for mental state on the
PANNS scale (3 RCTs, n = 108, MD -5.71, 95%CI -9.32 to -2.10, very low evidence).We found no difference for clinical improvement,
cognitive state, number of headaches, and leaving the study early (very low-quality evidence).
None of the included studies reported satisfaction with care.
Authors’ conclusions
Based on this review, there is insufficient evidence to support or refute the use of TMS to treat symptoms of schizophrenia. Although some
evidence suggests that TMS, and in particular temporoparietal TMS, may improve certain symptoms (such as auditory hallucinations
and positive symptoms of schizophrenia) compared to sham TMS, the results were not robust enough to be unequivocal across the
assessment measures used. There was insufficient evidence to suggest any added benefit with TMS used as an adjunctive therapy to
antipsychotic medication.
The overall quality of evidence was graded as very low due to risk of bias, and this was accompanied by an imprecision in estimates due
to the relatively small number of participants in the studies. Thus, consideration is required in improving the quality of trial processes,
as well as the quality of reporting of ongoing and future TMS trials, so as to facilitate accurate future judgements in assessing risk of
bias. Differences in TMS techniques in relation to stimulation intensity, stimulation length, brain areas stimulated and variations in the
design of sham TMS all contributed to the heterogeneity of study findings and limited the interpretation and applicability of the results.
In addition, the trials assessed their outcomes with a variety of scales, and usable data were limited. Therefore, to better evaluate the
treatment effects of TMS in people with schizophrenia, we favour the use of standardised treatment protocols and outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Transcranial magnetic stimulation (TMS) for the treatment of schizophrenia
Review Question
Is transcranial magnetic stimulation (TMS) useful in treating people with schizophrenia?
Background
Transcranial magnetic stimulation is a relatively new and sophisticated device-based therapy. TMS involves the skilful application of a
strong magnetic field close to the surface of the scalp. The TMS device delivers strong and very brief magnetic pulses that stimulate
the brain and its network of neurons. TMS is a relatively painless and non-invasive technique that stimulates parts of the brain (the
cerebral cortex). Brain activity has been shown to differ in people with schizophrenia compared to other people.
People with schizophrenia often experience symptoms, such as hearing voices or seeing things (hallucinations), which fail to fully
respond to medication. TMS has been proposed as a new treatment for people with schizophrenia, especially those who experience
persistent auditory hallucinations. Antipsychotic medication also often has debilitating side effects, such as weight gain, apathy or lack
or drive, and shaking. TMS could be an alternative treatment for people who do not cope well with standard medication.
Description of Studies
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A search for trials was run in 2013 and 41 randomised controlled studies are now included in this review. The studies included people
diagnosed with schizophrenia and randomised participants to receive either temporoparietal TMS, prefrontal TMS, sham TMS or
standard care.
Results
At this time, there is not strong evidence to support the use of TMS to treat schizophrenia. Some very low-quality evidence appears
to tentatively indicate that TMS may improve global state and certain symptoms such as hearing voices, compared to sham TMS.
However, the research at present is not robust, consistent and standardised enough to support any firm conclusions about using TMS
for schizophrenia.
There was no evidence to indicate TMS may improve symptoms of schizophrenia when used alongside the standard treatment of
antipsychotic medication. There were also limitations related to differing TMS techniques. It was difficult to compare the results of
studies in this review, as there were various different TMS procedures used, different symptom measures of schizophrenia, and data
were limited. More robust and consistent research is therefore required. The authors of the review suggest that in the future, with more
research, there is the possibility that TMS may be useful for treating some of the symptoms of schizophrenia.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia
Patient or population: people with schizophrenia
Settings: inpatients and outpatients
Intervention: TEMPOROPARIETAL TMS
Comparison: SHAM TMS
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
SHAM TMS TEMPOROPARIETAL
TMS
Clinical improvement in
global state
CGI
Follow-up: after treatment
0 per 1000 0 per 1000
(0 to 0)
RR 7
(0.38 to 128.33)
46
(1 study)
⊕©©©
very low1,2
Global state score
CGI
Follow-up: after treatment
to 30 days
The mean scores for the
sham TMS group ranged
from 2.4 to 5.1
The mean global state
score in the intervention
groups was
0.5 lower
(0.76 to 0.23 lower)
224
(7 studies)
⊕⊕©©
low3
Mental state
PANSS
Follow-up: after treatment
to 30 days
The mean mental state
scores in the sham TMS
group ranged from 63.92
to 85.8
The mean mental state
in the intervention groups
was
6.09 lower
(10.95 to 1.22 lower)
127
(5 studies)
⊕⊕©©
low4,5
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Cognitive state
Various measures
Follow-up: after treatment
See comment See comment Not estimable 82
(3 studies)
⊕⊕©©
low6
Cognitive state was re-
ported in 3 studies using
39 different measures.
Results were equivocal
for all measures
Adverse effects: general
or specific
Follow-up: after treatment
to 30 days
See comment See comment Not estimable 442
(11 studies)
⊕⊕©©
low5,7
There
were more headaches
and jaw and facial con-
traction in the TMS group.
Results for other adverse
events - concentration
problems, earache, light-
headedness, mild amne-
sia, restless legs, somatic
discomfort, tingling sen-
sation in the arm, worsen-
ing hallucinations - were
equivocal
Adverse effects: Leaving
the study early
152 per 1000 118 per 1000
(70 to 200)
RR 0.78
(0.46 to 1.32)
320
(8 studies)
⊕©©©
low5,8
Satisfaction with care -
not reported
See comment See comment Not estimable - See comment No studies reported on
this outcome
*The basis for the assumed risk is the median control group risk across studies for pooled data and the control group risk for single studies. The corresponding risk (and its 95% confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1Risk of bias: serious - this study had an unclear risk of bias for randomisation, allocation concealment, blinding and incomplete outcome
data. Downgraded one level.
2Imprecision: very serious - there were very few participants and very few events; there are wide confidence intervals that include both
appreciable benefit and appreciable harm. Downgraded two levels
3Risk of bias: very serious - five studies had an unclear risk of bias for randomisation, six for allocation concealment, four studies
for blinding of participants and four blinding of outcome assessors. One study had a high risk of bias for incomplete outcome data.
Downgraded two levels.
4Risk of bias: serious - four studies had an unclear risk of bias for randomisation, five for allocation concealment, four for blinding of
participants and two for blinding of outcome assessors. Three studies also had an unclear risk for incomplete outcome data. Downgraded
one level.
5Imprecision: serious - there are wide confidence intervals for this outcome that include appreciable and non-appreciable benefit.
Downgraded one level.
6Imprecision: very serious - different scales were used to measure this outcome, all had wide confidence intervals. Downgraded two
levels.
7Risk of bias: serious - six studies had an unclear risk of bias for randomisation and nine for allocation concealment. All studies had
an unclear risk of bias for blinding of participants and three for blinding of outcome assessors. Six studies also had an unclear risk for
incomplete outcome data. Downgraded one level.
8Risk of bias: serious - six studies had an unclear risk of bias for randomisation, five for allocation concealment, five studies for blinding
of participants and four for blinding of outcome assessment. One study had a high risk of bias for incomplete outcome data. Downgraded
one level.
9Imprecision: very serious - there are wide confidence intervals for this outcome that include appreciable benefit and appreciable harm.
Downgraded two levels.
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B A C K G R O U N D
Description of the condition
People with schizophrenia typically experience auditory halluci-
nations (hearing voices) or delusions (false beliefs) during acute
episodes. Although several effective treatments are available, many
patients have intractable symptoms that do not recover between
acute episodes. In addition, motivation and social behaviour may
also be adversely affected (negative symptoms). Relatively high
numbers of people with schizophrenia have persistent symptoms
in spite of apparently adequate drug treatment. In some cases
treatment failure is associated with non-adherence, although it is
understood that many people have enduring symptoms in spite
of adequate treatment. Transcranial magnetic stimulation (TMS)
could prove an alternative treatment for patients who do not cope
well with standard medication.
Description of the intervention
Transcranial magnetic stimulation is a relatively new sophisti-
cated device-based therapy which involves the skilful application
of a strong magnetic field close to the surface of the scalp. The
procedure is a non-invasive and relatively painless technique for
stimulating the cerebral cortex and altering neuronal function
(Chouinard 2003). The device uses specifically-designed insulated
wire coils which deliver strong and very briefmagnetic pulses, pass-
ing from carefully chosen surface landmarks without hindrance
into underlying brain regions. The magnetic field then induces
small transient electrical currents in the neural circuitry of treated
individuals. By varying the intensity, duration and frequency of
the magnetic field, the neuronal systems may be excited or inhib-
ited for as long as the current pulses in the coil (Barker 2002).
How the intervention might work
Brain activity has been shown to differ in people with schizophre-
nia compared to the brain activity of people who do not have this
condition. Whereas activity in the temporoparietal cortex (TPC)
appears to increase in people with schizophrenia experiencing au-
ditory hallucinations (Shergill 2000), activity in the dorsolateral
prefrontal cortex (DLPFC) appears to be reduced in people with
schizophrenia (Weinberger 1996). Reduced activity also appears
to be correlated with negative symptoms (e.g. decreased motiva-
tion and social function) experienced by the patient. It is possible
that by normalising activity in these brain regions, auditory hal-
lucinations and negative symptoms would also improve.
Transcranial magnetic stimulation has been applied in several trials
in two main paradigms: high-frequency TMS and low-frequency
TMS. Low-frequency TMS (1 Hz) is typically applied to the left
TPC of patients, aiming to decrease brain activity and reduce
auditory hallucinations. High-frequency TMS is applied to left
DLPFC in an attempt to increase activity and reduce negative
symptoms. Low-frequency TMS is considered to inhibit cortical
activity (Chen 1997) and high-frequency TMS generally increases
cortical activity in stimulated areas (Pascual-Leone 1998). Positive
(Hoffman 2005) and negative (McIntosh 2004) controlled studies
have been published using both treatment approaches, and it is
unclear whether TMS represents a significant treatment advance.
In schizophrenia, there is evidence of both decreased and increased
cortical activity compared to unaffected controls, and in some
cases the altered activity correlates with the presence of a known
symptom of cognitive deficit. Studies have demonstrated an asso-
ciation between temporal lobe activity and auditory hallucinations
in people with schizophrenia (D’Alfonso 2002; Hoffman 2000;
Lee 2005; Poulet 2005). Active stimulation has been found to
significantly reduce hallucinations in comparison to sham stimu-
lation (Hoffman 2000). Not all attempts at replication have un-
equivocally supported Hoffman’s findings (McIntosh 2004; Saba
2006b).
Why it is important to do this review
Placebo arms of TMS trials often use sham treatments. There are
limitations to this approach; no satisfactory placebo condition has
been established and individuals may not have identical expecta-
tions of real or sham TMS. Placebo or sham TMS should result
in scalp and noise sensation identical to active TMS, without the
cortical stimulation. Although noise sensation can be mimicked,
generating the scalp sensation may also produce a therapeutic cor-
tical stimulation. Avoiding the confounding of cortical stimula-
tion with sham TMS yields a control arm of the trial which typ-
ically controls for noise sensation but not for scalp sensation. In
trials which implement sham TMS, double-blinding of observer
and participant is not guaranteed and estimated efficacy rates of
TMS will possibly be confounded if participants are aware which
treatment arm they are in.
Bearing in mind the limitations of the trial methodology and in
the absence of an entirely inactive sham condition thatmimics real
TMS, this systematic review aims to evaluate the current evidence
base of TMS in the treatment for schizophrenia. We wish to ascer-
tain the efficacy and safety of TMS, explore sources of heterogene-
ity that might explain contradictory positive and negative effects,
investigate whether pooled effect sizes can be derived and whether
they are statistically robust, and lastly, provide recommendations
where possible for future research.
O B J E C T I V E S
To estimate the effects of TMS alone comparedwith shamTMS or
with ’standard management’ and any other comparison interven-
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tions in reducing psychotic symptoms associated with schizophre-
nia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials with group sizes of at least
five. Where a trial was described as ’double-blind’ but it implied
that the study is randomised and the demographic details of each
group are similar, we included it. We excluded quasi-randomised
studies, such as those allocated by using alternate days of the week.
Types of participants
People with schizophrenia and related affective psychoses, diag-
nosed according to standardised operational criteria, irrespective
of age and sex.
Types of interventions
1. Transcranial magnetic stimulation: at any stimulus voltage,
frequency or charge, administered to the head at any location
2. Sham TMS: TMS administered using fake instruments or
with the coil applied at an oblique angle, greater than or
equal to 45 degrees, to the skull
3. Standard treatment: any treatment (including
antipsychotic medication) provided as part of routine care,
however defined
4. Any other pharmacological or non-pharmacological
treatments given as part of an experimental intervention.
Examples might include electroconvulsive therapy (ECT)
and cognitive behaviour therapy (CBT).
Types of outcome measures
We classified outcomes in the eight categories detailed below:
Primary outcomes
1. Global state
1.1 Clinical improvement in global state (as defined by individual
studies)
1.2 Mean endpoint global state score
1.3 Mean change in global state scores
Secondary outcomes
2. Mental state
2.1 Clinical improvement in general mental state (as defined by
individual studies)
2.2 Mean endpoint general mental state score
2.3 Mean change in general mental state scores
2.4 No clinically important change in specific symptoms
2.5 Mean endpoint-specific symptom score
2.6 Mean change in specific symptom scores
3. Cognitive state
3.1 Clinical improvement in cognitive state (as defined by indi-
vidual studies)
3.2 Mean endpoint cognitive state score
3.3 Mean change in cognitive state scores
3.4 Mean endpoint-specific cognitive state score
3.5 Mean change in specific cognitive state scores
4. Adverse effects
4.1 Incidence of adverse effects, general or specific
4.2 Leaving the study early
4.3 Measured acceptance of treatment
4.4 Use of antiparkinsonian treatment
4.5 Sudden and unexpected death
5. Hospital and service outcomes
5.1 Hospitalisation of people in the community
5.2 Duration of hospital stay
5.3 Severity of symptoms when discharged from hospital
5.4Changes in hospital status (for example, changes from informal
care to formal detention in care, changes of level of observation
by ward staff and use of secluded nursing environment)
5.5 Changes in services provided by community teams
6. Satisfaction with care
6.1 Recipient of care
6.2 Informal care givers
6.3 Professional carers
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7. Economic outcomes
8. Quality of Life
8.1 Clinical improvement in quality of life (as defined by individ-
ual studies)
8.2 Mean endpoint quality of life score
8.3 Mean change in quality of life scores
’Summary of findings’ table
Weused theGRADEapproach to interpret findings (Schünemann
2008) and used GRADE profiler to import data from Review
Manager 5 (RevMan) to create ’Summary of findings’ tables.
These tables provide outcome-specific information concerning the
overall quality of evidence from each included study in the com-
parison, the magnitude of effect of the interventions examined,
and the sum of available data on all outcomes we rated as im-
portant to participant care and decision making. We included the
following short- or medium-term outcomes in ’Summary of find-
ings’ tables:
1. Global state
1.1 Clinical improvement in global state
1.2 Mean endpoint score
2. Mental state
2.1 Mean endpoint score
3. Cognitive state
3.1 Mean change score
4. Adverse effects
4.1 Incidence of adverse effects, general or specific
4.2 Leaving the study early
5. Satisfaction with care
5.1 Recipient of care
Search methods for identification of studies
Electronic searches
1. The Cochrane Schizophrenia Group’s Trials Register
We searched this in June 2006, June 2008 and April 2013 using
the phrase:
[((*TMS* OR *transcranial* OR *trans-cranial* OR *magnetic *)
in REFERENCE) and (magn* in STUDY)]
This register is compiled by systematic searches ofmajor databases,
handsearches and conference proceedings (see Group Module).
We applied no language restriction for the searching.
2. Requests for additional data
We contactedMagstim Company Ltd., the company whomarkets
TMS machines in the UK, for published and unpublished data
on the treatment (Table 1).
Searching other resources
1. Reference lists
We retrospectively searched reference lists of included and ex-
cluded studies for additional relevant studies, and contacted au-
thors of relevant studies to enquire about other sources of relevant
information. We prospectively searched for studies which cited
included relevant studies up to April 2013
Data collection and analysis
Selection of studies
Two review authors (ND, AM for the 2006 and 2008 searches,
and two members of the Enhance Reviews team (NM and KSW)
for the 2013 update search) independently inspected all abstracts
of studies identified as above and identified potentially relevant
reports. Where disagreement occurred we resolved it by discus-
sion, or where there was still doubt, we acquired the full article
for further inspection. Jun Xia screened Chinese language studies.
We acquired the full articles of relevant reports for reassessment
and carefully inspected them for a final decision on inclusion (see
Criteria for considering studies for this review). The review au-
thors were not blinded to the names of the authors, institutions
or journal of publication. Where difficulties or disputes arose, we
added these studies to those awaiting assessment and contacted
the authors of the papers for clarification.
Data extraction and management
1. Data extraction
Review authors ND and AM extracted data independently from
included studies resulting from the 2006 and 2008 searches, and
two members of the Enhance Reviews team (NM and KSW) ex-
tracted data independently for the included studies from the 2013
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search. Again, we discussed any disagreement, documented deci-
sions and, if necessary, contacted authors of studies for clarifica-
tion. JX extracted data for all Chinese studies. We extracted data
presented only in graphs and figures whenever possible, but only
included them if two review authors independently had the same
result. Where possible, we extracted data relevant to each compo-
nent centre of multicentre studies separately.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if: a) the
psychometric properties of the measuring instrument have been
described in a peer-reviewed journal (Marshall 2000); and b) the
measuring instrument is not written or modified by one of the
trialists for that particular trial. Ideally the measuring instrument
should either be a self report or completed by an independent rater
or relative (not the therapist).
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint) which can be difficult in un-
stable and difficult-to-measure conditions such as schizophrenia.
We decided to primarily use endpoint data and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we used weighted mean differences
rather than standardised mean differences throughout (Higgins
2011b, chapter 9.4.5.2). All data in the analyses are endpoint data
unless specifically noted as change data in the footnote of the anal-
ysis.
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards to
all data before inclusion: a) standard deviations (SDs) and means
were reported in the paper or obtainable from the authors; b) when
a scale starts from the finite number zero, the standard deviation,
when multiplied by two, was less than the mean (as otherwise
the mean is unlikely to be an appropriate measure of the centre
of the distribution, (Altman 1996); c) if a scale started from a
positive value (such as the positive and negative syndrome scale
(PANSS) which can have values from 30 to 210) we modified the
calculation described above to take the scale starting point into
account. In these cases skew is present if 2SD > (S - S min), where
S is the mean score and S min is the minimum score. Endpoint
scores on scales often have a finite start and endpoint and these
rules can be applied. When continuous data were presented on a
scale that includes a possibility of negative values (such as change
data), it is difficult to tell whether data were skewed or not. We
entered skewed data from studies of fewer than 200 participants
in additional tables rather than into an analysis. Skewed data pose
less of a problem when looking at means if the sample size is large,
and we entered them into syntheses.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we tried to convert outcome measures to dichoto-
mous data. This could be done by identifying cut-off points on
rating scales and dividing participants accordingly into ’clinically
improved’ or ’not clinically improved’. We generally assumed that
if there had been a 50% reduction in a scale-derived score such as
the Brief Psychiatric Rating Scale (BPRS,Overall 1962) or the Pos-
itive and Negative Syndrome Scale (PANSS, Kay 1986), we could
consider this as a clinically significant response (Leucht 2005a;
Leucht 2005b). Data based on these thresholds were not available,
so we used the primary cut-off presented by the original authors.
2.7 Direction of graphs
We extracted and entered data into RevMan in such a way that
the area to the left of the line of no effect indicated a ’favourable’
outcome for TMS. For some outcomes this was not possible, and
we reported datawhere the left of the line indicates anunfavourable
outcome. We have noted this in the relevant graphs.
Assessment of risk of bias in included studies
ND and AM independently allocated trials from the 2006 and
2008 searches to Categories A or B in the review. When upgraded
criteria for risk of bias became available, LMcD correspondingly
upgraded the trial quality assessments using criteria described in
the Cochrane Handbook (Higgins 2011b). Two members of the
Enhance Reviews team assessed the risk of bias of studies included
from the 2013 search, also using the upgraded criteria. This set of
criteria is based on evidence of associations between overestimate
of effect and high risk of bias of the article, such as sequence gen-
eration, allocation concealment, blinding, incomplete outcome
data and selective reporting.When the raters disagreed, theymade
the final rating by consensus, with the involvement of another
member of the review team. When there were inadequate details
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of randomisation and other characteristics of trials, we contacted
authors of the studies in order to obtain further information. We
reported non-concurrence in quality assessment, but if disputes
arose as to the appropriate category to which a trial should be al-
located, we resolved the matter by discussion. We noted the level
of risk of bias in both the text of the review and in the ’Summary
of findings’ tables.
Measures of treatment effect
1. Binary data
For binary outcomeswe calculated a standard estimationof the risk
ratio (RR) and its 95% confidence interval (CI). It has been shown
that the RR is more intuitive (Boissel 1999) than the odds ratios
and that odds ratios tend to be interpreted as RRs by clinicians
(Deeks 2000).
2. Continuous data
For continuous outcomes we estimated the mean difference (MD)
between groups with 95% CIs.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data pose problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
None of the included studies was cluster-randomised. Measures to
deal with cluster RCTs that we would have employed, and that we
shall use for updates of this review for such designs, are described
in the section Differences between protocol and review.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It
occurs if an effect (e.g. physiological or pharmacological) of the
treatment in the first phase is carried over to the second phase.
As a consequence, on entry to the second phase the participants
can differ systematically from their initial state, despite a wash-out
phase. For the same reason cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). As both
effects are very likely in schizophrenia, we only used data from the
first phase of cross-over studies.
3. Studies with multiple treatment groups
When a study involved more than two treatment arms, if relevant,
we presented the additional treatment arms in comparisons. If
data were binary these were simply added and combined within
the two-by-two table. If data were continuous, we combined data
using theRevMan calculator.Where the additional treatment arms
were not relevant, we did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
To some degree, loss of follow-up data must lose credibility (Xia
2009). We choose that, for any particular outcome, if more than
50% of data were unaccounted for, we did not reproduce these
data or use them within analyses. If more than 50% of those in
one arm of a study were lost, but the total loss was less than 50%,
we would have flagged such data with an asterisk (*) to indicate
that such a result may well be prone to bias.
2. Binary
All analyses have been conducted per number analysed in the
studies. For the primary outcome ’clinical improvement in global
state’, if there was attrition, we compared in sensitivity analyses
the results per number analysed with results of all the participants
randomised (an intention-to-treat analysis). For the intention-to-
treat analysis, we assumed that those leaving the study early all
have the same rates of negative outcome as those who completed
the trial.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0
and 50% and completer-only data were reported, we have repro-
duced these.
3.2 Standard deviations
We first tried to obtain themissing values from the authors. When
these were not available, we did not add the data to the analysis.
Measures to deal with missing SDs that we shall use for updates
of this review are described in the section Differences between
protocol and review.
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3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results (Leucht 2007). Therefore, where LOCFdata had been used
in the trial, if less than 50% of the data had been assumed, we
reproduced these data and indicated that they are the product of
LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
all studies for clearly outlying situations or people which we had
not predicted would arise. When such situations or participant
groups arose, we discussed them fully.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arose,
we discussed them fully.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I² statistic
We investigated heterogeneity between studies by considering the
I² method alongside the Chi² P value. The I² provides an estimate
of the percentage of inconsistency thought to be due to chance
(Higgins 2003). The importance of the observed value of I² de-
pends on: a) magnitude and direction of effects, and b) strength
of evidence for heterogeneity (e.g. P value from Chi² test, or a
confidence interval for I²). An I² estimate greater than or equal
to 50% accompanied by a statistically significant Chi² statistic,
we interpreted as possibly evidence of substantial levels of hetero-
geneity (Section 9.5.2 - Deeks 2011). When we found substantial
levels of heterogeneity in the primary outcome measure, we cau-
tiously explored reasons for heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 8 of the Cochrane Handbook
(Higgins 2011a). We are aware that funnel plots may be useful in
investigating reporting biases, but are of limited power to detect
small-study effects. We did not use funnel plots for any outcomes
as there were 10 or fewer studies, or where all studies were of
similar sizes; in the case of the adverse effect headache, we did
not produce a funnel plot, as this outcome was not systematically
reported by all studies. Had we used funnel plots, we would have
sought statistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference use
of fixed-effect or random-effects models. The fixed-effect model
assumes each trial makes an estimate of a common effect size of
the same population. The random-effects method incorporates an
assumption that the different studies are estimating different, yet
related, intervention effects. The random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model. It puts added weight onto small studies,
which are often the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
For this reason we favoured using fixed-effect models, employing
random-effects only when investigating heterogeneity.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analysis
We planned no subgroup analyses for this review. We knew the
literature would yield sparse amounts of data and that any sub-
group analysis would most likely be inadequately powered for us
to draw any conclusions.
2. Investigation of heterogeneity
If inconsistency was high, we reported it. First we investigated
whether data had been entered correctly. Second, where data were
correct, we visually inspected the graph, and successively removed
outlying studies, to see if heterogeneity remained. For this review,
we decided that should this occur with data contributing to the
summary findingnomore than around10%of the total weighting,
we would present the data. If not, we did not pool data, but
discussed the issues. We know of no supporting research for this
10% cut-off but are investigating the use of prediction intervals
as an alternative to this unsatisfactory state. When unanticipated
clinical or methodological heterogeneity was obvious, we simply
stated hypotheses regarding these for future reviews or versions of
this review. We did not undertake analyses relating to these.
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Sensitivity analysis
1. Implication of randomisation
We planned to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. All studies were
reported as randomised, so we did not undertake any sensitivity
analysis related to implication of randomisation.
2. High attrition rates
We planned a sensitivity analysis to test how prone results were to
change when we compared ’completer’ data only to the imputed
data, using the above assumption. If there had been a substantial
difference, we would have reported results and discussed them
but continued to employ our assumption. However, we did not
make any assumptions about lost binary data and undertook no
sensitivity analysis.
R E S U L T S
Description of studies
For a full description of studies please see: Characteristics of
included studies and Characteristics of excluded studies.
Results of the search
The search strategy identified 99 reports that were potentially rel-
evant. Agreement about which reports may have been randomised
was 100%. In total, we included 41 studies in the review and in
the analysis (see Figure 1). One study (Jin 2012) met the inclu-
sion criteria but did not report data in a usable way, and is in the
excluded studies table.
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Figure 1. Study flow diagram.
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Included studies
1. Length of studies
The duration of trials ranged from four days (McIntosh 2004) to
10 weeks (Wing 2012); 26 trials were short (from five days to two
weeks), 12 were medium length (three to six weeks) and four trials
were long (eight weeks or longer).
2. Design
All but two included studies presented a parallel longitudinal de-
sign and two studies had a cross-over design (McIntosh 2004;
Poulet 2005).
3. Participants
Most studies included participants with schizophrenia or schizoaf-
fective disorder according to the DSM-IV. Of those that did not
use DSM-IV, seven studies diagnosed schizophrenia according to
theCCMD-3 (Gao 2009a; Gao 2009b; Gao 2010;Hao 2008; Liu
2008; Xu 2011; Zheng 2012). Rosenberg 2012 diagnosed accord-
ing to DSM-IV-TR. Bagati 2009, Guse 2013, and Prikryl 2007
used ICD-10, and De Jesus 2011 OPCRIT 4.0.
In total, 1473 participants are included in the review, and the
number of people included in individual studies ranged from 10
(Poulet 2005) to 100 (Liu 2011).
4. Settings
Eleven studies included inpatients (Chen 2011; Cordes 2010; Gao
2009a; Hao 2008;Holi 2004; Klein 1999; Liu 2008; Poulet 2005;
Prikryl 2007; Saba 2006a; Zheng 2012), five studies included out-
patients (Fitzgerald 2005; Fitzgerald 2008;Mogg 2005; Schneider
2008; Wing 2012) and five studies included both inpatients and
outpatients (Bagati 2009; Guse 2013; Novak 2006; Rosenberg
2012; Vercammen 2009a). In 22 studies the setting was either
unclear or not reported.
Fourteen studies were carried out in China (Chen 2011; Gao
2009a; Gao 2009b; Gao 2009c; Gao 2010; Hao 2008; Liu 2008;
Liu 2011; Ren 2010; Ren 2011; Xu 2011; Yu 2010; Zhang 2010;
Zheng 2012), 13 in Europe, including three in the Czech Re-
public (Klirova 2010; Novak 2006; Prikryl 2007), three in France
(Brunelin 2006; Poulet 2005; Saba 2006a), two in Germany
(Cordes 2010;Guse 2013), two in theNetherlands (Slotema2011;
Vercammen2009a), two in theUK (McIntosh 2004;Mogg 2005),
and one in Finland (Holi 2004). Of the remainder, six were con-
ducted in the USA (Hoffman 2005; NCT00308997; Schneider
2008) or Canada (Barr 2013; Blumberger 2012;Wing 2012), two
in Australia (Fitzgerald 2005; Fitzgerald 2008), two in Brazil (De
Jesus 2011; Rosa 2007), two in Israel (Klein 1999; Rosenberg
2012), one in India (Bagati 2009), and one in Korea (Lee 2005).
5. Interventions
5.1 Temporoparietal TMS
Twenty-two studies used temporoparietal TMS,most using the left
temporoparietal region, Lee 2005 also using right temporopari-
etal TMS, and NCT00308997 using Wernicke’s area and right
homologous area. Most studies used low-frequency TMS with 1
Hz at 80 to 110% motor threshold; Hao 2008 and Liu 2008 both
used 10 Hz at 110% motor threshold, Saba 2006a used 1 Hz at
20% of motor threshold and Klirova 2010 used 0.9 Hz at 100%
motor threshold. Blumberger 2012 included two TMS groups,
one with priming TMS of 6 Hz at 90% motor threshold.
In regards to length of TMS stimulations, a wide variety were
reported across studies, ranging from five sessions of one minute,
with one minute gaps (Saba 2006a) to 12 sessions of 20 minutes
each a day (Vercammen 2009a). Blumberger 2012 used MRI-
targeted TMS, and Klirova 2010 and Slotema 2011 both included
an MRI-targeted TMS arm and a non-targeted TMS arm. De
Jesus 2011, Hoffman 2005, and McIntosh 2004 reported using
the 10 - 20 EEG electrode position system. Rosenberg 2012 used
deep H1 coil TMS with single pulse stimulation, which allows
stimulation of deeper brain areas.
5.2 Prefrontal TMS
Nineteen studies used prefrontal TMS, with most using left pre-
frontal TMS or left dorsolateral prefrontal cortex TMS. Klein
1999 reported using right prefrontal TMS and Barr 2013;
Fitzgerald 2008; Ren 2010; Ren 2011 and Wing 2012 reported
using bilateral prefrontal TMS. Various stimulations of TMS were
administered. Seven studies reported using 10 Hz at 90 to 110%
motor threshold, Gao 2009c used 15 Hz at 90% motor thresh-
old, three studies used 20 Hz at 90% motor threshold (Barr 2013;
Novak 2006; Wing 2012). Klein used low-frequency TMS with
1 Hz at 10% above threshold. Two studies (Chen 2011; Zhang
2010) used theta burst stimulation (TBS) TMS, in which 50 Hz
are applied in bursts, and Zheng 2012 used three arms of TMS
10 Hz, 20 Hz and TBS (50 Hz).
In terms of stimulation length for each session of TMS, there was
much variation reported across the studies. TMS ranged from two
trains of one minute with a three-minute gap (Klein 1999), to 40
trains of 2.5 seconds with a 30-second gap (Novak 2006). Barr
2013 used MRI-targeted TMS and Guse 2013 and Poulet 2005
reported using the 10 - 20 EEG electrode position system.
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5.3 Sham TMS
For the sham TMS condition a variety of techniques were used.
Seventeen studies described using the same stimulation as for ac-
tive TMS but with the edge resting at a 90 degree angle to the
scalp, six studies used a 45 degree angle (De Jesus 2011; Fitzgerald
2005; Gao 2009b; Guse 2013; Hoffman 2005; McIntosh 2004)
and two at 180 degrees (Hao 2008, Liu 2008). Zhang 2010 and
Zheng 2012 used the reverse side of the coil plane to the scalp.
NCT00308997 used placebo stimulation, which feels similar to
real rTMS but does not produce direct brain effects, Vercammen
2009a used sham designed to produce an identical sound, Wing
2012 administered sham in the single-wing tilt position. Addi-
tionally, some studies described further sham methods which in-
cluded using the same stimulation as for active TMS but with a
sham coil designed to produce identical sound (Brunelin 2006;
Chen 2011; Cordes 2010; Mogg 2005; Poulet 2005; Rosa 2007;
Rosenberg 2012; Saba 2006a), and a sham treatment which used a
magnetically non-translucent headpiece (Schneider 2008). Bagati
2009 and Liu 2008 did not use sham but compared TMS to an-
tipsychotics only.
5.4 Standard treatment
Two studies (Bagati 2009; Liu 2011) compared temporoparietal
TMS to standard treatment, which was treatment with antipsy-
chotics. In both trials, participants in the TMS group also re-
ceived antipsychotics. We found no studies that compared pre-
frontal TMS to standard treatment.
6. Use of antipsychotics
In 10 studies participants in both treatment groups received first-
generation and second-generation antipsychotics (Bagati 2009;
Barr 2013; Blumberger 2012;Chen2011;Cordes 2010; Liu 2011;
McIntosh 2004; Mogg 2005; Ren 2011; Slotema 2011), although
in McIntosh 2004 participants on clozapine were excluded from
the trial. In 12 studies participants used second-generation an-
tipsychotics: in De Jesus 2011 and Rosa 2007 all participants took
clozapine; in Fitzgerald 2005 a significant number in each treat-
ment group used clozapine; in Gao 2009b and Yu 2010 partic-
ipants received risperidone; and in three studies all participants
used second-generation antipsychotics apart from one participant
in the TMS group who used first-generation antipsychotics (Holi
2004; Novak 2006; Fitzgerald 2008). Six studies did not report
whether antipsychotics were used in the study (Brunelin 2006; Lee
2005; NCT00308997; Wing 2012; Xu 2011; Zhang 2010) and
in the remaining studies all participants received antipsychotics,
but the type was not reported.
7. Outcomes
A variety of scales, used to assess clinical response and cognitive
performance, are described in Appendix 1. They assessed global
state, mental state, cognitive state, adverse events and quality of
life.
8. Missing outcomes
Nousable data were available for a number of outcomes, including
adverse events, hospital and service outcomes, satisfaction with
care, and economic outcomes.
Excluded studies
We excluded 58 studies. Reasons for exclusion were that 20
studies were not randomised controlled trials; one study was
not randomised and the number of participants was less than
five (Hoffman 1999); one study used no allocation conceal-
ment (Jandl 2006); one study included participants with de-
pression and not schizophrenia (Hasey 2000); one study used
healthy controls (NCT01620086); for 12 studies the inter-
vention was transcranial direct current stimulation and not
TMS (ACTRN12611000731998; ACTRN12612000217808;
ACTRN12612001112853; Brunelin 2012;
Mattai 2011; NCT00757497; NCT00870909; NCT01378078;
NCT01607840; NCT01623726; Rushby 2010; Weickert 2010);
for one study the intervention was an antidepressant plus fMRI
and not TMS (NCT01041274); for two studies both intervention
and comparison arms included TMS (NCT01595503; Slotema
2012); for one study the number of participants in each arm of
the trial was less than five (Schonfeldt-Lecuona 2004); 16 stud-
ies provided insufficient data for use (Alva 2001; Arends 2005;
Benitez 2005; Cordes 2008; Daskalakis 2007; Grenier 2008;
Hajak 2004; Hasan 2010; Hoffman 2000; Hoffman 2003; Jin
2003; Jin 2006; Loo 2010;Mobascher 2005; Potkin 2000; Rollnik
2000; Schneider 2001); and one study was terminated as theywere
unable to recruit participants (NCT00517075). We excluded Jin
2012 as data were not reported separately for temporoparietal and
prefrontal TMS
Awaiting assessment
There is one study, Mohr 2006, awaiting assessment because
we could not find the full article. See Characteristics of studies
awaiting classification for more details.
Ongoing studies
We identified 18 ongoing studies, with 790 planned participants.
One trial out of the 18 ongoing trials compares TMS with treat-
ment as usual, and the remaining studies compare TMSwith sham
TMS, although one trial (NCT01370291) plans to compare both
treatments with and without the use of risperidone. Three studies
use high-frequency prefrontal TMS, five use low-frequency tem-
poroparietal TMS, but a further nine studies use otherTMSproce-
dures (deep-coil TMS in one study, high-frequency temporopari-
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etal TMS in another, and theta burst stimulation TBS in seven).
See Characteristics of ongoing studies for details of each study.
Risk of bias in included studies
See Characteristics of included studies for our judgements and
motivation for risk of bias for each study, Figure 2 for an overview
of our judgements of risk of bias for each study and Figure 3 for
an overview of percentages of low, unclear and high risk of bias
for each category.
17Transcranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All included studies were reported as randomised. Seventeen
studies adequately described the method of sequence generation
(Bagati 2009; Chen 2011; De Jesus 2011; Fitzgerald 2008; Gao
2009a; Gao 2009b; Guse 2013; Hao 2008; Hoffman 2005; Liu
2008; Liu 2011; McIntosh 2004; Prikryl 2007; Slotema 2011; Yu
2010; Zhang 2010; Zheng 2012) and thus had a low risk of selec-
tion bias; the remaining studies did not provide details and were at
unclear risk of selection bias. Seven studies were rated at low risk of
bias as they had adequate allocation concealment (De Jesus 2011;
Fitzgerald 2005; Fitzgerald 2008; Holi 2004; McIntosh 2004;
Mogg 2005; Slotema 2011). However, most studies had unclear
allocation concealment.
Blinding
Only seven studies adequately described the blinding of partici-
pants and personnel (Brunelin 2006;Hoffman 2005; Poulet 2005;
Prikryl 2007; Rosenberg 2012; Saba 2006a; Schneider 2008) and
had a low risk of performance bias, and 34 studies had unclear risk
of performance bias as the method of blinding participants and
personnel was not adequately described. Most studies had a low
risk of detection bias as the raters were adequately blinded, but
with 13 studies at unclear risk of detection bias as they did not ade-
quately describe blinding of outcome assessment (Gao 2009a;Gao
2009c; Gao 2010; Hao 2008; Klirova 2010; Liu 2008; Liu 2011;
Ren 2010; Ren 2011; Wing 2012; Xu 2011; Yu 2010; Zhang
2010).
Incomplete outcome data
Most studies had an unclear risk of attrition bias because reasons
for loss to follow-up were not consistently indicated or were un-
reported. Nineteen studies had a low risk of attrition bias: three
studies were analysed on an intention-to-treat basis (Blumberger
2012; Hoffman 2005; Mogg 2005), seven studies adequately re-
ported and dealt with attrition (Barr 2013; Chen 2011; Cordes
2010; Liu 2008; NCT00308997; Zhang 2010; Zheng 2012) and
nine studies reported no losses to follow-up (Gao 2009b; Gao
2009c; Liu 2011; McIntosh 2004; Poulet 2005; Ren 2010; Ren
2011; Xu 2011; Yu 2010). Two studies had a high risk of attri-
tion bias. For Wing 2012, losses to follow-up were not balanced
between treatment groups, and Rosenberg 2012 had a very high
(44%) attrition rate.
Selective reporting
Most studies had a low risk of reporting bias as they fully reported
all stated outcomes. In five studies we considered the risk of report-
ing bias to be unclear (De Jesus 2011; Klirova 2010; Poulet 2005;
Prikryl 2007; Wing 2012). In 14 studies we considered the risk of
reporting bias to be high, as some stated outcomes were not ade-
quately reported (Bagati 2009; Fitzgerald 2005; Fitzgerald 2008;
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Gao 2009a; Gao 2009c; Guse 2013; Holi 2004; Klein 1999; Liu
2011; McIntosh 2004; Novak 2006; Schneider 2008; Yu 2010;
Zhang 2010). We attempted to obtain any data which were not
reported in published literature by contacting the authors.
Other potential sources of bias
We rated 22 studies at low risk of bias, as we detected no other
potential sources of bias. The remaining 19 had an unclear risk of
bias as there was insufficient information to make a judgement.
Effects of interventions
See: Summary
of findings for the main comparison TEMPOROPARIETAL
TMS compared to SHAM TMS for schizophrenia; Summary
of findings 2 TEMPOROPARIETAL TMS compared to
STANDARD TREATMENT for schizophrenia; Summary of
findings 3 PREFRONTAL TMS compared to SHAM TMS for
schizophrenia; Summary of findings 4 PREFRONTAL TBS
TMS compared to SHAM TMS for schizophrenia
COMPARISON 1: TEMPOROPARIETAL TMS vs
SHAM TMS
Twenty trials randomised 692 participants and compared TEM-
POROPARIETAL TMS (n = 399) vs SHAM TMS (n = 293)
(Blumberger 2012; Brunelin 2006; De Jesus 2011; Fitzgerald
2005; Gao 2009a; Gao 2010; Hao 2008; Hoffman 2005; Klirova
2010; Lee 2005; Liu 2008;McIntosh 2004;NCT00308997; Rosa
2007; Rosenberg 2012; Saba 2006a; Slotema 2011; Vercammen
2009a; Xu 2011; Yu 2010).
1.1 Global state
a. Clinical improvement (CGI)
One study (Gao 2009a) found that the number of participants
with a clinical improvement in global state did not differ between
temporoparietal TMS and shamTMSwhenmeasured on theCGI
scale; however they did not report the response criteria used to
define clinical improvement (Analysis 1.1; 46 participants).
b. Average scores for clinical improvement (CGI, high = poor)
Seven studies reported global state measured on the CGI scale
and found a clear difference in favour of temporoparietal TMS (7
RCTs, n = 224, MD -0.50, 95% CI -0.76 to -0.23, Analysis 1.2).
1.2 Mental state
a. General
i. Clinical improvement (PANSS > 30% reduction)
Blumberger 2012 reported clinical improvement in mental state,
defined as more than a 30% reduction in total PANSS score; the
proportionof participants that had a clinical improvement inmen-
tal state did not differ between the treatment groups (Analysis 1.3;
51 participants).
ii. Average total score (various scales)
Mental state was measured on the BPRS by De Jesus 2011 (17
participants), which found no clear difference in scores between
treatment groups. In contrast, total PANSS scores were clearly
lower in the temporoparietal TMS group than the sham TMS
group (5 RCTs, n = 127, MD -6.09, 95% CI -10.95 to -1.22,
Analysis 1.4).
iii. Average general psychopathology score (PANSS general)
Four studies provided data regarding general psychopathology
measured on the PANSS general subscale. There was no signifi-
cant difference in scores between temporoparietal TMS and sham
TMS (Analysis 1.5; 87 participants).
b. Specific
i. Average depression score (various scales)
Hao 2008 found that participants showed significantly less de-
pression when measured on the SDS (1 RCT, n = 25, MD -5.59,
95% CI -11.57 to 0.39, Analysis 1.6) , but results were equivocal
when measured on the HAMD by the same small study. De Jesus
2011 also reported data for depression and excitement factor on
the BPRS, but these data were skewed so we have not presented
them in analyses (see Table 2).
ii. Hallucinations - clinical improvement (various scales)
Significantly more participants that received temporoparietal
TMS showed a clinical improvement in hallucinations when de-
fined as an HCS score of 5 or less (3 RCTs, n = 133, RR 2.26,
95% CI 1.18 to 4.35) or more than a 30% decrease on the AHRS
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(3 RCTs, n = 120, RR 2.99, 95% CI 1.12 to 7.98, Analysis 1.7).
However, AHRS pooled data showed moderate heterogeneity (I²
= 55%) and when we applied the random-effects model the results
became non-significant. Rosa 2007 reported “Reality” and “Atten-
tional Salience” scores from the AHRS in figures, which showed a
significant group effect (P = 0.0493 and P = 0.0360, respectively).
We found no clear difference for clinical improvement in halluci-
nations when defined as improvement of one or more points on
the PANSS hallucination item score, or more than a 30% reduc-
tion on the PSYRATS score.
iii. Average hallucinations score (various scales)
Hallucinations scores were significantly lower in the temporopari-
etal TMS when measured on the HCS (3 RCTs, n = 162, MD
-1.64, 95% CI -2.80 to -0.48) and by the PANSS hallucination
item (4RCTs, n = 125,MD-1.01, 95%CI -1.97 to -0.04, Analysis
1.8). However, the PANSS hallucination item data were highly
heterogenous (I² = 81%), with no obvious clinical or methodolog-
ical reason for the heterogeneity. Removal of the outlying study,
Gao 2010, reduced the heterogeneity (I² = 30%).
In contrast, when hallucinations were measured using AVH-re-
lated items from the PSYRATS and the AHRS, there was no signif-
icant difference in hallucination scores between treatment groups.
However, the latter showed high levels of heterogeneity (I² = 62%),
which we could not explain by differences in the treatment as
all used low frequency (1 Hz). Furthermore, when we removed
Rosenberg 2012, which used deep temporoparietal TMS, the het-
erogeneity was unchanged. However, when we removed change
data from the analysis (NCT00308997; Poulet 2005) the hetero-
geneity was reduced (I² = 20%).
Poulet 2005 also reported endpoint data for hallucinations on the
AHRS, but these data were skewed so we have not presented them
in analyses (see Table 2).
iv. Average negative symptom scores (various scales)
Negative symptoms weremeasured using the BPRS, PANSS nega-
tive and SANS scales. We found no significant difference in scores
on the BPRS and PANSS; however one small study, Hao 2008,
which used high-frequency temporoparietal TMS (10Hz) showed
a significant difference favouring temporoparietal TMS (1 RCT,
n = 25, MD -23.58, 95% CI -37.06 to -10.1, Analysis 1.9).
Rosenberg 2012 also reported data for negative symptoms on the
SANS, but these data were skewed so we have not presented them
in analyses (see Table 2).
v. Positive symptoms - clinical improvement (PANSS > 30%
reduction)
Blumberger 2012 found no difference in clinical improvement
of positive symptoms, which was defined as more than a 30%
reduction in PANSS positive subscale score (Analysis 1.10; 51
participants).
vi. Average positive symptom score (various scales)
Positive symptom scores were significantly lower in the tem-
poroparietal TMS group than in the shamTMS group whenmea-
sured on the PANSS positive subscale (11 RCTs, n = 333, MD -
2.14, 95% CI -3.15 to -1.14, Analysis 1.11), but not significantly
different when measured on the BPRS in one study (De Jesus
2011; 17 participants) or the SAPS used by Brunelin 2006 and
Hao 2008. Poulet 2005 and Rosenberg 2012 also reported data
for positive symptoms on the SAPS, but these data were skewed
so we have not presented them in analyses (see Table 2).
1.3 Cognitive state
Cognitive state was reported in three studies (Hoffman 2005;
Liu 2008; Xu 2011) using 39 different measures. These data are
reported in Table 3. Results were equivocal for all measures. Xu
2011 also reported cognitive data on the CPT, but these data were
skewed so we did not present them in Table 3 (see Table 2).
1.4 Adverse effects
a. General
i. Serious
NCT00308997 and Vercammen 2009a reported that there were
no serious adverse events in either treatment group (Analysis 1.12;
130 participants).
ii. Leaving the study early
The number of participants leaving the study early did not differ
significantly between treatment groups (Analysis 1.13; 8 studies,
320 participants).
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b. Specific
Participants receiving temporoparietal TMS clearly experienced
more headaches (10RCTs, n=392,RR2.65, 95%CI1.56 to 4.50)
and jaw and facial contraction (2 RCTs, n = 70, RR 8.32, 95%
CI 1.13 to 61.17, Analysis 1.14) than those receiving sham TMS.
Other adverse events - concentrationproblems, earache, lighthead-
edness/dizziness, mild memory impairment/amnesia, restless legs,
somatic discomfort, tingling sensation in the arm, worsening hal-
lucinations/audible thoughts - were not clearly different between
treatment groups.
1.5 Quality of life
a. Average score (Q-LES-Q, low = poor)
Rosenberg 2012 measured quality of life on the Q-LES-Q and
found no clear difference between deep temporoparietal TMS and
sham TMS (Analysis 1.15; 20 participants).
COMPARISON 2: TEMPOROPARIETAL TMS vs
STANDARD TREATMENT
Two trials randomised 140 participants and compared TEM-
POROPARIETAL TMS (n = 70) versus STANDARD TREAT-
MENT (n = 70) (Bagati 2009; Liu 2011). In both studies the
participants received first- and second-generation antipsychotics
in both treatment groups.
2.1 Global state
a. Clinical improvement (CGI ≤2)
Liu 2011 found that there was no clear difference in the num-
ber of participants experiencing clinical improvement when tem-
poroparietal TMS and antipsychotics were compared to antipsy-
chotic treatment alone (Analysis 2.1; 100 participants).
2.2 Mental state
a. Average hallucinations score (AHRS)
Bagati 2009 reported data for hallucinations on the AHRS, but
these data were skewed so we have not presented them in analyses
(see Table 4).
2.3 Adverse effects
a. General - leaving the study early
The number of participants leaving the study early was not clearly
different between temporoparietal TMS and antipsychotics alone
(Analysis 2.2; 140 participants).
COMPARISON 3: PREFRONTAL TMS vs SHAM TMS
Seventeen trials randomised 502 participants and compared PRE-
FRONTAL TMS (n = 266) versus SHAM TMS (n = 236) (Barr
2013; Cordes 2010; Fitzgerald 2008; Gao 2009b; Gao 2009c;
Guse 2013; Holi 2004; Klein 1999; Mogg 2005; Novak 2006;
Poulet 2005; Prikryl 2007; Ren 2010; Ren 2011; Schneider 2008;
Wing 2012; Zheng 2012).
3.1 Global state
a. Average scores (various scales)
Three small studies (Guse 2013;Holi 2004; Klein 1999)measured
global state on the CGI, CGI-S, GAF and SCL-90, none of which
showed a significant effect between prefrontal TMS and sham
TMS (Analysis 3.1; 85 participants).
3.2 Mental state
a. General
i. Clinical improvement (> 20% decrease in total PANSS
score)
Results from one small trial (Holi 2004) show that more partici-
pants in the prefrontal TMS group had a clinical improvement in
mental state than those that received sham TMS (1 RCT, n = 22,
RR 0.14, 95% CI 0.02 to 0.98, Analysis 3.2).
ii. Average total score (various scales)
Mental state was measured using the BPRS and PANSS scales.
We found no clear difference in participants’ mental state between
treatment groups on either scale (Analysis 3.3; 219 participants).
However, the pooled data for the PANSS scale were heterogeneous
(I² = 68%).Whenwe removed the low-frequency trial (Ren 2010),
the heterogeneity remained. Removing outlying trials, Fitzgerald
2008 andGao 2009b, eliminated the heterogeneity, but the studies
account for more than 40% of the weight for this outcome and
we therefore did not pool the data.
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iii. Average general psychopathology score (PANSS,
high=poor)
Six studies reported data on general psychopathology of partici-
pants, measured on the PANSS scale. The pooled data were highly
heterogenous (I² = 81%) and removal of the two low-frequency
trials (Klein 1999; Ren 2010) did not reduce the heterogeneity.
Removal of the outlying trials, Gao 2009b and Klein 1999, elim-
inated the heterogeneity, but as these trials accounted for 36% of
the weighting, we did not pool the data (Analysis 3.4; 199 partic-
ipants).
b. Specific
i. Average depression score (various scales)
Depression was reported on four scales by four different studies.
There were no significant differences on the HDRS and SCL-
90 DEP subscale, whereas, when measured on the HAMD-17 (1
RCT, n = 43, MD -2.40, 95% CI -3.88 to -0.92) and MADRS (1
RCT, n = 22, MD -4.36 95% CI -7.05 to -1.67), prefrontal TMS
was efficacious when compared to sham TMS (Analysis 3.5). Barr
2013 and Fitzgerald 2008 also reported data for depression on
the Calgary depression scale (CDS) and Calgary depression rating
scale (CDRS) respectively, but as these data are skewed we have
not presented them in analyses (see Table 5).
CDRS - Calgary depression rating scale
CDS - Calgary depression scale
ii. Average hallucinations score (PANSS)
Ren 2010 foundnodifference in hallucinations between treatment
groups (1 RCT, n = 25,MD -0.68, 95%CI -1.68 to 0.32, Analysis
3.6).
iii. Negative symptoms - clinical improvement (> 20%
decrease in PANSS negative)
One small study (Novak 2006) found no difference in the number
of participants that experienced a clinical improvement in negative
symptoms (Analysis 3.7; 16 participants).
iv. Average negative symptom score (various scales)
Pooled data for 10 studies that reported negative symptoms on
the PANSS positive subscale were highly heterogeneous. Remov-
ing the low-frequency studies (Fitzgerald 2008; Klein 1999) did
not reduce the heterogeneity. Removal of the outlying trials (Gao
2009b; Gao 2009c) reduced the heterogeneity (I² = 16%), and
results show no significant difference between treatment groups.
When measured on the SANS, three small studies found that par-
ticipants receiving prefrontal TMS had a significant improvement
compared to sham TMS (3 RCTs, n = 71, MD -12.68, 95% CI
-18.60 to -6.77, Analysis 3.8). Barr 2013 also reported data for
negative symptoms on the PANSS, but these data were skewed so
we have not presented them in analyses (see Table 5).
v. Average positive symptom score (various scales)
Positive symptoms were not significantly different between treat-
ment groups for 10 studies (279 participants) that used the PANSS
positive subscale and one small study (Prikryl 2007; 22 partici-
pants) on the SAPS (Analysis 3.9). Fitzgerald 2008 also reported
data for positive symptoms on the PANSS, but these data were
skewed so we have not presented them in analyses (see Table 5).
vi. Average psychotism score (SCL-90 PSY)
Holi 2004 also found no difference in psychotismmeasured on the
SCL-90 PSY subscale between prefrontal TMS and sham TMS
(Analysis 3.10; 22 participants).
3.3 Cognitive state
Cognitive effects were reported in four studies (Guse 2013; Mogg
2005; Novak 2006; Zheng 2012), using 19 different measures.
These data are reported in Table 6. Results were equivocal for
most of the outcome measures, with limited evidence to suggest a
beneficial effect of TMS for five cognitive test scores. One study
(Mogg 2005) reported significantly increased cognitive test scores
on average in the TMS arm compared with the control arm for
four outcomes: Hopkins verbal learning test (HVLT)-delayed re-
call (after two weeks follow-up), controlled oral word association
test (COWAT) (two weeks after TMS), and the Stroop test (within
24hours of treatment and at twoweeks follow-up) . A second study
(Guse 2013) reported significantly increased scores for Wiscon-
sin card sorting test (WCST) categories (for people with WCST
categories pre-treatment median ≤ 4). More trials are needed to
confirm or refute the beneficial effects of these cognitive test out-
comes.
3.4 Adverse effects
a. General
i. Leaving the study early
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The number of participants leaving the study was reported in eight
studies and did not differ significantly between treatment groups
(8 RCTs, n = 174, RR 1.19, 95% CI 0.56 to 2.50, Analysis 3.12).
b. Specific
i. Various
Participants in the prefrontal TMS group experienced more
headaches than those in the sham TMS group (6 RCTs, n = 164,
RR 2.77, 95% CI 1.22 to 6.26), and more TMS-related site dis-
comfort or pain (2 RCTs, n = 42, RR 8.33, 95% CI 1.68 to 41.27,
Analysis 3.13). Cordes 2010 reported no adverse events measured
on the UKU side effect rating scale and Klein 1999 reported no
cognitive difficulties in either treatment group. Klein 1999 also
found no significant difference in facial twitching and worsening
of pre-existing akathisia and OCD.
ii. Average scores (CSSES)
Mogg 2005 measured subjective side effects and cognitive com-
plaints on theCSSES and found no significant differences between
prefrontal TMS and sham TMS (Analysis 3.14; 17 participants).
COMPARISON 4: PREFRONTAL TBS TMS vs SHAM
TMS
Three trials randomised 115 participants and compared PRE-
FRONTALTBSTMS (n = 59) versus SHAMTMS (n = 56) (Chen
2011; Zhang 2010; Zheng 2012).
4.1 Global state
a. Clinical improvement
Zhang 2010 found no difference in the number of participants
showing a clinical improvement in global state between prefrontal
TBS TMS and sham TMS (Analysis 4.1; 27 participants).
4.2 Mental state
a. General
i. Average total score (PANSS, high = poor)
Three studies (Chen 2011; Zhang 2010; Zheng 2012) reported
data formental state on the PANSS scale and found that prefrontal
TBS TMSwas efficacious when compared to shamTMS (3 RCTs,
n = 108, MD -5.71, 95% CI -9.32 to -2.10, Analysis 4.2).
ii. Average general psychopathology score (PANSS, high =
poor)
General psychopathology was also significantly better in the pre-
frontal TBS TMS group (3 RCTs, n = 108, MD -2.47, 95% CI -
4.21 to -0.73, Analysis 4.3).
b. Specific
i. Average negative symptom score (PANSS, high = poor)
Negative symptoms were significantly lower in the prefrontal TBS
TMS group than in the sham TMS group when measured on the
PANSS (3 RCTs, n = 108, MD -2.67, 95% CI -4.25 to -1.09)
and the SANS (1 RCT, n = 27, MD -11.55, 95% CI -21.90 to -
1.2, Analysis 4.4).
ii. Average positive symptom score (PANSS, high = poor)
Positive symptoms were not significantly different between treat-
ment groups (Analysis 4.5; 108 participants).
4.3 Cognitive state
a. Average scores on various measures
We found no difference in cognitive state between treatment
groups when measured using the digit span test and the verbal
fluency test in one small study (Zheng 2012) (Analysis 4.6; 39
participants).
4.4 Adverse effects
a. General - Leaving the study early
The number of participants leaving the study early did not differ
between the treatment groups (Analysis 4.7; 2 RCTs, 76 partici-
pants).
b. Specific
Participants did not experience significantly different numbers of
adverse events (headaches or sleep disorder) between prefrontal
TBS TMS and sham TMS (Analysis 4.8; 1 RCT, 27 participants).
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Unusable data
Jin 2012 reported data for clinical improvement combined for
the two TMS groups (frontal and parietal) in the study, and so
could not be added to any of the comparisons on the analyses.
Clinical improvement was defined as at least a 30% improvement
in PANSS score; 17 of 41 patients responded to the TMS (42%),
whereas three of 24 responded to sham TMS (12%).
Sensitivity analysis
There were no losses to follow-up for the outcome ’clinical im-
provement in global state’ for temporoparietal TMS compared to
sham TMS or standard treatment, and no studies reported on this
outcome when prefrontal TMS was compared with sham TMS.
For prefrontal TBS TMS versus sham TMS there were no dif-
ferences when completer-only data were compared with all ran-
domised in an intention-to-treat analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia
Patient or population: people with schizophrenia
Settings: inpatients and outpatients
Intervention: TEMPOROPARIETAL TMS1
Comparison: STANDARD TREATMENT1
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
STANDARD TREATMENT TEMPOROPARIETAL
TMS
Clinical improvement in
global state
CGI
Follow-up: after treatment
620 per 1000 738 per 1000
(564 to 973)
RR 1.19
(0.91 to 1.57)
100
(1 study)
⊕⊕©©
low2,3
Global state score - not
reported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
Mental state - not re-
ported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
Cognitive state - not re-
ported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
Adverse effects: general
or specific - not reported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
Adverse effects: Leaving
the study early
Follow-up: after treatment
86 per 1000 28 per 1000
(7 to 125)
RR 0.33
(0.08 to 1.46)
140
(2 studies)
⊕©©©
very low4,5
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Satisfaction with care -
not reported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
*The basis for the assumed risk is the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Participants received first and second generation antipsychotics in both treatment groups
2Risk of bias: serious - this study had an unclear risk of bias for allocation concealment and blinding of participants and outcome
assessors
3Imprecision: serious - the confidence intervals are wide and include both benefit and harm
4Risk of bias: serious - one study had an unclear risk of bias for randomisation and both studies for allocation concealment. One study
had a unclear risk of bias for blinding of participants
5Imprecision: very serious - there were few participants and very few events; there are wide confidence intervals.
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PREFRONTAL TMS compared to SHAM TMS for schizophrenia
Patient or population: people with schizophrenia
Settings: inpatients and outpatients
Intervention: PREFRONTAL TMS
Comparison: SHAM TMS
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
SHAM TMS PREFRONTAL TMS
Clinical improvement in
global state - not re-
ported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
Global state score
Various scales
Follow-up: after treatment
See comment See comment Not estimable 85
(3)
See comment 3 small studies measured
global state on the CGI,
CGI-S, GAF and SCL-90,
none of which showed a
significant treatment ef-
fect
Mental state
PANSS
Follow-up: after treatment
See comment See comment Not estimable 188
(6 studies)
⊕©©©
very low1,2
There was very high het-
erogeneity for this out-
come, so we did not pool
the data
Cognitive state
Various measures
Follow-up: after treatment
to 6 weeks
See comment See comment Not estimable 138
(4 studies)
⊕⊕©©
low3,4
Cognitive state was re-
ported in 4 studies using
19 different measures.
Results were equivocal
for all measures apart
from 4
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Adverse effects: general
or specific
Follow-up: after treatment
See comment See comment Not estimable 199
(7 studies)
⊕⊕©©
low5
There were more
headaches and TMS-re-
lated site discomfort or
pain in the TMS group.
Results for other adverse
effects - cognitive diffi-
culties, facial twitching,
worsening of pre-existing
akathisia and OCD - were
equivocal
Adverse effects: Leaving
the study early
Follow-up: after treatment
to 2 weeks
106 per 1000 126 per 1000
(59 to 265)
RR 1.19
(0.56 to 2.5)
174
(8 studies)
⊕⊕©©
low6,7
Satisfaction with care -
not reported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Risk of bias: serious - two studies had an unclear risk of bias for randomisation and five for allocation concealment. Five studies had
an unclear risk for blinding of participants and two for blinding of outcome assessors and incomplete outcome data.
2Incosistency: very serious - there was a very high heterogeneity for this outcome and we did not pool results
3Risk of bias: serious - two studies had an unclear risk of bias for randomisation and three for allocation concealment. All studies had
an unclear risk for blinding of participants and two studies had an unclear risk for incomplete outcome data
4Imprecision: serious - different scales were used to measure this outcome, the majority had wide confidence intervals
5Risk of bias: very serious - five studies had an unclear risk of bias for randomisation and allocation concealment. All had an unclear risk
for blinding of participants, and two for blinding of outcome assessors. Four had an unclear risk for incomplete outcome data
6Imprecision: serious: there are wide confidence intervals
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7Risk of bias: serious - seven studies had an unclear risk of bias for randomisation and five for allocation concealment. All had an unclear
risk for blinding of participants, and three were unclear for blinding of outcome assessors. Four had a high or unclear risk for incomplete
outcome data
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia
Patient or population: people with schizophrenia
Settings: inpatients and outpatients
Intervention: PREFRONTAL TBS TMS
Comparison: SHAM TMS
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
SHAM TMS PREFRONTAL TBS TMS
Clinical improvement in
global state
Follow-up: after treatment
0 per 1000 0 per 1000
(0 to 0)
RR 4.06
(0.21 to 77.37)
27
(1 study)
⊕©©©
very low1,2
Global state score - not
reported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
Mental state
PANSS
Follow-up: after treatment
The mean scores for the
sham TMS group ranged
from 67.6 to 68.4
The mean mental state
in the intervention groups
was
5.71 lower
(9.32 to 2.1 lower)
108
(3 studies)
⊕⊕©©
low1,3
Cognitive state
Various measures
Follow-up: after treatment
See comment See comment Not estimable 39
(1 study)
⊕⊕©©
low1,4
This was measured on
2 scale, both showed
equivocal results
Adverse effects: general
or specific
Follow-up: after treatment
See comment See comment Not estimable 27
(1 study)
⊕⊕©©
low1,3
No
differences in headaches
and sleep disorders
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Adverse effects: Leaving
the study early
139 per 1000 50 per 1000
(10 to 242)
RR 0.36
(0.07 to 1.74)
76
(2 studies)
⊕⊕©©
low1,2
Satisfaction with care -
not reported
See comment See comment Not estimable - See comment No studies reported data
for this outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Risk of bias: serious - there was an unclear risk of bias for allocation concealment and blinding
2Imprecision: serious - there were very few participants and very few events; the confidence intervals are wide
3Imprecision: serious - there are wide confidence intervals
4Imprecision: serious - this was measured on two scales by one study, both of which had wide confidence intervals
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D I S C U S S I O N
Overall the quality of the evidence was rated as very low based
on the ’Summary of findings’ tables (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4).
Summary of main results
COMPARISON 1: TEMPOROPARIETAL TMS
VERSUS SHAM
Very low-quality evidence fromone small trial showed no evidence
of effect of temporoparietal TMS compared to sham TMS for
clinically improving global state. However, there is some very low-
quality evidence to show that global state scores on the CGI scale
are superior with temporoparietal TMS. There is also very low-
quality evidence from the PANSS scale that temporoparietal TMS
is superior to sham TMS in improving mental state. While there
may be some benefits with TMS over sham TMS, the clinical sig-
nificance of some of the scale-driven data is unclear. Very low-qual-
ity evidence shows that temporoparietal TMS does not affect cog-
nitive state; however, participants receiving temporoparietal TMS
experienced more headaches than those in the sham TMS group.
No more participants left the study early in the temporoparietal
TMS than the shamTMS group, but again, this is very low-quality
evidence. No studies reported whether participants were satisfied
with their care.
COMPARISON 2: TEMPOROPARIETAL TMS
VERSUS STANDARD CARE
Limited low-quality evidence shows that temporoparietal TMS is
not superior to standard treatment (first- and second-generation
antipsychotic medication) in clinically improving global state, and
the number of participants leaving the study early does not differ
between temporoparietal TMS and standard treatment. No stud-
ies reported on participants’ mental state and cognitive state, ex-
perience of adverse effects and whether they were satisfied with
their care.
COMPARISON 3: PREFRONTAL TMS VERSUS
SHAM
We found no evidence that prefrontal TMS is superior to sham
TMS in improving global state, mental state and cognitive state,
although the quality of the evidence is very low. Prefrontal TMS
does not cause more headaches than sham TMS, and the num-
ber of participants leaving the study early did not differ between
treatment groups, but again the evidence is of very low quality.
No studies reported whether participants were satisfied with their
care.
COMPARISON 4: PREFRONTAL TBS TMS VERSUS
SHAM
Prefrontal TBS TMS is not superior to sham TMS in improving
global state and cognitive state, but there is some evidence that it
improvesmental state, although the evidence is of very low quality.
Prefrontal TBS TMS does not cause participants to experience
more headaches or to leave the study earlier than sham TMS, but
again this is from very low-quality evidence. No studies reported
whether participants were satisfied with their care.
Overall completeness and applicability of
evidence
1. Duration
Studies reported substantial differences in the length of trials,
which ranged from four days (McIntosh 2004) to 10 weeks (Wing
2012). This issue is therefore potentially problematic for compar-
ison, and caution should be considered in relation to any conclu-
sions. Difference in study length may arise from the nature of the
population samples in terms of the associated high attrition rates.
The lack of consistency across studies in relation to study length
may also reflect the novel aspect of the intervention and the lack of
a standardised procedure. We did not stratify the data by the dif-
ferent time periods specified in Types of outcome measures in the
protocol, as there were not enough data (see Differences between
protocol and review).
2. Participants
Participants were consistently classified with schizophrenia or
schizoaffective disorder, with most studies using a diagnosis ac-
cording to the DMS-IV. Prikryl 2007 reported the ICD-10, and
Schneider 2008 reported the use of both a diagnosis of schizophre-
nia with at least one year prior hospitalisation. The sample groups
included for review were therefore well matched.
3. Control condition
A wide variety of sham TMS techniques were reported across the
included studies. Although most studies reported use of the same
stimulation as for active TMS, additional descriptions of this pro-
cedure varied from the edge of the coil resting at a 45 degree angle,
a 90 degree angle, with one wing touching or with both wings
touching. In addition further descriptions included a sham coil
which produced identical sounds to the active TMS, and a sham
coil which had a magnetically non-translucent headpiece. Draw-
ing a comparison across results and the interpretation of findings
is therefore hindered.
Surprisingly, there is very little information on TMS compared
to other treatments for schizophrenia. No studies compared TMS
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with other physical methods of treatment such as electroconvulsive
therapy (ECT), and two (out of 41 included) studies compared
TMS with standard treatment. The standard treatment in these
studies (Bagati 2009; Liu 2011)was antipsychotics, although those
given TMS also received them.
One trial out of the 18 ongoing trials compares TMS with treat-
ment as usual, and the remaining studies compare TMSwith sham
TMS, although one trial (NCT01370291) plans to compare both
treatments with and without the use of risperidone. This indicates
that the evidence base for TMS is still being studied against sham
TMS, before comparisonswith active treatments can be envisaged.
4. Intervention
The active TMS intervention in both the prefrontal and tem-
poroparietal conditions varied substantially across studies in terms
of stimulation intensity, length of stimulation, and location of
TMS. Studies which conducted prefrontal TMS reported the
greatest variations. Stimulation intensity included ranges of 1 Hz,
10% above threshold to 20 Hz at 80% motor threshold, and three
studies used TBS of 50 Hz. Length of stimulation for prefrontal
TMS studies ranged from two trains of one minute with a three-
minute gap (Klein 1999), to 40 trains of 2.5 seconds with a 30-
second gap (Novak 2006) with a number of different variations
across studies. Location of prefrontal TMS stimulation also dif-
fered, with reports of left prefrontal TMS, left dorsolateral pre-
frontal cortex TMS, right prefrontal TMS, and bilateral prefrontal
TMS. For studies which used temporoparietal TMS, there was
some consistency in that all but two studies reported using TMS
stimulations of 1 Hz. However the level of motor threshold did
vary, with reports of 20% below motor threshold to 100% mo-
tor threshold. As with the prefrontal TMS studies, in the case of
temporoparietal TMS a wide variety of stimulation length was re-
ported, which ranged from five sessions of one minute with one-
minute gaps (Saba 2006a) to two session of 20 minutes each a day
(Vercammen 2009a).There was also more consistency with stud-
ies of temporoparietal TMS in regards to location, as all but one
study reported left temporoparietal TMS, with the exception of
Lee 2005 which reported also using right temporoparietal TMS.
Comparing data within each intervention is therefore problem-
atic, particularly for the prefrontal TMS for which the procedure
varied more widely.
5. Outcomes
Of the seven categories of predefined outcomes, six were addressed
in both the prefrontal TMS and temporoparietal TMS interven-
tions. No data were available for analysis in the categories of hos-
pital and service outcomes, satisfaction with care, and economic
outcomes. There was a lack of data for quality of life, with only one
study reporting this outcome for temporoparietal TMS. Future
trials should consider including mechanisms for collecting these
additional data; however, the authors acknowledge the tension be-
tween doing limited good-quality data collection at the expense
of quantity.
Quality of the evidence
This review includes 41 studies with 1473 participants. Although
all studies were reported as randomised, most studies reported
unclear allocation concealment (Figure 2 and Figure 3). There is
therefore a risk of selection bias due to a possible lack of good
methods to conceal the allocation. Overall, only seven papers re-
ported adequate allocation concealment. Most studies included in
the review were described as double-blind. However, only seven
studies reported an adequate blinding procedure. This can influ-
ence both performance and attrition bias, and is of particular im-
portance in such study designs, due to the use of subjective mea-
sures. In many studies data were not fully reported and we had
to contact authors in order to obtain both means and standard
deviations for individual measures.
Overall, we judged the quality of the evidence to be low to very low.
In general, the results were consistent, although scale data results
for mental state showed some heterogeneity. We downgraded the
evidence in the ’Summary of findings’ tables mostly because of the
risks of bias in the studies mentioned above, and the imprecision
of the results due to wide confidence intervals.
Potential biases in the review process
We tried to identify all relevant trials in our search strategy. It is,
however, possible that we may not have identified all studies. We
are also aware the search date is old at time of publication and
there may be new studies available.
The extraction of data and the risk of bias assessments for the Chi-
nese language studies were completed by only one review author.
There is the possibility that this may have introduced some bias
into the results, as it was not possible to cross-check these data.
Agreements and disagreements with other
studies or reviews
Previous research has found that TMS can significantly reduce
symptoms of schizophrenia. However, not all studies have subse-
quently replicated these findings. This was also reflected in the
findings of the current review, as although there was some evi-
dence to support the benefit of TMS in schizophrenia, findings
were inconsistent across measures.
This review concluded that there was limited evidence for tem-
poroparietal TMS as superior to sham TMS in improving audi-
tory hallucinations; two meta-analyses of sham-controlled studies
are in agreement with this finding, both concluding that there was
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a large and significant effect size for improving auditory halluci-
nations (Freitas 2009; Matheson 2010a). This review found lim-
ited evidence that temporoparietal TMS is superior to sham TMS
for improving positive symptoms when measured on the PANSS
scale; ameta-analysis of sham-controlled studies was in agreement,
finding a large and significant effect size (Freitas 2009).
Limited evidence that prefrontal TMS is superior to sham in im-
proving negative symptoms has also been reported elsewhere in
two meta-analyses (Dlabac-de Lange 2010; Freitas 2009), the for-
mer finding a statistically significant improvement in an analysis
of both PANSS and SANS, and the latter finding a non-signifi-
cant small effect size for negative symptoms. Further agreement
that prefrontal TMS can be effective in improving negative symp-
toms has been reached in a follow-up communication to a review
(Matheson 2010b).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
At present there is not strong evidence to support the use of TMS
(temporoparietal or prefrontal) to treat or manage symptoms of
schizophrenia. There was some evidence that TMS may help re-
duce some symptoms (such as auditory hallucinations and nega-
tive symptoms, which include apathy), compared to sham TMS,
although the results were unclear and the findings were not the
same across all of the small studies identified in the review. More-
over, very few studies compared TMS with standard treatments,
including antipsychotic drugs such as clozapine that are often used
when troublesome symptoms persist. However, in the future once
more high-quality studies have been conducted, there is a possi-
bility that TMS may be useful for treating and managing some
symptoms of schizophrenia in addition to usual care.
2. For clinicians
Based on this review, we can make no recommendations for the
use of TMS to treat symptoms of schizophrenia. The review found
that temporoparietal TMS may help reduce auditory hallucina-
tions and positive symptoms of schizophrenia, and that prefrontal
TMS helps to reduce some negative symptoms of schizophrenia.
However, any significant results were not consistent across various
symptom measures, and there were a limited number of studies
for each finding. Although the evidence does not support the use
of TMS as a treatment option at present, further research with
consistent protocols may lead to the development of an effective
procedure for its use in future practice.
3. For managers/policy makers
Findings from this review do not provide robust data to support
the use of TMS in clinical practice for schizophrenia. However
there was a suggestion that TMS may improve some symptoms of
schizophrenia, although this was equivocal. Future research that
uses routine protocols for both TMS and sham treatment proce-
dures should therefore be supported where possible.
Implications for research
1. General
There are 18 studies currently ongoing, which plan to include 790
participants, and all but one compare TMS to sham TMS. Future
studies should aim to adhere to more standardised procedures for
both TMS and sham protocols. However, given the range of pro-
cedures in the included and ongoing studies, it appears that we
are still at an exploratory stage and no clear evidence-based pro-
tocol has emerged. Research should aim for the use of standard-
ised outcomes and measures with which to analyse findings, with
publication of analysis protocols before completion of the study
itself. This would improve comparability of results across studies
and provide a clearer insight into the potential benefits of TMS.
2. Specific
2.1 More studies
In order to clarify some of the findings presented in this review,
we require further research to investigate the possibility of TMS
as a viable treatment option for schizophrenia. Research should
specifically aim to identify which symptoms would benefit from
the technique and which methods could be most effective. This
will need both more high-quality studies and the recruitment of
samples with sufficient statistical power to address the primary
questions posed by the research teams.
2.2 Duration
There should be standardised procedures in terms of study du-
ration in order to improve compatibility of findings. Although
we acknowledge that there are difficulties about adherence for the
participant group, research should aim to be more consistent to
allow a greater basis for comparison and to extend the clinical data
collection period beyond the duration of the treatment phase it-
self, so as to assess the sustainability of any observed effect.
2.3 Sham protocol
The protocol for sham treatment should be standardised to reduce
variation and ensure that the control condition refers to a similar
procedure across research. Efforts should be made to ensure that
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the experience of the treatment procedure using the sham proto-
col is indistinguishable from the active intervention, to improve
blinding of participants and their carers.
2.4 Intervention protocol
For both temporoparietal and prefrontal TMS, a consistent proto-
col in relation to stimulation intensity, length of stimulation, and
location of treatment should be developed. This would reduce the
large variation in procedures and greatly improve the comparabil-
ity of findings.
2.5 Randomisation
There should be clear reporting of study design, in particular the
methods to guarantee allocation concealment and double-blind-
ing, to provide comprehensive information on study procedures
which can be compared. There should be good-quality blinding
at allocation, to reduce any risk of selection bias.
2.6 Outcome measures
Research should aim to provide consistency of outcome measures
for both the type of measure (e.g. endpoint or change score) and
the scales used. Comparison of findings is greatly hindered by dif-
ferences in outcome measures, and consistency in this area would
provide a stronger basis for informed conclusions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bagati 2009
Methods Allocation: randomised
Blinding: assessor blind
Duration: 2 weeks
Design: parallel
Setting: inpatients and outpatients
Country: India
Participants Diagnosis: schizophrenia (ICD-10 criteria)
N = 40
Age: rTMS group mean 29.40 years (SD = 7.32); control group mean 7.25 years (SD =
9.79)
Sex: M 36, F 4
History: Auditory Hallucinations Rating Scale (AHRS) score > 20, duration of illness
in the active group 5.36 years and in the control group, 4.35 years
Interventions 1. TMS: Low-frequency rTMS to the left temporoparietal region at the centre of T3T4,
1 Hz and 90% motor threshold, 10 sessions 5 days per week for 2 weeks, 2400 pulses/
sessions, 60 trains, 2 sec stimulation, 28 sec inter-train interval. Add on to conventional
antipsychotic treatment (N = 20)
2. Control: Antipsychotics only (N = 20)
Both groups received FGAs and SGAs
Outcomes Adverse events: leaving the study early
Unable to use -
Global state: CGI (no data reported)
Mental state: PANSS (no data reported), AHSR (skewed data)
Notes Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation by coin-toss method
Allocation concealment (selection bias) Unclear risk Allocation concealment procedures not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The patients receiving rTMS were not
blind to the procedure”, blinding of per-
sonnel not reported
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Bagati 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The rater was blind to the procedure.
The ratings and the rTMS application were
done by different individuals so as to pre-
vent the bias”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not reported
Selective reporting (reporting bias) High risk The study does not report all outcomes:
PANSS, CGI
Other bias Unclear risk Insufficient information. Source of funding
not reported
Barr 2013
Methods Allocation: randomised
Blinding: double-blind
Duration: 6 weeks
Design: parallel
Setting: not reported
Country: Canada
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 33 (25 completed)
Age: TMS group mean 41.15 (SD 12.01); sham group mean 49 (SD 12.42)
Sex: M 17, F 8*
History: score of 85 or below on the Repeated Battery for the assessment of Neuropsy-
chological Status
Interventions 1. TMS: bilateral MRI-guided rTMS in the dorsolateral prefrontal cortex (DLPFC) at
20 Hz, 90% resting motor threshold for 25 trains, 30 pulses/train, inter-train interval
of 30 sec, 20 sessions (5 days/week for 4 weeks) (N = 16)
2. Sham: at the same parameters with the coil held in a single wing-tilt position at 90º to
induce similar somatic sensations as in the active stimulation with minimal direct brain
effects (N = 17)
Both groups received FGAs and SGAs
Outcomes Mental state: PANSS, SANS, CDS
Unable to use -
Cognitive state: n-back performance (skewed data)
Notes The randomised clinical trial is ongoing, only pilot data reported
N is different for Mental state and Cognitive state outcomes as the trial was at an earlier
stage when the mental state outcomes were reported (N = 31)
Source of funding: Canadian Institutes of Health Research (CIHR) CIHR Operating
Grant, CIHR Post-Doctoral Award, Operating and Studentship Award from theOntario
Mental Health Foundation, National Health andMedical Research Council (NHMRC)
48Transcranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Barr 2013 (Continued)
Practitioner Fellowship (PBF), Brain and Behaviour Research Foundation Young Inves-
tigator award, the Grant Family through the Centre for Addiction and Mental Health
(CAMH) Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, “computer-gener-
ated random number sequence”
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, no further details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors “were blind to treat-
ment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 schizophrenic participants did not com-
plete the study (3 in the active and 3 in the
sham group)
Selective reporting (reporting bias) Low risk All outcomes are reported
Other bias Low risk None detected
Blumberger 2012
Methods Allocation: randomised
Blinding: double-blind
Duration: 8 weeks
Design: parallel
Setting: not reported
Country: Canada
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV criteria)
N = 51
Age: rTMS groupmean 36.6 (SD 8.2); priming groupmean 43.8 (SD11.7); sham group
mean 40.8 (SD12.1)
Sex: not reported
History: moderate severity on item 3 of the positive subscale of PANSS, medication
resistance dened as daily auditory hallucinations
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Blumberger 2012 (Continued)
Interventions 1. TMS: MRI-guided left-sided rTMS (LFL) to the temporoparietal cortex (TPC), at
an intensity of 115% RMT for 20 min, 20 trains with an inter-train interval of 25 secs.
20 sessions (5 days/week for 4 weeks) (N = 17)
2. Priming TMS: (6 Hz followed by 1 Hz rTMS), 10 min of 6 Hz (20 5 second trains
with 25 second inter-train interval) at 90%RMT followed by 10min of 1Hz stimulation
at 115% RMT, a total of 20 min of stimulation, 20 sessions (5 days/week for 4 weeks)
(N = 17)
3. Sham: identical parameters to those for the LFL condition but with the coil angled
at 90º off the scalp in a single wing-tilt position, 1 Hz for 20 min, 20 sessions (5 days/
week for 4 weeks) (N = 17)
Stimulation site: Heschl’s gyrus
Both groups received FGAs and SGAs
Outcomes Mental state: PSYRATS hallucinations subscale, PSYRATS, PANSS, HCS, AHRS
Cognitive state: RBANS
Notes Data from the 2 TMS groups were combined in the analyses
N not reported for RBANS data - assumed to be 14 for rTMS, 13 for priming TMS
and 13 for sham TMS
Source of funding: Ontario Mental Health Foundation (OMHF), Canadian Institutes
of Health Research (CIHR) Clinician Scientist Award, CIHR Fellowship, by a National
Health and Medical Research Council (NHMRC) Practitioner Fellowship and by Con-
stance and Stephen Lieber through a National Alliance for Research on Schizophrenia
and Depression (NARSAD) Lieber Young Investigator award
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” no further details reported
Allocation concealment (selection bias) Unclear risk “Randomised” no further details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Subjects ... were blind to randomization
group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical raters were blind to randomiza-
tion group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The analysis was conducted on an inten-
tion-to-treat basis. A completer analysiswas
also conducted.”
There were 3 losses to follow-up in the
rTMS group, 4 in the priming group and
4 in the sham control group. “Subjects re-
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Blumberger 2012 (Continued)
ported lack of perceived benefit and inabil-
ity to attend appointments as reasons for
discontinuation. One subject was hospi-
talised due to hyponatremia and could not
complete the study protocol.”
Selective reporting (reporting bias) Low risk All outcomes were reported
Other bias Low risk None detected
Brunelin 2006
Methods Allocation: randomised
Blindness: double-blind
Duration: 5 days
Design: parallel
Setting: not reported
Country: France
Participants Diagnosis: schizophrenia (DSM-IV)
N = 24
Age: average 34.5 years
Sex: not reported
History: antipsychotic medication-resistant auditory hallucinations
Interventions 1. TMS: left temporoparietal rTMS, 1 Hz at 90% of motor threshold, 10 sessions over
5 days (2 treatments of 1000 stimulations per day) (N = 14)
2. Sham: Simulation was as for active TMS but with a sham coil designed to produce
an identical sound. (N = 10)
Not reported whether antipsychotics were used
Outcomes Mental state: AHRS, SAPS
Cognitive state: Source memory task
Notes Source of funding: Conseil Scientifique de la Recherche, CH “Le Vinatier”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly allocated” - no further details
provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The protocol was carried out under dou-
ble blind condition.”
“Ten patients received sham rTMS stimu-
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Brunelin 2006 (Continued)
lations given at the same location, strength
and frequency with a placebo-coil indistin-
guishable to the active coil. The placebo
coil and its active counterpart look identi-
cal and produce an identical sound without
superficial scalp stimulation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Cognitive and clinical evaluationswere as-
sessed by a blinded investigator.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study did not report on losses to fol-
low-up
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk None detected
Chen 2011
Methods Allocation: randomised
Blinding: double-blind
Duration: 4 weeks
Design: parallel
Setting: inpatients
Country: China
Participants Diagnosis: schizophrenia (DSM-IV)
N = 46
Age: 23 - 55, mean 37.4 (SD 1.8)
Sex: M 27, F 15 (Gender is reported only for completed patients. 42 patients completed
the trial: Intervention N = 23, control N = 19)
History: PANSS negative subscale score ≥ 20; stable medication regimen
Interventions 1. TMS: left DLPFC rTMS, intermittent theta burst stimulation pattern 50 Hz at 80%
of motor threshold, 2400 pulses over 22 minutes. 4 weeks, 5 days/week, total 20 sessions
(N = 24)
2. Sham: Simulation was as for active TMS but coil designed to produce an identical
sound without magnets being activated (N = 22)
Both groups received FGAs and SGAs
Outcomes Mental state: PANSS
Not used in the review -
EEM (Exploratory Eye Movements): Number of eye fixations, Responsive search score,
Discriminant (D) score
Notes Source of funding: National High Tech Research and Development (863 Program of
China; the Natural Science Foundation of China; the Janssen Science Foundation; and
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the Shanghai Science Committee Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible subjects were randomized to
rTMS therapy or sham rTMS therapy
based on a computerized algorithm”
Allocation concealment (selection bias) Unclear risk “Provided to the rTMS technician the first
time the patient entered the rTMS treat-
ment room.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The technician who conducted the EEM
tests was blind to the treatment status of
the patients.”
“The evaluating researchers were blind to
the treatment status and EEM results of the
subject they evaluated”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Four subjects dropped out in the first week
of the trial : 1 patient from the intervention
group refused to continue rTMSbecause of
transient headaches during the treatment
sessions, 2 control group subjects were dis-
charged from the hospital by the ir fam-
ily members for reasons unrelated to the
rTMS treatment and one control group
subject stopped because of an exacerba-
tion of hallucinations and delusions that re-
quired changing his medication regimen.”
Selective reporting (reporting bias) Low risk All outcomes have been reported
Other bias Low risk None detected
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Cordes 2010
Methods Allocation: randomised
Blinding: double-blind
Duration: 2 weeks
Design: parallel
Setting: inpatients
Country: Germany
Participants Diagnosis: schizophrenia (DSM-IV)
N = 32
Age: TMS group mean 34.3 (SD 9.7); sham group mean 34.4 (SD 10.5)
Sex: M 25, F 7
History: at least 3 episodes documented in their medical history
Interventions 1. TMS: 10 Hz rTMS applied over the left dorsolateral prefrontal cortex (LDPC) for 10
times during 2 weeks (5 days/week for 2 weeks), 1000 stimuli applied at a frequency of
10 Hz during 20 trains, 5sec/train, stimulation intensity 110% of the motor threshold
(N = 18)
2. Sham: conducted in a similar manner by using a sham coil system without induction
of a magnetic field (N = 14)
Both groups received FGAs and SGAs
Outcomes Global state: CGI
Mental state: PANSS
General functioning: GAF
Adverse events: UKU side effect rating scale
Unable to use -
Adverse events: headaches (not reported)
Notes Source of funding: Technical support was provided by MedTronic
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Block-wise randomisation (active rTMS
to shamgroup relation4:3)”, further details
not reported
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Study participants...and all personnel re-
sponsible for the clinical care of the patients
remained blind to the allocated treatment
conditions.” Details of blinding procedure
not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical raters ... remained blind to the
allocated treatment conditions”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 35 participants were randomised, 3 (2 in
the TMS group and 1 in the sham group)
refused to participate after randomisation.
All participants receiving allocated inter-
vention completed the study andwere anal-
ysed
Selective reporting (reporting bias) Low risk All outcomes are reported
Other bias Low risk “The funding source had no involvement
in study design, in collection, analysis, in-
terpretation of data, writing of the report
and in the decision to submit the paper for
publication”
De Jesus 2011
Methods Allocation: randomised
Blinding: double blind
Duration: 4 weeks
Design: parallel
Setting: not reported
Country: Brazil
Participants Diagnosis: schizophrenia (OPCRIT 4.0 criteria)
N = 17
Age: TMS group mean 46 (SD 9.84); sham group mean 36.5 (SD 6.36)
Sex: M 12, F 5
History: Refractory schizophrenia with daily AHs at least 5 times/day despite treatment
with a stable dose of ≥ 400 mg/day of clozapine for a period longer than 4 months and
≥ 2 adequate trials of antipsychotic medications in the past, including ≥ 1 SGA drug
other than clozapine, BPRS score of ≥ 27
Interventions 1. TMS: stimulation administered to the LTPC using 10 - 20 EEG electrode position
system, 1 Hz at 90% of the motor threshold, 8 min of stimulation on day 1, 16 min
on day 2, and 20 min for the next 18 days, a total of 20 sessions, (5 sessions/week for 4
weeks (N = 8)
2. Sham: using the same coil at 45° angle with stimulation intensity reduced to 80% of
MT (N = 9)
Both groups also received clozapine
Outcomes Global state: CGI, FAST
Mental state: BPRS, AHRS
Quality of life: QLS
Notes After the completion of the study, participants randomised to the sham condition were
offered active rTMS utilising the same parameters
Source of funding: Fundo de Incentivo a Pesquisa (FIPE) from Hospital de Clinicas de
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Porto Alegre, UFRGS (Project No. 06382), Neuro-MS magnetic stimulator donated by
Gerdau S.A
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly allocated”, allocation conceal-
ment method reported, assume that the
randomisation procedure is adequate
Allocation concealment (selection bias) Low risk “Sequentially-Numbered, Opaque, Sealed
Envelopes (SNOSE)”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Study participants ... and all personnel re-
sponsible for the clinical care of the pa-
tient remained masked to allocated condi-
tion and allocation parameters.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical raters ... remainedmasked to allo-
cated condition and allocation parameters.
”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants randomised and
number lost to follow-up not reported
Selective reporting (reporting bias) Unclear risk Not all outcomes reported: mean and SD
not reported forQLS and FAST.Outcomes
covered benefit and harm
Other bias Low risk None detected
Fitzgerald 2005
Methods Allocation: randomised
Blindness: double-blind
Duration: 2 weeks
Design: parallel
Setting: patients from 2 mental health services and several referring psychiatrists
Country: Australia
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 33
Age: not reported
Sex: not reported
History: failed to respond to aminimum of 2 adequate trials of antipsychotic medication,
experiencing auditory hallucinations
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Interventions 1. TMS: left temporoparietal TMS, 15 minutes at 1Hz, 90% above motor threshold,
10 sessions over 2 weeks (daily basis 5 days each week) (N = 17)
2. Sham: Simulation was as for active TMS but with the coil angled away at 45º from 1
side of 1 wing of the coil (N = 16)
Both groups received FGAs and SGAs
Outcomes Mental state: HCS, PANSS positive and hallucinations
Adverse events: leaving the study early
Unable to use -
Mental state: PSYRATS hallucination sub-scale (total scores not reported)
Global state: GAF (no mean and SD)
Cognitive state: Hopkins Verbal Learning Test immediate recall (no mean and SD)
Notes Source of funding:The StanleyMedical Research Institute andbyConstance andStephen
Lieber through a NARSAD Lieber Young Investigator award (PF)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details given
Allocation concealment (selection bias) Low risk Sealed envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The patients and raters were blind to treat-
ment but the clinician administering rTMS
was aware of the treatment group”, “Sham
stimulation was provided with the coil an-
gled away from the scalp at 45 degrees from
the side of one wing of the coil”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Raters were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One patient withdrew consent prior to
commencement of treatment. Thirty of the
32 subjects completed 2 weeks of double-
blind treatment: 2 patients (both in the
sham group) were withdrawn in the second
week due to a deterioration in mental state,
one who stopped antipsychotic medication
after 7 days of the trial. Both received an as-
sessment after 5 days of treatment and these
data were carried forward in the analysis.”
Selective reporting (reporting bias) High risk Not all outcomes fully reported
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Other bias Low risk None detected.
Fitzgerald 2008
Methods Allocation: randomised
Blindness: double-blind
Duration: 3 weeks
Design: parallel
Setting: outpatients from 2 public area mental health services and referral from private
psychiatrists
Country: Australia
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 20
Age: average 35.6 years
Sex: M 16, F 4
History: failed to respond to a minimum of 2 adequate trials of antipsychotic medication
+ persistent negative symptoms of moderate-to-severe intensity (SANS total score > 50)
Interventions 1.TMS: bilateral prefrontal rTMS, 10Hz, 110%abovemotor threshold, 20 trains to each
hemisphere of 5 seconds each with 25 second gap (1000 stimulations per hemisphere per
day, 20 trains/hemisphere, 5 sec/train, inter-train interval 55 sec), left-sided stimulation
always provided first, 15 sessions of treatment on daily basis 5 days per week (N = 10)
2. Sham: stimulation as for active TMS but with side edge resting on scalp at 90º (N =
10)
Both groups received SGAs, except one participant in the TMS group who received FGA
Outcomes Mental state: PANSS negative, SANS
Adverse effects: headache, TMS-related sit discomfort, leaving the study early
Unable to use -
Mental state: PANSS positive, CDRS (skewed data)
Cognitive state: Stroop test, the controlled oral word association test, and trail making
A&B (no data reported)
Notes Source of funding: Practitioner Fellowship grant from the National Health and Medical
Research Council (NHMRC), by NARSADYoung Investigator awards, a grant from the
Marian & E. H. Flack Trust, a NHMRC project grant (436710), and the Neurosciences
AustraliaClinicalNeurobiology of Psychiatry Platform.Also received support for research
conducted with Neuronetics Inc, a TMS equipment manufacturer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using random number se-
quence
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Fitzgerald 2008 (Continued)
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The patients and raters were blind to
treatment, but the clinician administering
rTMS was aware of the treatment group.”
“Sham stimulation was provided at the site
of active treatment but with only the side
edge resting on the scalp at 90 degrees.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All assessments were performed by a
blinded rater.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “All analyses were conducted on an inten-
tion to treat basis with the last observation
carried forward.”
Selective reporting (reporting bias) High risk Not all outcomes reported - no data for
cognitive measures
Other bias Unclear risk Role ofNeuronetics Inc in design, conduct,
reporting of study is not clear
Gao 2009a
Methods Allocation: randomised
Blindness: double-blind
Duration: 2 weeks
Design: parallel
Setting: inpatients
Country: China
Participants Diagnosis: schizophrenia (CCMD-3)
N = 46
Age: TMS mean 36.1 years (SD 13), Sham group mean 35 years (SD 12)
Sex: M 39, F 7
History: length of illness 2 to 30 years, accepted at least 2 kinds of antipsychotic drugs
with sufficient dose treatment, consistent dose of antipsychotic medication use for more
than 4 weeks at present, hallucinations for more than 6 months
Interventions 1. TMS: left temporal and parietal lobes rTMS, 1 Hz at 80% motor threshold, stimu-
lating for 90 sec, 30 sec interval, repeat for 10 times/day, 5 times/week for 2 weeks (N
= 23)
2. Sham: coil plane 90º to the scalp, stimulation as for active TMS (N = 23)
All received antipsychotics, type not reported
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Outcomes Global state: CGI
Adverse events: TESS, headache
Unable to use -
Mental state: PANSS (no mean and SD)
Notes In Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but untested
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double- blind, but untested
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported
Selective reporting (reporting bias) High risk Detailed results of PANSS is not reported
except P > 0.05
Other bias Unclear risk Insufficient information. Source of funding
not reported
Gao 2009b
Methods Allocation: randomised
Blinding: assessor blind
Duration: 5 days
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (CCMD-3)
N = 43
Age: 19 - 65, mean ~34.5
Sex: M 43
History: duration of illness 2 - 20 years
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Interventions 1. TMS: leftDLPFC rTMS, 10Hz at 100%motor threshold, 20 sequential stimulation/
day, stimulation for 5 sec, 35 sec interval, total 1000/day. 5 sessions for 5 days (N = 21)
2. Sham: coil plane 45º to the scalp (N = 22)
All participants received risperidone
Outcomes Mental state: PANSS, HAMD
Adverse events
Not used in review -
Prolactin, event-related potential P300, EEG
Notes In Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table used
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
Selective reporting (reporting bias) Low risk All measured outcomes were reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
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Gao 2009c
Methods Allocation: randomised
Blinding: double-blind
Duration: 4 weeks
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia
N = 42
Age: 36 ± 6 years
Sex: M 37, F 5
History: chronic auditory hallucinations
Interventions 1. TMS: left prefrontal dorsolateral area rTMS, 15 Hz at 90% motor threshold, pulse
count 2 sec/train, 28 sec interval, 60 train/day, 5 times/week for 4 weeks (N = 21)
2. Sham: coil plane 90º to the scalp (N = 21)
All participants received a consistent dose of antipsychotics, type not reported
Outcomes Mental state: PANSS negative, HAMD-17
Adverse events: TESS
Unable to use -
Mental state: other PANSS subscales, HAMD-17 (no mean and SD)
Notes In Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
Selective reporting (reporting bias) High risk PANSS subscale score and HAMD17 were
measured, but only reported P value > 0.
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05 (5)
Other bias Unclear risk Insufficient information. Source of funding
not reported
Gao 2010
Methods Allocation: randomised
Blinding: double-blind
Duration: 2 weeks
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (CCMD-3)
N = 42
Age: 29 ± 5 years
Sex: M 38, F 4
History: refractory auditory hallucinations
Interventions 1. TMS: left temporal and parietal lobes rTMS, 1 Hz at 80% motor threshold, pulse
count 90 sec/train, 30 sec interval, 10 train/day, 10 times for 2 weeks (N=21)
2. Sham: coil plane 90º to the scalp (N = 21)
All participants received a consistent dose of antipsychotics, type not reported
Outcomes Mental state: PANSS
Adverse events: headache
Notes In Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further detail
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further detail
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear if all participants completed
treatment.
Selective reporting (reporting bias) Low risk All the outcomes were fully reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
Guse 2013
Methods Allocation: randomised
Blinding: double-blind
Duration: 15 weeks (3 weeks with verum or sham rTMS, and a 12-week follow-up
phase)
Design: parallel
Setting: inpatients and outpatients
Country: Germany
Participants Diagnosis: schizophrenia (ICD 10)
N = 25
Age: mean 36 years, range 20 - 58
Sex: M 19, F 6
History: predominant negative symptoms (> 20 PANSS)
Interventions 1. rTMS: 3 weeks treatment with 5 sessions per week of the left DLPFC (LDLPFC)
, 10 Hz rTMS, stimulation intensity 110% related to the individual resting motor
threshold, 1000 stimuli per session, inter-train interval 30 sec, in total 15,000 stimuli
per participant, coil position guided by the 10 - 20 EEG system over (N = 13)
2. Sham: 3 weeks treatment with 5 sessions per week, stimulation parameters identical
to the treatment group but magnetic coil 45º away from the skull (N = 12)
All participants received SGAs
Outcomes Global state: CGI, GAF
Cogntive state: n-back working memory tasks, Trail Making Test (TMT-A/B), Tabinger
Aufmerksamkeitsprung (TAP), WCST
Unable to use-
Mental state: PANSS, MADRS, CDSS (data not reported)
Notes Trial registration: clinicaltrials.gov NCT00783120
Source of funding: German Research Foundation (DFG: grant FA 241/10-1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated multi-block ran-
domization schedule generated at the coor-
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dination centre for clinical trials”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Rater, investigators and patients were
blind across all parts of the study”, sham
coil at same position with“one wing angu-
lated 45º away from the skull”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Rater, investigators and patients were
blind across all parts of the study.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported
Selective reporting (reporting bias) High risk Data for mental state outcomes not re-
ported
Other bias Low risk None detected
Hao 2008
Methods Allocation: randomised
Blinding: double-blind
Duration: 4 weeks
Design: parallel
Setting: inpatients
Country: China
Participants Diagnosis: schizophrenia (CCMD-3)
N = 25
Age: TMS group mean 34.46 (SD 12.99) years, control group mean 32.42 years (SD 8.
18)
Sex: M 20, F 5
History: mean length of illness TMS group ~5years, control group ~8years
Interventions 1. TMS: left temporal and parietal lobes rTMS, 10 Hz at 110% motor threshold; pulse
count: 30, 5 sec/pulse, 30 sec interval, total 1500, 20min/day; for 4 weeks ,5 treatments/
week, total 20 times (N = 13)
2. Sham: coil plane 180º to the scalp (N = 12)
All participants received SGAs
Outcomes Mental state: PANSS, SANS, SAPS, HAMD, SDS
Adverse events: TESS
Notes Article in Chinese
Source of funding: not reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants refused intervention because
of headache and dizziness, not reported
from which group
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
Hoffman 2005
Methods Allocation: randomised
Blindness: double-blind
Duration: 9 days
Design: parallel
Setting: unclear
Country: USA
Participants Diagnosis: schizophrenia or schizoaffective disorder
N = 24
Age: average 35.4 years
Sex: M 13, F 11
History: medication resistant auditory hallucinations
Interventions 1. TMS: left temporoparietal rTMS using 10 - 20 EEG electrode position system, 1 Hz,
90% above motor threshold, 10 second gaps between stimulations, 8 minutes on day 1,
12 on Day 2, 16 minutes for next 7 days (N = 12)
2. Sham: as for active treatment but sham stimulation at 45º single-wing tilt (N = 12)
Participants received steady psychotropic medication for duration of trial, details not
reported
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Outcomes Global state: CGI
Mental state: PANSS positive and negative
Adverse effects: headaches, lightheadedness, cognitive difficulties
Notes Source of funding: grant RR00125 from the National institutes of Health, National
Center for Research Resources, General Clinical Research Centers Program, Bethesda,
Md
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using coin toss
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Sham simulation was administered at the
same location, strength, and frequency
with the coil angled 45 degrees away from
the skull in a single-wing tilt position. This
method reproduces sound and some so-
matic sensations (e.g., contraction of scalp
muscles) similar to those of active simula-
tion with minimal brain effects.”
“Knowledge of intervention type was ex-
clusive to the psychiatrists administering
rTMS and a research technician assist-
ing the procedure. Their interactions with
the patients once the trial was underway
was limited to administration of rTMS
and assessment of safety and tolerability of
the procedure. Study participants, clinical
raters, and all personnel responsible for the
clinical care of the participants remained
blind to allocated condition and allocation
parameters.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Raters were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A patient in the sham group withdrew
from the study because of absence of clini-
cal improvement, and second patient in the
sham group was removed by clinical staff
because of clinical worsening. A patient in
the active double-blind group was removed
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from the study because of ischemic chest
pain.” Data were analysed using an inten-
tion-to-treat-analysis
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None detected
Holi 2004
Methods Allocation: randomised
Blindness: double-blind
Duration: 2 weeks
Design: parallel
Setting: inpatients
Country: Finland
Participants Diagnosis: schizophrenia (DSM-IV)
N = 22
Age: average 36.7 years
Sex: M 19, F 3
History: chronic inpatients, mean duration of current hospitalisation 4.4 years, mean
duration of illness 13.2 years
Interventions 1. TMS: left prefrontal rTMS, 10 Hz, 100% of motor threshold, 20 trains of 5 seconds
each with 30 seconds gap, sessions over 10 days, treatment given over 2 weeks in 10
separate treatment sessions (N = 11)
2. Sham: as for active treatment but with coil held at 90º to scalp with both wings
touching (N = 11)
Both groups received SGAs, except 1 participant in the TMS group who received FGA
Outcomes Global state: SCL-90 GSI
Mental state: PANSS positive, negative, total, SCL-90 DEP (depression) and PSY (psy-
choticism)
Adverse events: headache, pain, leaving the study early
Unable to use -
Cognitive function: MMSE (no data reported)
Notes Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - no further details provided
Allocation concealment (selection bias) Low risk Sealed envelopes
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” “In the sham condition,
the coil was held at 90 degrees to the scalp
with both wings touching the scalp”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Psychiatrists blind to the treatment groups
assessed symptoms at baseline and at the
end of 2 weeks’ rTMS”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One patient dropped out because of para-
noid thoughts about the treatment. The
sham group dropout had received 5 days
of treatment and could be rated at the end
of the 2-week period, whereas the rTMS
dropout stopped the trial during the first
session and refused further ratings”
“Intention to treat analysis was used”
Selective reporting (reporting bias) High risk Not all outcomes reported - no data for
MMSE
Other bias Unclear risk Source of funding not reported
Klein 1999
Methods Allocation: randomised
Blindness: double-blind
Duration: 2 weeks
Design: parallel
Setting: inpatients
Country: Israel
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 35
Age: average 29.9 years
Sex: M 22, F 13
History: non-chronic (mean number of 1.7 hospitalisations) with no history of treatment
refractoriness, mean duration of illness 7.9 years
Interventions 1. TMS: right prefrontal rTMS, 1 Hz, 10% above threshold, 10 sessions over 10 days,
each included 2 x 1 min treatments with 3 min gap (N = 18)
2. Sham TMS: coil perpendicular to scalp, otherwise identical to active TMS (N = 17)
All participants were on antipsychotic medications prior to entering the study, did not
change their medications for the duration of the trial, type not reported
Outcomes Global state: CGI
Mental state: PANSS, BPRS, HDRS
Adverse effects: facial twitches, headache, akathisia, worsening of OCD, subjective cog-
nitive complaints, AIMS
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Notes Source of funding: Stanley Foundation, NAMI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - no further details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Stimulationparameters for the sham treat-
ment group were the same except that the
stimulation coil was placed perpendicular
to the scalp surface, thus minimizing cur-
rent flow into the skull”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The ratings were performed by a psychia-
trist who was blind to the nature of treat-
ment and who avoided asking the patients
questions that could disclose their group
assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Thirty-one patients (16 rTMS and 15
sham) completed the 2-week treatment
protocol. Four patients (2 rTMS and 2
sham) withdrew after three to five sessions
for clinical reasons. Twenty-five (13 rTMS
and 12 sham) of these 31 subjects were
available for follow-up assessment 1 and 4
weeks after treatment completion.”
Selective reporting (reporting bias) High risk CGI reported in results but not mentioned
in methods. Data measured at 1 week, 2
weeks (end of treatment) and 4 weeks, but
only reported for end of treatment
Other bias Low risk None detected
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Klirova 2010
Methods Allocation: randomised
Blinding: double-blind
Duration: 2 weeks
Design: parallel
Setting: not reported
Country: Czech Republic
Participants Diagnosis: schizophrenia (DSM-IV)
N = 30
Age: not reported
Sex: not reported
History: paranoid schizophrenia, medication-resistant auditory hallucinations, stable on
antipsychotic medication ≥ 4 weeks
Interventions 1. Neuronavigated TMS: rTMS coil focused over the highest contrast of metabolic
activity in the left temporoparietal area (according to the SPM analysed 18FDG PET
data), at 0.9 Hz of 100% motor threshold, 10 sessions over 2 weeks, 1080 pulses/each
session (N = 10)
2. TMS: rTMS coil administered over the left temporoparietal region using 10/20 EEG
electrode system, at 0.9 Hz of 100% motor threshold, 10 sessions over 2 weeks, 1080
pulses/each session (N = 10)
3. Sham: coil angled 90º away from the skull (N = 10)
Patients were on a stable dose of antipsychotic medication for at least 4 weeks, type not
reported
Outcomes Mental state: PANSS, AHRS
Notes Data were combined for theTMS groups
Source of funding: “Supported by the CNPS, VZ 00 216 208 16,CNS, MZCR
MZPCP2005 and MSMT 1M0517”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, details of method not re-
ported
Allocation concealment (selection bias) Unclear risk Method not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “double blind”. Details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “double blind”. Details not reported
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Klirova 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not reported
Selective reporting (reporting bias) Unclear risk Outcome data for AHRS not fully reported
Other bias Unclear risk Role of the funding source was unclear
Lee 2005
Methods Allocation: randomised
Blindness: double-blind
Duration: 10 days
Design: parallel
Setting: unclear
Country: Korea
Participants Diagnosis: schizophrenia (DSM-IV)
N = 39
Age: average 40.3 years
Sex: M 16, F 23
History: medication resistant auditory hallucinations, mean number previous hospital-
isations 4
Interventions 1. TMS: left temporoparietal rTMS, 1 Hz, at motor threshold, 10 sessions over 10 days,
each of 20 minutes duration (N = 13)
2. TMS: right temporoparietal rTMS delivered using same parameters but to midpoint
between T4 and P4 (N = 12)
3. Sham: coil perpendicular to scalp with 1 wing touching, otherwise identical to active
TMS (N = 14)
Not reported whether antipsychotics were used
Outcomes Global state: CGI
Mental state: PANSS
Adverse effects: twitches, headache, amnesia
Unable to use -
Mental state: AHRS (total scores not reported)
Notes Data were combined for the 2 TMS groups: “either temporoparietal cortex significantly
reduces the symptoms in
patients with schizophrenia who are having refractory auditory hallucinations, but the
left sided rTMS is not superior to right or sham rTMS”
Source of funding: grant No. R01-2003-000-10432-0 from the Basic Research Program
of the Korea Science & Engineering Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
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Lee 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Randomised” - no further details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The sham group received identical rTMS
treatment as the group receiving real rTMS,
but we raised the lateral wing of the coil 90
degrees off the head with the edge of the
medial wing of the coil still touching the
scalp”
“rTMS was administered each day by a
trained psychiatrist who purposefully had
very limited verbal interaction with the
subject”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical assessmentswere conducted by an
independent investigator who was blind to
the stimulation condition”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study does not address this outcome
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None detected
Liu 2008
Methods Allocation: randomised
Blinding: not reported
Duration: 4 weeks
Design: parallel
Setting: inpatients
Country: China
Participants Diagnosis: schizophrenia (CCMD-3)
N = 23
Age: mean ~34 years
Sex: M 18, F 5
History: mean length of illness ~6 years
Interventions 1. TMS: left temporal and parietal lobe rTMS, 10 Hz at 110% motor threshold, pulse
count 30, 5 sec/pulse, 30 sec interval, total 1500, 20 min/day, 5 treatments/week for 4
weeks (N = 12)
2. Sham: coil plane 180º to the scalp (N = 11)
Both groups received SGAs
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Liu 2008 (Continued)
Outcomes Cognitive state: ANT, WCST
Adverse events: leaving the study early, headache
Notes Article in Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using random number table
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients (1 in rTMS group,1 in sham
rTMS group) refused intervention because
of headache. They were excluded from the
final analysis
Selective reporting (reporting bias) Low risk All the outcomes were reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
Liu 2011
Methods Allocation: randomised
Blinding: not reported
Duration: 6 weeks
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (DSM-IV)
N = 100
Age: 18 - 56, mean 32.84 (SD 7.3)
Sex: M 51, F 49
History: length of illness mean 8.44 years (SD 6.6)
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Liu 2011 (Continued)
Interventions 1. TMS: with 1st generation antipsychotics, rTMS to the left temporal and parietal lobes,
1 Hz at 80% motor frequency, pulse count 30, 20 sec interval, repeat for 40 times, total
1200/day, for 6 weeks 5 treatments/week for 0 - 2 weeks and 5 - 6 weeks, no therapy
during 3 - 4 weeks (N = 25)
2. TMS: with 2nd generation antipsychotics, rTMS to the left temporal and parietal
lobes, 1Hz at 80% motor frequency, pulse count 30, 20 sec interval, repeat for 40 times,
total 1200/day, for 6 weeks 5 tre atments/week for 0 - 2 weeks and 5 - 6 weeks, no
therapy during 3 - 4 weeks (N = 25)
3. 2nd generation antipsychotic drugs (N = 25)
4. 1st generation antipsychotic drugs (N = 25)
Not used - TMS: Healthy controls (N = 25)
Outcomes Global state: improvement on CGI
Unable to use -
Mental state: PANSS, adaption of the Miller auditory hallucinations scale (data not
reported)
Notes In Chinese
5 groups were included in the study: we combined data for the TMS groups and the
antipsychotics groups, and did not use data from healthy controls
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table used
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts, the number of participants
were reported and fully accounted for with
all assessments
Selective reporting (reporting bias) High risk PANSS, CGI-GI were measured, but no
score provided
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Liu 2011 (Continued)
Other bias Unclear risk Insufficient information. Source of funding
not reported
McIntosh 2004
Methods Allocation: randomised
Blindness: double-blind
Duration: 4 days
Design: cross-over
Setting: psychiatric hospital
Country: UK
Participants Diagnosis: schizophrenia and related disorders (DSM-IV)
N = 16
Age: average 35.9 years
Sex: M 7, F 9
History: inpatients and outpatients, medication-resistant auditory hallucinations of at
least 3 months duration
Interventions 1. TMS: left temporoparietal TMS using the 10 - 20 electrode placement system, 1 Hz,
at 80% motor threshold. For 4 days, duration: 4 mins on day 1, 8 mins day 2, 12 mins
day 3, 16 mins day 4, 15 sec gap between each sequential minute of treatment (N = 8)
2. Sham TMS: same as TMS, but with coil tilted by 45º (N = 8)
Both groups received FGAs and SGAs, people on clozapine excluded from trial
Outcomes Mental state: PANSS total, positive; visual analogue scale for hallucinations
Cognitive state: AVLT
Unable to use -
Mental state: PANSS negative, depressive and hallucinations (data skewed, median and
IQR reported)
Notes Data were used only for the 1st period of the cross-over; data provided by the authors
Source of funding: Stanley Medical Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using computer-generated
random numbers
Allocation concealment (selection bias) Low risk The randomisation code was held by a sin-
gle researcher with no clinical responsibili-
ties for the referred patients on his person
or in a locked filing cabinet
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McIntosh 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Sham TMS was administered over the
same point, tilting the coil to an angle of
45 degrees away from the skull.”
“Patients, their clinicians and nursing staff
were unaware of the group to which they
had been randomised.”
No details provided as to whether person-
nel administering the TMS were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The investigators rating treatment re-
sponse were also blind to group allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “No patient dropped out of the study”
Selective reporting (reporting bias) High risk Median and IQR reported for PANSS neg-
ative, depressive and hallucinations
Other bias Low risk None detected
Mogg 2005
Methods Allocation: randomised
Blindness: double-blind
Duration: 10 days over consecutive weekdays
Design: parallel
Setting: patients attending for treatment in South London hospital
Country: UK
Participants Diagnosis: schizophrenia (DSM-IV)
N = 17
Age: average 41.7 years
Sex: M 16, F 1
History: prominent negative symptoms (> 19 on PANSS scale) and at least 3 months of
stable drug treatment
Interventions 1. TMS: 10 Hz left prefrontal (DLPFC) rTMS at 110% motor threshold for 20 x 10-
second trains separated by 50 sec gaps (10 days) 4.15 sec gap between each sequential
minute of treatment (N = 8)
2. Sham: same as TMS, but with sham coil with identical appearance (N = 9)
Both groups received FGAs and SGAs
Outcomes Mental state: PANSS general, positive, negative
Cognitive state: Controlled oral word association test, Stroop, Hopkins Verbal Learning
Test, Grooved pegboard test
Adverse effects: CSSES, leaving the study early
Unable to use -
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Mogg 2005 (Continued)
Mental state: HADS anxiety, depression (skewed data)
Quality of life: Schizophrenia Quality of Life Scale (skewed data)
Notes Source of funding: 2003 Ritter independent Investigator Award from the National Al-
liance for research on Schizophrenia and Depression, the Guy’s and St Thomas’ Chari-
table Foundation (R01126), the NHS R&D National Coordinating Centre for Health
Technology Assessment (NCCHTA) (98/11/04), and the Psychiatry Research Trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - no further details provided
Allocation concealment (selection bias) Low risk “Allocation concealment was achieved by
using sequentially numbered sealed opaque
envelopes, opened just before the first treat-
ment session”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Sham rTMS was similarly given but using
a purpose-built sham coil that is identical
in appearance to the real coil andmakes the
same noise but does not deliver a substan-
tial stimulus”
“Only the research physicians administer-
ing rTMS knewwhether real or sham treat-
ment was being delivered while both pa-
tients and rater were blind to treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Raters were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Outcomes were analysed on an intention-
to-treat basis”
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None detected
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NCT00308997
Methods Allocation: randomised
Blinding: double-blind
Duration: 3 weeks
Design: parallel
Setting: not reported
Country: USA
Participants Diagnosis: Schizophrenia or schizoaffective disorder
N = 85 (83 completed)
Age: mean 35.8 (SD 10.7)
Sex: M 39, F 44
History: auditory hallucinations that occur ≥ 5 times/day on average
Interventions 1. TMS: Wernicke’s area and right homologous area MRI-guided rTMS, 1 Hz, 16 min/
day for 5 days, for week 1, same for week 2 with switch from right to left or left to right,
and 5 more stimulation sessions (16 minutes per session) to the side producing greater
benefit for week 3. (N = 56)
2. Sham: placebo stimulation, which feels similar to real rTMS but does not produce
direct brain effects (N = 29)
Not reported whether antipsychotics were used
Outcomes Global state: CGI
Mental state: HCS, HCS-right, HCS-left, AHRS, change in hallucination frequency
Notes Results posted on clinical trials website clinicaltrials.gov/ NCT00308997
NCT00567281 is an extension study of NCT00308997
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, details not reported
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind”, outcome assessors blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant (1/56) in the TMS arm left
the study early; the reason given was “un-
able to tolerate intervention” and 1 partici-
pant (1/29) in the sham TMS arm did not
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NCT00308997 (Continued)
complete the trial due to “subject feigned
clinical data”
Selective reporting (reporting bias) Low risk All outcomes fully reported
Other bias Unclear risk Insufficient information
Novak 2006
Methods Allocation: randomised
Blindness: double-blind
Duration: 8 weeks
Design: parallel
Setting: psychiatric inpatients and outpatients
Country: Czech Republic
Participants Diagnosis: schizophrenia (DSM-IV)
N = 16
Age: average 34 years
Sex: M 12, F 4
History: predominantly negative symptoms on stable antipsychotic medication
Interventions 1. TMS: left prefrontal rTMS20Hz at 90%motor threshold, 10 daily sessions, duration:
40 trains of 2.5 seconds each, 30 second gap (N = 8)
2. Sham: same as TMS, but with coil tilted by 90º with both coil wings in contact with
scalp (N = 8)
Both groups received SGAs, except one participant in the TMS group who received FGA
Outcomes Mental state: non-responders (20% decrease in negative PANSS score)
Adverse events: leaving the study early
Unable to use -
Global state: CGI (reported as median and IQR)
Mental state: PANSS Positive and Negative, MADRS (reported as median and IQR)
Cognitive state: AVLT, CPT, ROCF, TMT (reported as median and IQR)
Notes Source of funding: grant of IGA Ministry of Health of Czech Republic No.7578-3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, no further details provided
Allocation concealment (selection bias) Unclear risk No details provided
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Novak 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” “The coil was tangential to
the scalp for real treatment and at 90° (both
wings touching) for sham treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An experienced psychiatrist blinded to the
rTMS condition performed the rating”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One patient randomized to the sham
group dropped out immediately after en-
rolment and one patient from the active
group concluded the study after the second
session because of discomfort during stim-
ulation”
Selective reporting (reporting bias) High risk No data for means and standard deviations
of outcome measures
Other bias Low risk None detected
Poulet 2005
Methods Allocation: randomised
Blindness: double-blind
Duration: 5 working days (phase 1), 1 week wash-out, 5 working days (phase 2)
Design: cross-over
Setting: psychiatric inpatients
Country: France
Participants Diagnosis: schizophrenia (DSM-IV)
N = 10
Age: average 34.9 years
Sex: M 7, F 3
History: right-handed patients with DSM-IV diagnosis of schizophrenia and antipsy-
chotic-medication-resistant auditory verbal hallucinations. All participants were on an-
tipsychotic medication for at least 3 months without changes in doses and remained on
treatment throughout study period. Average illness duration 10.6 years
Interventions 1. TMS: left DLPFC based on 10 - 20 placement system, rTMS at 1 Hz at 90% of
motor threshold, 10 sessions over 5 consecutive days, 2 per day with 1000 stimulations
each session, (N = 5)
2. Sham: sham placebo coil which looks and sounds the same as the active coil and
produces the same sound but without the superficial scalp stimulation, (N = 5)
All participants were on antipsychotic medications prior to entering the study, did not
change their medications for the duration of the trial, type not reported
Outcomes Mental state: SAPS, AHRS
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Poulet 2005 (Continued)
Notes Only data for the 1st phase of the cross-over used, provided by the authors
Source of funding: grant from Conseil Scientifique de la Recherche, CH “Le Vinatier.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients randomly received”, no further
details reported
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both patients and evaluators were blind of
the attributed sequence”
“Sham stimulation was given at the same
location, strength, and frequency with a
placebo coil being indistinguishable to the
active coil. The placebo coil looks identical
to its active counterpart and produces the
same sound, but there is no superficial scalp
stimulation, and neither the operator nor
the patient knew which coil is the active”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Both patients and evaluators were blind of
the attributed sequence”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All patients performed the entire proto-
col”
Selective reporting (reporting bias) Unclear risk No data for means and standard deviations
of outcomemeasures for first phase of cross-
over study, unpublished data provided by
the authors
Other bias Low risk None detected
Prikryl 2007
Methods Allocation: random-number generated
Blindness: double-blind
Duration: 15 consecutive days
Design: parallel
Setting: psychiatric inpatients
Country: Czech republic
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Prikryl 2007 (Continued)
Participants Diagnosis: schizophrenia (ICD-10)
N = 22
Age: average 33.9 years
Sex: M 22
History: significant negative symptoms without other psychiatric comorbidity such as
mood, anxiety or personal disorders
Interventions 1. TMS: left DLPFC rTMS at 10 Hz at 110% of motor threshold, each session consisted
of 15 applications of 10 second duration with 30-second intervals, treatments given over
15 consecutive days (N = 11)
2. Sham: stimulation coil rotated to an angle of 90º to scalp, given using same protocol
as for active treatment group (N = 11)
Participants were stabilised long-term (for at least 6 weeks) on antipsychotics, type not
reported
Outcomes Mental state: PANSS positive, negative, MADRS, CDSS, SANS, SAPS
Adverse effects: headache
Unable to use -
Mental state CDSS (mean and SD of TMS group reported as 0 and 0, respectively)
Notes Data taken from primary reference and erratum
Source of funding: Internal Grant Agency of the Ministry of Health (Project No. 7986-
3) and by the Ministry of
Education Czech Republic (Project MSM 0021622404)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number generator
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The ineffectiveness of the sham rTMS
was ensured by adjusting the location of
the stimulation coil. It formed an angle of
90° against the surface of the head, which
was sufficient to prevent stimulation of the
brain cortex”
“Blinding of patientswas also ensuredusing
a background sound that occurs during the
real stimulation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Evaluation of the severity of the clinical
status and performance of rTMS was mu-
tually blinded. It means that the assessor
of the clinical status did not know whether
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Prikryl 2007 (Continued)
the patients were treated with the real or
sham stimulation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up not reported
Selective reporting (reporting bias) Unclear risk All outcomes reported, mean and SD re-
ported as 0 for TMS group for CDSS
Other bias Low risk None detected
Ren 2010
Methods Allocation: randomised
Blinding: not reported
Duration: 10 days
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (DSM-IV)
N = 25
Age: 19 - 55 years, mean (32 ± 7 years)
Sex: M 11, F 14
History: duration of illness 5.1 ± 4.2 years, auditory hallucinations with stable antipsy-
chotic drugs
Interventions 1. TMS: dorsolateral prefrontal cortex, both sides (F3, F4), rTMS 1 Hz at 80% motor
threshold, frequency 40/min, repeat for 20 minutes/day, total 800/day for 10 days (N =
12)
2. Sham : coil plane 90º to the scalp (N = 13)
All participants received a consistent dose of antipsychotics, type not reported
Outcomes Mental state: PANSS
Adverse events: TESS
Not used in the review -
biochemical test, blood routine examination, ECG, EEG
Notes Article in Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details
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Ren 2010 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation method not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
Selective reporting (reporting bias) Low risk All the outcomes were reported
Other bias Unclear risk Insufficient information: source of funding
not reported
Ren 2011
Methods Allocation: randomised
Blindness: double-blind
Duration: 10 days
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (DSM-IV)
N = 23
Age: TMS group mean 31 years (SD 7), sham group mean 37.7 years (SD 12.3)
Sex: M 19, F 4
History: length of illness mean 8.2 (SD 3.8) years, 2 or more antipsychotic drugs use
with a fixed dose for more than 2 months, with unchanged negative symptoms, PANSS
negative symptoms score ≥ 19,auditory hallucinations < 4
Interventions 1. TMS: double dorsolateral prefrontal at F3 and F4, rTMS 20 Hz at 80% of motor
threshold, repeat for 40 times/min, 20min/day for 10 days (N = 12) 10HZ:
2. Sham: coil plane 90º to the scalp, given using same protocol as for active treatment
group (N = 11)
Both groups received FGAs and SGAs
Outcomes Mental state: PANSS
Adverse events: TESS, leaving the study early
Not used in the review -
Blood routine examination, blood biochemistry, ECG, EEG
Notes Article in Chinese
Source of funding: Beijing Science and Technology Commission Foundation
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Ren 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised: no further detail
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, but untested
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, but untested
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Low risk All measured outcomes are reported
Other bias Low risk None detected
Rosa 2007
Methods Allocation: randomised
Blinding: double-blind
Duration: 10 days
Design: parallel
Setting: not reported
Country: Brazil
Participants Diagnosis: paranoid schizophrenia (DSM-IV)
N = 11
Age: TMS group mean 29.83 (SD 8.40); sham group mean 33.00 (SD 12.08)
Sex: M 6, F 5
History: Auditory hallucinations, treated with ≥ 350 mg/d clozapine for ≥ 6 m, treat-
ment failed≥ 2 adequate trials with standard antipsychotic medication from 2 different
pharmacologic groups with a minimum dose of 1000 mg chlorpromazine equivalents
Interventions 1. TMS: left temporoparietal cortex using the international 10 - 20 placement system,
rTMS 1 Hz at 90% of motor threshold, 10 sessions, 16 min/session, total 9600 pulses
in 10 days (5 days/week for 2 weeks) (N = 6)
2. Sham: same procedure with placebo coil supplied by manufacturer, magnetic field
reduced by 95% (N = 5)
Both groups received clozapine
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Rosa 2007 (Continued)
Outcomes Global state: CGI
Mental state: PANSS, AHRS
Not used in review -
Subjective characteristics change: VAS
Notes Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, details of method
not reported.
Allocation concealment (selection bias) Unclear risk Details of method not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Patients were blinded to treatment”.
“Placebo coil (produced by the manufac-
turer)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Rater blinded to treatment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not reported.
Selective reporting (reporting bias) Low risk Data not reported for VAS, other outcomes
fully reported
Other bias Low risk “The authors report no financial or other
relationships relevant to the subject of this
article”
Rosenberg 2012
Methods Allocation: randomised
Blinding: double-blind
Duration: 10 days
Design: parallel
Setting: outpatients and inpatients
Country: Israel
Participants Diagnosis: schizophrenia (DSM-IV-TR)
N = 18
Age: TMS group mean 40.8 (SD 16.6); sham group mean: 38.4 (SD 12.6)
Sex: M 14, F 4
History: Auditory hallucinations ≥ 5 times/day, stable on antipsychotic medication for
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Rosenberg 2012 (Continued)
≥ 1 month prior to enrolment
Interventions 1. TMS: left temporoparietal cortex, 1 Hz at 110% of motor threshold. Deep H1 coil,
single pulse stimulation, 10 min/day, 10 sessions (1 session/day for 10 days) (N = 9)
2. Sham: same stimulation as for active but with sham coil (n = 9)
All participants were on antipsychotic medication during the study, with medication
dosage kept stable throughout the study, type not reported
Outcomes Global state: CGI
Mental state: AHRS (hallucinations)
Quality of Life: Q-LES-Q
Adverse events
Unable to use -
Mental state: SANS, SAPS (skewed data)
Notes Source of funding: educational grant from the Brainsway Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, details of method not re-
ported
Allocation concealment (selection bias) Unclear risk Method not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo stimulation was performed with
a sham coil placed in the same helmet en-
casing the active TMS coil. An electronic
system controlled which of the two coils
was connected to the stimulator in a cer-
tain session. This operation was carried out
by a magnetic card specific to each patient
so that both the patient and the operator
remained blind to the operation mode”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Raters were blind to the type of treatment
being given”
Incomplete outcome data (attrition bias)
All outcomes
High risk “Out of 18patients, 10 (5 fromeach group)
completed the study.”
“The dropout rate was 44% in both the real
and sham groups.”
“Patients that dropped out of either group
were excluded from analysis.”
Selective reporting (reporting bias) Low risk All stated outcomes are reported
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Other bias Unclear risk 4 of the 6 authors have conflict of interest.
“PD and OR received an unrestricted edu-
cational grant for deep TMS treatment re-
search from the Brainsway Company. RG
is a scientific consultant of the Brainsway
Company. AZ serves as a research consul-
tant and has financial interest in the Brain-
sway Company”
Saba 2006a
Methods Allocation: randomised
Blindness: double-blind
Duration: 2 weeks
Design: parallel
Setting: inpatient adult psychiatric unit
Country: France
Participants Diagnosis: schizophrenia (DSM-IV)
N = 16
Age: average 30.6 years (SD 8)
Sex: M 13, F 3
History: experiencing delusions and auditory hallucinations, mean hospitalisations 3.5,
mean duration of illness 8 years
Interventions 1. TMS: left temporoparietal rTMS, 1Hz, 20% belowmotor threshold, 14 daily sessions
over 2 weeks, each included 5 x 1 min treatments with 1 min gap (N = 8)
2. Sham: Sham coil designed to produce a similar noise administered at the same location
on the scalp (N = 8)
All participants weremaintained under antipsychotics medication at steady dosages, type
not reported
Outcomes Global state: CGI
Mental state: PANSS positive, negative, total, general
Notes Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - no further details provided
Allocation concealment (selection bias) Unclear risk No details provided
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Saba 2006a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind” “Sham stimulationwas ad-
ministered at the same location using a
sham coil that produces sound similar to
the active stimulation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The ratings were performed by a psychia-
trist who was blind to the nature of rTMS
treatment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Two patients withdrew their consent be-
fore beginning the session”, not reported
which group they were from
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
Schneider 2008
Methods Allocation: randomised
Blindness: double-blind
Duration: 4 weeks
Design: parallel
Setting: outpatient clinical practices and board & care facilities
Country: USA
Participants Diagnosis: schizophrenia
N = 51
Age: average 41.1 years
Sex: M 17, F 34
History: SANS score of ≥ 35 with a minimum score of ≥ 2 on items 5, 9, 14, 16 and
22, mean duration of illness 18 years, diagnosis of schizophrenia of > 5 years with > 1
prior psychiatric hospitalisation
Interventions 1. TMS: left prefrontal cortex rTMS, 1 Hz at 110% of motor threshold (100 pulses per
day, 52,000 total), 5 second treatment with 15 second inter-train intervals, 20 trains
each weekday (Monday - Friday) over 4 weeks (N = 17)
2. TMS: left prefrontal cortex rTMS, 10Hz at 110% of motor threshold ((1000 pulses
per day, 520,000 total), 5 second treatment with 15 second inter-train intervals, 20 trains
each weekday (Monday - Friday) over 4 weeks (N = 17)
3.Sham: stimulation parameters as for 10 Hz active treatment using a magnetically non-
translucent headpiece (N = 17)
All participants received SGAs
Outcomes Mental state: SANS
Unable to use -
Global state: CGI, SF-36 (no SDs)
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Schneider 2008 (Continued)
Cognitive state: WCST (no SDs)
Notes Not reported the number randomised to each group
Only data from the 10 Hz TMS group used in the analysis
Unpublished data regarding SANS received from authors
Source of funding: Stanley Medical Research Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised” - no further details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “After localization of motor threshold [...
] the investigator left the treatment room.
Then a research associate fitted one of two
head covers on the magnet (one allowing
transmission of the magnetic field and one
blocking it) with magnetic field strength
previouslymeasured for both. This resulted
in blinding of the investigator and subject
to the nature of the 10 Hz treatment (real
or sham)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “To maintain appropriate blinding the in-
vestigator and rater (two different individ-
uals) were both blinded as to the nature of
treatment rendered. Only the research as-
sociate remained unblinded as to the actual
treatment each subject received”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “GroupA (sham)had15 completers, group
B (1 Hz) had 17 completers, and group
C (10 Hz) had 16 completers. Three sub-
jects withdrew consent at baseline and were
not included in the analysis. Seven subjects
were lost to follow-up”
Selective reporting (reporting bias) High risk Not all outcomes fully reported, no SDs
reported
Other bias Low risk None obvious
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Slotema 2011
Methods Allocation: randomised
Blinding: double-blind
Duration: 3 weeks
Design: parallel
Setting: not reported
Country: The Netherlands
Participants Diagnosis: schizophrenia, schizoaffective disorder, bipolar disorder, psychotic disorder
NOS (criteria not reported)
N = 62
Age: fMRI guided group mean 36 (SD 10.0), left TP group mean 38 (SD 9.6), sham
group mean 41 (SD 10.3)
Sex: M 36, F 26
History: AVH more frequently than once/hour, medication-resistant AVH (i.e. insuffi-
cient response to ≥ 2 antipsychotic agents, administered at adequate dosages for ≥ 6
weeks); stable dosage of antipsychotic medication since a month before inclusion, an
fMRI scan showing significant hallucinatory activity in at≥ 1 superficially located brain
area
Interventions 1. fMRI guided TMS: rTMS targeted at the area of maximal hallucinatory activation
calculated for fMRI scans,1 Hz at 90% of the individual motor threshold, 15 sessions
of 20 min each (5 days/week for 3 weeks) (N = 20)
2. TMS: left temporoparietal rTMS,1 Hz at 90% of the individual motor threshold, 15
sessions of 20 min each (5 days/week for 3 weeks) (N = 22)
3. Sham: coil tilted away from the scalp at an angle of 90° (N = 20)
All groups received FGAs and SGAs
Outcomes Mental state: PANSS, PSYRATS
Unable to use -
Mental state: AHRS (total score not reported)
Notes Symptoms were monitored during treatment and 3 m follow-up
Also did a LOCF analysis, which did not change the results
Data were combined for the 2 TMS groups
Source of funding: grants from NWO ZonMW (Dutch Scientic Research Foundation-
Dutch National Institute of Health Research) and Stichting tot Steun (Dutch Support
Foundation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization was performed with
the aid of www.randomizer.org/form.htm”,
a random generator
Allocation concealment (selection bias) Low risk “The three treatment conditions were as-
signed in a random order by a psychologist
who was not involved in the study”
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Slotema 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” “coil titled away from the
scalp at an angle of 90 degrees”
“Participants were notified of the treatment
condition after the last follow-up assess-
ment.”
“This outcome confirms that patients were
actually blind for their treatment condi-
tions, because the vast majority of patients
in all three groups expected to have had ac-
tive rTMS treatment.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Treatment conditions were unknown to .
..raters.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses were not balanced across interven-
tion groups: in the fMRI guided rTMS
group 2/20 left the study early, in the stan-
dard rTMS group 3/22 left early, and 6/20
in the sham group
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk None detected
Vercammen 2009a
Methods Allocation: randomised
Blinding: double-blind
Duration: 6 days
Design: parallel
Setting: inpatients and outpatients
Country: The Netherlands
Participants Diagnosis: schizophrenia (DSM-IV)
N = 36
Age: left TP group mean 33.75 (SD 14.21); bilateral TP group mean 33.83 (SD 9.27);
sham group mean 36.50 (SD 12.92)
Sex: M 18, F18
History: Frequent medication-resistant AVH (the daily AVH occurring in≥ 2 adequate
trials of antipsychotic medications; treated with stable doses of antipsychotic medication
for ≥ 4 weeks prior to study inclusion)
Interventions 1. TMS: left temporoparietal rTMS using 10 - 20 placement system, 1 Hz at 90% of
motor threshold,12 sessions, each lasting 20 mins with a minimum 5 hour delay between
subsequent sessions (total of 14,400 pulses) (N = 12)
2. TMS: bilateral temporoparietal rTMS, 1Hz at 90% of motor threshold,12 sessions,
each lasting 20 mins with a minimum 5 hour delay in between subsequent sessions (total
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Vercammen 2009a (Continued)
of 14,400 pulses) (N = 12)
3. Sham: on the same location as the left-sided stimulation designed to produce an
identical sound (N = 12)
All participants were maintained under antipsychotics at steady dosages, type not re-
ported
Outcomes Mental state: PANSS, AHRS, PANAS
Notes Duration: 6 working days with a 2-day weekend delay after day 3
36 completed participants
Data were combined for the 2 TMS groups
Source of funding: Ubbo Emmius Grant (180/800514) of the University of Groningen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”, method not reported
Allocation concealment (selection bias) Unclear risk Method not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Participants... all personnel responsible for
the clinical care of the patients were blind
to the allocated condition.”, details not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Clinical raters were blind to the allocated
condition.” “Sham stimulation was per-
formed... with the use of a Magstim sham
coil, which does not deliver a measurable
magnetic eld, but does produce the same
clearly audible clicking sound, at the same
frequency of 1 Hz.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One subject withdrew from the study,
during the rst week of treatment, due
to exacerbation of psychotic symptoms .
.. ascribed to personal circumstances... A
second subject was excluded, because she
failed to comply with the medication re-
quirement”. Unclear towhich the interven-
tion group these participants had been as-
signed
Selective reporting (reporting bias) Low risk All outcomes stated have been reported
Other bias Low risk None detected
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Wing 2012
Methods Allocation: randomised
Blinding: double-blind
Duration: 10 weeks
Design: parallel
Setting: outpatients
Country: Canada
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 15
Age: not reported
Sex: not reported
History: smoking ≥ cigarettes/day, CO levels ≥ 10 ppm, Fagerstrom test of Nicotine
Dependence score ≥ 4, motivated to quit within a month
Interventions 1. TMS: bilateral DLPFC rTMS, 20 Hz at 90% of the resting motor threshold for 25
trains (30 pulses/train; 30 sec inter-train interval; 750 pulses/hemisphere), 20 sessions, 5
treatments/week in weeks 1 - 4 as an adjunctive to weekly group therapy and transdermal
nicotine (TN; 21 mg) provided in weeks 3 - 9 (N = 6)
2. Sham: administered in the single-wing tilt position (N = 9)
Not reported whether antipsychotics were used
Outcomes Mental state: PANSS
Not used in the review -
Smoking: self report and breath carbon monoxide [CO] levels
Cravings: TQSU
Withdrawal: Minnesota Nicotine Withdrawal Scale
Notes Source of funding: IdeaGrant (#19588) from theCanadian Institute forHealth Research
and Canadian Tobacco Control Research Initiative, Chair in Addiction Psychiatry from
the University of Toronto, Fellowship Award from the Centre for Addiction and Mental
Health (CAMH)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”, details of method not re-
ported
Allocation concealment (selection bias) Unclear risk Method not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind”, details not reported
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Wing 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk “6/9 participants in the sham group and 6/
6 in the active group completed the trial.”
Reasons for losses not reported. Losses not
balanced across intervention groups
Selective reporting (reporting bias) Unclear risk PANSS not reported.
Other bias Low risk None detected
Xu 2011
Methods Allocation: randomised
Blinding: double-blind
Duration 2 weeks
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (CCMD-3)
N = 35
Age: mean ~ 32 years
Sex: M 24, F 11
History: duration of illness ~ 7.5 years, refractory hallucinations
Interventions 1. TMS: left temporoparietal region, 1 Hz at 80% motor threshold, pulse count 10 for
10 sec, 5 sec interval, repeat for 20 minutes/day, total 800/day,10 times for 2 weeks (N
= 18)
2. Sham TMS: coil plane 90º to the scalp (N = 17)
Not reported whether antipsychotics were used
Outcomes Mental state: PANSS
Cognitive state: WCST, CPT reaction time
Unable to use -
Cognitive state: Continuous Performance Test (CPT) false items and missing items
(skewed data)
Notes In Chinese
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no further details
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Xu 2011 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the participants complete the treatment
Selective reporting (reporting bias) Low risk All the outcomes were reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
Yu 2010
Methods Allocation: randomised
Blinding: double-blind
Duration: 10 days
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia
N = 61
Age: mean ~ 27.5 years
Sex: M 46, F 15
History: chronic schizophrenia with hyperprolactinemia by risperidone
Interventions 1. TMS: left temporal and parietal lobes rTMS, 1 Hz at 100% motor threshold, stimu-
lating for 200 sec,10 sec interval, repeat for 5 times/day, total 1000/day, for 10 days (N
= 31)
2. Sham: coil placed 90º to the scalp (N = 30)
Participants were given risperidone (2 - 6 mg/day) treatment
Outcomes Adverse events: headache
Unable to use -
Mental state: PANSS, HAMD-17 (no mean and SD)
Not used in the review -
EEG, prolactin
Notes Article in Chinese
Source of funding: not reported
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Yu 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table was used
Allocation concealment (selection bias) Unclear risk Allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no details reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
Selective reporting (reporting bias) High risk PANSS and HAMD-17 score were mea-
sured, but not reported
Other bias Unclear risk Insufficient information. Source of funding
not reported
Zhang 2010
Methods Randomised: randomised (random number table)
Blinding: double-blind
Duration: 4 weeks
Design: parallel
Setting: not reported
Country: China
Participants Diagnosis: schizophrenia (DSM-IV)
N = 30
Age: TMS group mean 28 ± 8 years, sham group 27 ± 8 years
Sex: M 19, F 11
History: length of illness median 16 years TMS group and 12 years sham group, negative
symptoms last for more than 6 weeks
Interventions 1. TBS TMS: rTMS to the left DLPFC, 80%motor threshold TBS mode, base sequence
of 5 Hz, stimulating for 200 ms with 3 single pulses of 50 Hz for 20 minutes, total 2400/
day. 20 sessions (5 times/week for 4 weeks) (N = 15)
2. Sham: sham rTMS reverse side of coil plane to the scalp (N = 15)
Not reported whether antipsychotics were used
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Zhang 2010 (Continued)
Outcomes Global state: clinical improvement
Mental state: PANSS, SANS, HAMD
Adverse events: sleep disorder, headache, leaving the study early
Unable to use -
Mental state: HAMD (no data)
Notes Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table
Allocation concealment (selection bias) Unclear risk Allocation concealment method not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind, no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind, no further details
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants left the study early in the
sham group due to early discharge and 1 the
TMS group due to headache during rTMS
treatment. They were not included in the
final analysis
Selective reporting (reporting bias) High risk Data not reported for the HAMD
Other bias Unclear risk Insufficient information. Source of funding
not reported
Zheng 2012
Methods Allocation: randomised
Blinding: double-blind (participants and assessor blind)
Duration: 5 days
Design: parallel
Setting: inpatients
Country: China
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Zheng 2012 (Continued)
Participants Diagnosis: schizophrenia (CCMD-3)
N = 80
Age: mean ~ 56 years
Sex: M 80
History: length of illness mean ~ 32 years
Interventions 1. TMS 10 Hz: DLPFC,10 Hz at 80% motor threshold, pulse count 40, 15 sec interval,
30 series of stimulus for 10 mins, total 1200/day for 5 days (N = 20)
2. TMS 20Hz: DLPFC, 20Hz at 80%motor threshold, pulse count: 40, 28 sec interval,
30 series of stimulus for 15 min, total 1200/day for 5 days (N = 21)
3. TBS TMS 50 Hz: TBS to the DLPFC, base sequence for 5 Hz every 200 ms, 3 single
pulses of 50 Hz at 80% motor threshold (N = 19)
4. Sham: reverse side of coil plane to the scalp, stimulation as for active TMS (N = 20)
All participants received antipsychotics, type not reported
Outcomes Mental state: PANSS
Cogntive state: Digit Span Test, verbal fluency test
Notes Data combined in the analysis for the 10 Hz and 20 Hz groups
In Chinese
Source of funding: Shanghai Committee of Science and Technology,China and the
National Natural Science Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, using computer-generated
(SAS software) random numbers
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind. Assessors and participants
were blinded to the allocation and detail
of rTMS therapy (but, trialists are aware of
the allocation)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were not allowed to enter the in-
tervention room and were blinded to the
allocation and detail of intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 people left the study early. Although rea-
sons for dropout were given, these 7 people
were not included in the final analysis
Selective reporting (reporting bias) Low risk All measured outcomes were reported
Other bias Low risk None detected
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Diagnostic Manuals
DSM - Diagnosic and Statistical Manual of Mental Disorders (American Psychiatric Association)
ICD - International Classification of Diseases
General
ECG: electrocardiogram
EEG - electro-encephalogram
IM - intramuscular
Ht - haematocrit
Hb - haemoglobin
RBC - red blood cell
WBC - white blood cell
ESR - erithrocyte sedimentation rate
IV - intravenous injection
LOCF - last observation carried forward
M - male
F - female
FGA - first generation antipsychotics
SD - standard deviation
SGA - second generation antipsychotics
Scales
AHRS - auditory hallucination rating scale
ANT - attentional networking test
AVLT - Auditory-Verbal Learning Test
BPRS - brief psychiatric rating scale
CDRS - Calgary depression rating cale
CDS - Calgary depression scale
CGI - clinical global impression
CPT - continuous performance test
CVLT - California verbal learning test
CSSES - Columbia ECT subjective side effects schedule
GSI - global severity index
HCS - Hoffman hallucination change scale
MADRS - Montgomery-Asberg depression rating scale
PANSS - positive and negative symptoms scale
ROCF - Rey-Osterrieth Complex Figure Test
PRSS - psychiatric rating scale for schizophrenia
SANS - scale for assessment of negative symptoms
SAPS - scale for the assessment of positive symptoms
SF-36 - short form
TPT - Tactile Performance Test
UKU - udvalg for kliniske undersøgelser
VAS - visual analogue scale
WCST - Wisconsin card sorting test
WRAT-R - wide range achievement test - reading
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12611000731998 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
ACTRN12612000217808 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
ACTRN12612001112853 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
Alva 2001 Allocation: not randomised
Outcome data: insufficient data for use (conference abstract)
Arends 2005 Allocation: randomised
Participants: people with schizophrenia
Interventions: Left dorsolateral prefrontal high-frequency repetitive TMS vs unknown
Outcome data: insufficient data for use (conference abstract)
Benitez 2005 Allocation: randomised
Participants: people with schizophrenia and treatment-resistant auditory hallucinations
Interventions: TMS, 1 Hz at 90% of resting motor threshold for 15 minutes, 10 consecutive week days
vs sham TMS
Outcome data: insufficient data for use, no outcome measures given (conference abstract)
Brunelin 2012 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
Chibbaro 2005 Allocation: not randomised
Cohen 1999 Allocation: not randomised
Cordes 2008 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS vs sham TMS
Outcome data: insufficient data for use, no outcome measures given (conference abstract)
D’Alfonso 2002 Allocation: not randomised
Daskalakis 2003 Allocation: not randomised
Daskalakis 2007 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS versus sham TMS
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(Continued)
Outcome data: no usable data reported (conference proceeding)
Davey 1997 Allocation: not randomised
Feinsod 1998 Allocation: not randomised
Fitzgerald 2003 Allocation: not randomised
Geller 1997 Allocation: not randomised
Goyal 2007 Allocation: not randomised
Grenier 2008 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS versus placebo (not reported whether sham TMS)
Outcome data: no usable data reported
Hajak 2004 Allocation: randomised
Participants: people with schizophrenia
Interventions: Left dorsolateral prefrontal high-frequency repetitive TMS vs sham
Outcome data: insufficient data for use, wrote to author to request unpublished means and standard
deviations for phase one of the cross-over study with no reply
Hasan 2010 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS versus sham TMS
Outcome data: no usable data reported
Hasey 2000 Allocation: randomised
Participants: people with severe depression
Hoffman 1999 Allocation: not randomised
Participants: people with schizophrenia. The number of included participants was less than 5
Hoffman 2000 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS vs sham TMS
Outcome data: insufficient data for use; results of the 1st phase of the cross-over trial not reported
Hoffman 2003 Allocation: randomised
Outcome data: insufficient data for use (conference abstract)
Hoffman 2007 Allocation: not randomised
Jandl 2005 Allocation: not randomised
Jandl 2006 Allocation: randomised, no allocation concealment
Participants: people with schizophrenia but not on long-term stable antipsychotic medication ( 1 week
before randomisation)
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Jandl 2010 Allocation: not randomised
Jin 2003 Allocation: randomisation unclear
Participants: people with schizophrenia
Interventions: TMS versus sham TMS
Outcome data: insufficient data for use (conference abstract), mean scores on outcome measures are
not provided
Jin 2006 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS vs sham TMS
Outcome data: insufficient data for use; wrote to author to request unpublished means and standard
deviations for phase one of the cross-over study with no reply
Jin 2012 Allocation: randomised
Participants: people with schizophrenia.
Interventions:
1. TMS: Bilateral frontal (BF) αTMS
2. TMS: Bilateral parietal (BP) αTMS
3. TMS: Sham
Outcomes: unable to use any data
Mental state: MADRS, CDS (mean and SD not reported), PANSS (N not reported, % change and SE
reported graphically)
Adverse events: BARS, SAS (mean and SD not reported)
Levit-Binnun 2007 Allocation: not randomised
Lifshitz 1968 Allocation: not randomised
Loo 2010 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS vs sham TMS
Outcome data: insufficient data, does not report phase 1 of the cross-over study
Luber 2007 Allocation: not randomised
Mattai 2011 Allocation: randomised
Participants: people with childhood onset schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
Mobascher 2005 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS versus sham TMS
Outcome data: no usable data reported (conference proceeding)
NCT00517075 Allocation: randomised
Participants: people with schizophrenia
Intervention: TMS vs sham TMS
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Study terminated as unable to adequately recruit participants
NCT00757497 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
NCT00870909 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
NCT01041274 Allocation: randomised
Participants: people with schizophrenia
Interventions: citalopram plus standardized psychoeducation, CBT and fMRI vs placebo plus stan-
dardized psychoeducation, CBT and fMRI
NCT01378078 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
NCT01595503 Allocation: randomised
Participants: people with schizophrenia
Interventions: rTMS with fMRI-based targeting vs rTMS with landmark-based targeting
NCT01607840 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
NCT01620086 Allocation: randomised
Participants: people with schizophrenia and healthy controls
Intervention: TMS for people with schizophrenia vs fMRI for healthy controls
NCT01623726 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
Potkin 2000 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS versus sham TMS
Outcome data: no usable data reported
Puri 1996 Allocation: not randomised
Rollnik 2000 Allocation: randomised
Participants: people with schizophrenia
Interventions: TMS versus sham TMS
Outcome data: no usable data reported, data for 1st phase of the cross-over not reported
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Rushby 2010 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
Sachdev 2005 Allocation: not randomised.
Schneider 2001 Allocation: randomised
Participants: people with schizophrenia
Intervention: TMS vs sham TMS
Outcome data: insufficient data - no Ns and SDs reported. Number of completers per group reported
but 7 participants were lost to follow-up and it was not reported from which groups and whether an
intention-to-treat or LOCF analysis was performed
Schonfeldt-Lecuona 2004 Allocation: randomised
Participants: people with schizophrenia
Intervention: low- frequency rTMSwith fMRI-based targeting (superior temporal gyrus) vs sham rTMS
and low- frequency rTMS with stereotaxic navigation targeting (Broca’s area) vs sham rTMS (cross-
over trial). The number of participants in each phase 1 arm was less than 5
Slotema 2012 Allocation: randomised
Participants: people with schizophrenia
Intervention: low-frequency rTMS versus low- frequency rTMS preceeded by priming rTMS
Weickert 2010 Allocation: randomised
Participants: people with schizophrenia
Interventions: Transcranial Direct Current Stimulation (tDCS) vs sham treatment
Xu 2006 Allocation: not randomised
Yu 2002 Allocation: not randomised
IM - intramuscular injection
LOCF: last observation carried forward
RCT - randomised controlled trial
SD: standard deviation
Characteristics of studies awaiting assessment [ordered by study ID]
Mohr 2006
Methods Randomised, double-blind, placebo-controlled, parallel group
Participants Schizophrenia (DSM-IV criteria) patients treated with 2nd-generation antipsychotics (except clozapine)
N = 16
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Interventions 1. TMS: details not reported; N = 8
2. Sham: details not reported; N = 8
Outcomes Change in cognition
Notes This is part of a larger study (N = 34) investigating the efficacy of computer-assisted cognitive training in improving
cognitive deficits in schizophrenia. TMS vs sham was applied to the study participants. All participated in an 8-week
computer-based cognitive training programme
Missing PDF of full article - not available at British Library
Characteristics of ongoing studies [ordered by study ID]
Dlabac-de 2008
Trial name or title Effect of high frequency transcranial magnetic stimulation on negative symptoms and cognitive functioning
in schizophrenia: a combined treatment and neuroimaging study
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: ≥ 18 years of age; diagnosed with schizophrenia; prominent negative symptoms with a
PANSS negative subscore ≥ 15
Exclusion criteria: rTMS and MRI contraindications (e.g. a personal or family history of epileptic seizures,
history of brain surgery, intracerebral or pacemaker implants, inner ear prosthesis or other metal prosthetics/
implants; neurological disorders; history of head injury with loss of consciousness; substance dependency
within the previous 6 months; previous treatment with rTMS; severe behavioural disorders; claustrophobia;
pregnancy)
N = 32
Participants People with schizophrenia, with prominent negative symptoms
Interventions 1. TMS: bilateral DLPFC, high-frequency rTMS stimulation during 15 days, 2 sessions/day. N = 16
2. Sham: sham stimulation during 15 days, 2 sessions /day. Details not reported. N = 16
Outcomes Primary outcome:
Mental state: significant decline of negative symptoms (measure not reported, presumably PANSS negative
subscale); cognitive dysfunctioning (measure not reported)
Secondary outcome:
Increased cortical activation in the DLPFC: fMRI
Starting date May 1, 2008
Contact information Prof. Dr. A. Aleman
University Medical Center Groningen (UMCG)
Additional contact information not provided
Notes Planned closing date 1 May 2012
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Ebmeier 2001
Trial name or title TMS and auditory hallucination in schizophrenia
Methods RCT
Participants Treatment-resistant auditory hallucinations in people with schizophrenia, schizophreniform disorder and
schizoaffective disorder. N = 16
Interventions 1. rTMS: left temporoparietal cortex, 1 Hz
2. Sham
Outcomes Hallucinations; other positive and negative symptoms of schizophrenia (scale not reported; presumably
PANSS)
Starting date 1 June 2000
Contact information Professor KP Ebmeier
Kennedy Tower
Royal Edinburgh Hospital
Morningside Park
Edinburgh
EH10 5HF
Notes Study has been completed
Hunter 2003
Trial name or title A double-blind randomised controlled trial of repetitive Transcranial Magnetic Stimulation (rTMS) in the
treatment of persistent auditory hallucinations in schizophrenia
Methods Randomised, double-blind, factorial
Participants Inclusion criteria:
1. Men and women, aged 18 to 65
2. DSM-IV diagnostic criteria for schizophrenia
3. Experience auditory hallucinations defined as a score of 2 on the auditory hallucinations subscale of the
SAPS for 6 weeks despite standard clinical treatment
Exclusion criteria:
1. Organic brain disorder
2. Previous documented unconsciousness
3. Unstable coronary heart disease
4. Contra-indications to rTMS, e.g. history of fits, recent cerebrovascular accident, history of epileptic seizures,
metal implants, cardiac pacemakers
Total N = 126
Interventions 1. Left only: rTMS at a frequency of 1 Hz and amplitude 100% MT applied to left temporal cortex for 20
minutes, 10 working days
2. Right only: rTMS at a frequency of 1 Hz and amplitude 100% MT applied to right temporal cortex for
20 minutes, 10 working days
3. Left and right: rTMS at a frequency of 1 Hz and amplitude 100% MT applied to left temporal cortex for
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Hunter 2003 (Continued)
10 minutes followed by right temporal cortex for 10 minutes, 10 working days
4. Sham (placebo) stimulation, using a modified coil, which produces no magnetic field but has an acoustic
signature similar to that of an active coil,applied to left temporal cortex for 20 minutes, 10 working days
Outcomes Primary:
Mental state (auditory hallucinations): Change from baseline in auditory hallucinations score according to
a visual analogue measure of current intensity; change from baseline in the auditory hallucinations subscale
score (SAPS)
Secondary:
Mental state: total schizophrenic symptoms (SAPS, SANS)
Depression: HAMD
Psychological and social functioning: SF-36
Neuropsychological and audiometric tests (details not reported)
Starting date 1st December 2001
Contact information Dr Michael Hunter
Academic Department of Psychiatry
The Longley Centre
Norwood Grange Drive
Sheffield
United Kingdom
S5 7JT
phone: +44 (0)114 2716231
email: m.d.hunter@shef.ac.uk
Notes Trial status: completed
ISRCTN72210184
IRCT138903254191N1
Trial name or title The comparison of effectiveness of repetitive TMS and iTBS on negative symptoms and cognition in patients
with schizophrenia: a study randomized and double blind
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: male and female outpatients
18 - 50 years of age; DSM-IV-TR diagnosis of schizophrenia; stable symptoms (not requiring a change in
antipsychotic medication for ≥ 4 weeks or ≥ 2 weeks for psychotropic agents)
Exclusion criteria: history of rTMS treatment;
intracranial implant and other ferromagnetic materials close to the head; cardiac pacemaker; drug pumps;
acute heart attack; risk of seizures; high intracranial pressure; history of epilepsy or seizure in first relatives;
brain trauma, history of loss of consciousness for 5 minutes, pregnancy, breastfeeding, drug dependency,
high risk of suicide, significant positive symptoms
N = 30
Participants Male and female schizophrenia outpatients
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IRCT138903254191N1 (Continued)
Interventions 1. TMS: 15 Hz rTMS, 20 sessions of 20- - 30-minute duration
2. iTBS: 50 Hz theta burst, 20 sessions of 5- - 10-minute duration
3. Sham: Sham coil 20 sessions
Outcomes Primary outcomes:
Mental state: PANSS negative symptoms
Cognitive state: Neuropsychology Battery Tests (tests are not specified)
Secondary outcomes:
Depression: CDSS
Quality of life: SQLS
Social functioning: SOFAS
Starting date May 1, 2011
Contact information Dr. Reza Rostami (sponsor)
Atieh comprehensive psyche and nerve centre
23 No., Valinezhad St., Valiasr Ave., Tehran, Iran
phone: 009802184012000
e-mail: rrostami@ut.ac.ir
Notes Recruitment complete
ISRCTN61109178
Trial name or title Transcranial magnetic stimulation (TMS) treatment study in auditory verbal hallucinations: a randomised
controlled trial
Methods Randomised controlled trial
Inclusion criteria: age 18 - 65 years; diagnosis of schizophrenia or schizoaffective disorder according to ICD-
10; medication-resistant auditory verbal hallucinations; right-handed; therapy refractoriness (non response
to ≥ 2 antipsychotic treatments in common dosages, each administered for ≥ 8 weeks)
Exclusion criteria: history of epileptic seizures; signs of elevated neuronal activity by EEG; MR contraindica-
tions; medical disorders other than schizophrenia or schizoaffective disorder
N = 30 - 45
Participants People with treatment-resistant schizophrenic or schizoaffective disorder with auditory verbal hallucinations
Interventions 1. Theta burst transcranial magnetic stimulation (TBS)
2. 1 Hz transcranial magnetic stimulation (TMS) at 90% of the motor threshold
3. Control: treatment as usual
Duration: 10 days
Outcomes Mental state (psychopathology): PANSS, PSYRATS, AHRS;
Cerebral blood flow: MRI;
EEG
Starting date 15th December 2008
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ISRCTN61109178 (Continued)
Contact information Dr Jochen Kindler
University Hospital of Psychiatry, University of Bern
phone #: +41 31 930 9111
email: jochen.kindler@puk.unibe.ch
Notes Status of trial: completed
Lee 2007
Trial name or title Pilot study for a new treatment of schizophrenia: a double-blind crossover transcranial magnetic stimulation
Methods Randomised, double-blind, cross-over trial
Participants Diagnosis: schizophrenia
N = 12
Age: 18 - 55 years
History: severe negative symptoms
Interventions 1. TMS: Prefrontal stimulation TBS
2. TMS: Cerebellar stimulation TBS
3. Sham TMS
Outcomes Regional functional brain response measured with fMRI
A variety of standardised psychiatric ratings and neuropsychological tests will be used as secondary outcome
measures
Starting date 15 May 2006
Contact information Dr Kwang Hyuk Lee
Academic Department of Psychiatry
Longley Centre
Norwood Grange Drive
Sheffield
S5 7JT
United Kingdom
+44 (0)114 226 1511
md4khl@shef.ac.uk
Notes Sponsor: Department of Health
ISRCTN93378085
Status of trial: completed
111Transcranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00186771
Trial name or title Transcranial magnetic stimulation used to treat auditory hallucinations in schizophrenia
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: schizophrenia; auditory hallucinations occurring 5 times/day; adequate (6 wks) trial of
antipsychotic medication including ≥ 1 atypical antipsychotic medication; medication stable for 4 wks prior
to commencement of the study
Exclusion criteria: history of seizure disorder in patient or first degree relative; recent head injury; acute
suicidality; alcohol or substance abuse; implanted pacemaker or metal in head or neck; pregnancy
N = 10
Participants Men and women with schizophrenia, with auditory hallucinations. Age: 18 - 65
Interventions 1. TMS: temporoparietal cortex rTMS
2. Sham
Outcomes Primary outcome:
Mental state (hallucinations): Hoffman auditory hallucination scale
Secondary outcome:
Mental state: PANSS
Starting date November 2004
Contact information Rose Marie Mueller, RN
phone: 9055221155 ext 36629
email: rmueller@stjoes.ca
Sandra Chalmers, RN
phone: 9055221155 ext 35442
email: schalmer@stjoes.ca
Notes Estimated study completion date: January 2015
NCT00685321
Trial name or title A double-blind randomized controlled trial to explore the tolerability, safety and efficacy of the H-coil
deep transcranial magnetic stimulation (TMS) in subjects with negative symptoms and cognitive deficits of
schizophrenia
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: age 18 - 65 years; diagnosed in the past as suffering from schizophrenia; diagnosis reaffirmed
according to ICD criteria; right hand dominant; PANSS negative ≥ 21; negative answers on safety screening
questionnaire for TMS; stable on the same antipsychotic medication for ≥ 2 months prior to entering the
study; negative answers to all questions in the TMS safety
Exclusion criteria: suffering from another axis 1 disorder; PANSS positive score 24; history of epilepsy
within first-degree relatives; history of: epilepsy, seizure, or hot spasm, head injuries, metal in the head, surgery
including metal implant, migraines, hearing loss (not due to aging) or cochlear implants, drug or alcohol
abuse during the last year; pregnancy or not using a reliable method of birth control; suicide attempt in the
year prior to treatment or suicide risk; custodians
N = 45
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NCT00685321 (Continued)
Participants Men and women with schizophrenia, currently suffering mainly from negative symptoms
Interventions 1. H-Coil deep TMS
2. Sham
Outcomes Primary outcome:
Mental state: SANS
Secondary outcome:
General functioning: SOFAS
Starting date June 2008
Contact information Liron Rabani
Shalvata Mental Health Center, Israel
phone #: 972- 97478644
lironrab@clalit.org.il
PI: Yechiel Levkovitz MD
Notes Estimated study completion date: January 2013
NCT00763841
Trial name or title A pilot study using transcranial agnetic stimulation (TMS) to investigate the role of the temporal cortex in
schizophrenic patients with auditory hallucinations
Methods Randomised, double-blind, placebo-control, cross-over assignment
Inclusion Criteria: age 18; DSM-IV diagnosis of schizophrenia and auditory hallucinations of clear external
origins, refractory to pharmacotherapy and occurring at ≥ 5 times/day
Exclusion criteria: contraindications to TMS (e.g. epilepsy, pacemaker) or an unacceptably high risk (e.g.
suicide risk)
N = 18
Participants Men and women with schizophrenia
Interventions 1. Temporal cortex TMS
2. Sham TMS
Outcomes Daily voices ratings
Starting date September 1999
Contact information Colleen Loo, MBBS, FRANZCP. MD
The University of New South Wales, Australia (phone, e-mail not provided)
Notes This study has been completed. Results have not been posted at the NIH site
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NCT00875498
Trial name or title Intermittent theta burst stimulation (iTBS) for the treatment of negative symptoms in schizophrenia
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: DSM-IV diagnosis of schizophrenia; negative symptoms for ≥ 6 weeks; medication resis-
tance; age 18 - 50 years
Exclusion criteria: contraindication to TMS; pregnancy
N = 80
Participants Men and women with schizophrenia with persistent negative symptoms
Interventions 1. rTMS: Left dorsolateral prefrontal cortex iTBS at 80% motor threshold, 20 sessions of 6 minutes, 2/day
2. sham: procedure as active iTBS with sham coil
Outcomes Primary outcome:
Mental state (negative symptoms (SANS))
Secondary outcomes:
Neurochemical impact: 1H-MRS, DTI and resting MRI
Starting date November 2008
Contact information Emmanuel Poulet, MD,PhD
Hopital Le Vinatier
phone: 33437915100
e-mail: emmanuel.poulet@ch-levinatier.fr
Notes Estimated study completion date: June 2011
The recruitment status of this study is unknown because the information has not been verified recently
NCT01015001
Trial name or title A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with
refractory schizophrenia treated with clozapine
Methods Randomised, double-blind, placebo-control, parallel assignment
Inclusion criteria: DSM-IV-TR diagnosis of schizophrenia with treatment-resistant auditory hallucinations;
treated by ≥ 400mg/day of clozapine; age 18 - 65 years; BPRS score ≥ 27
Exclusion criteria: suicide risk; epilepsy, brain surgery and/or head trauma in the past, use of cardiac pacemaker
or metallic clip in the head; substance abuse/dependence; severe uncontrolled organic disease
N = 20
Participants Men and women with schizophrenia, with treatment-resistant auditory hallucinations
Interventions 1. rTMS: LTPC rTMS, low frequency (1 Hz), 20 sessions of 20 minutes each
2. Sham: same coil, same number of pulses but using an angled coil (90º) over the frontotemporal region
Outcomes Primary outcome:
Quality of life; general functioning (measurement scales not reported)
Secondary outcome:
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NCT01015001 (Continued)
Mental state: severity of hallucinations; general psychopathology (measurement scales not reported)
Starting date May 2008
Contact information PI: Danilo Jesus, MD
Hospital de Clinicas de Porto Alegre
Study Director: Paulo B Abreu, PhD HCPorto Alegre
(phone, email not provided)
Notes Updated title at the NIH site. The study has been completed, results not posted
NCT01022489
Trial name or title Evaluation of repetitive transcranial magnetic stimulation (rTMS) at high frequency with neuronavigation in
the treatment of auditory hallucinations : a randomized multicentric controlled study
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: schizophrenic disorders; age from 16 - 65 years; auditory hallucinations (score AHRS > 10)
undergoing antipsychotic treatments; clinically stabilised (no antipsychotic treatments modifications for ≥ 2
months)
Exclusion criteria: pregnancy or breastfeeding; brain tumour; history of epilepsy; already treated once by
rTMS; counter-indication to MRI or to rTMS
N = 72
Participants Male and femaleen and women with schizophrenia or schizoaffective disorder with auditory hallucinations
Interventions 1. TMS: rTMS, 20 Hz, at 80% of rest motor threshold, 4 sessions of 13 minutes, with 2 sessions a day
2. Sham: placebo coil
Outcomes Mental state (hallucinations): AHRS
Starting date August 2009
Contact information Sonia Dollfus, MD, PhD
phone: + 33 2 31 06 44 38
e-mail: dollfuss@chucaen.fr
Notes Estimated study completion date: March 2013
Study still recruiting participants
NCT01315587
Trial name or title Repetitive transcranial magnetic stimulation and intermittent theta burst (iTBS) in schizophrenia
Methods Randomised, double-blind, active and placebo-control, parallel assignment
Inclusion criteria: 18 - 50 years of age; diagnosis of schizophrenia according toDSM-IV-TR; stable symptoms
(not requiring a change in antipsychotic medication for≥ 4 weeks or≥ 2 weeks for psychotropic agents prior
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NCT01315587 (Continued)
to entering the study)
Exclusion criteria: history of rTMS treatment; intracranial implant and other ferromagnetic materials close
to the head; cardiac pacemaker; drug pumps; acute heart attack; risk of seizure; high intracranial pressure;
history of epilepsy or seizure in the first relatives; brain trauma; history of loss of consciousness for more than
5 minutes; pregnancy; breastfeeding; drug dependency; high risk of suicide; significant positive symptoms
N = 30
Participants Schizophrenia (DSM-IV criteria) outpatients
Interventions 1. rTMS: LDLPFC, 15 Hz at 110% of motor threshold
2. iTBS: TMS 3 pulses,50 Hz repeated each 200 ms for 2 seconds at 80% motor threshold
3. Sham: sham coil
Duration: 20 sessions
Outcomes Primary outcome:
Mental state: PANSS negative symptoms (primary outcome)
Secondary outcomes:
Depression: CDSS;
Quality of life: SQLS;
Social and occupational functioning: SOFAS;
Neuropsychological state: Digit Span in WAIS, Rey Auditory Verbal-learning Test, Stroop, Iowa Gambling
Task, Trail Making Test A/B, Verbal (word) Fluency Test, WCST, Wechsler Memory Scale (R-III);
Brainwaves patterns: QEEG and LORETA
Starting date January 2011
Contact information Reza Kazemi, MA
Atieh comprehensive psyche and nerve centre, Tehran,Iran
phone: +9802184012128
e-mail:rezakazemi@ut.ac.ir
PI: Reza Rostami, MD
phone: +9802184012101
email: rrostami@ut.ac.ir
Notes Estimated study completion date: January 2017
NCT01370291
Trial name or title Repetitive transcranial magnetic stimulation (rTMS) for first-episode schizophrenia patients: a double-
blinded, randomized and functional magnetic resonance imaging (fMRI) study
Methods Randomised, double-blind, placebo-control, parallel assignment
Inclusion criteria: age 16 - 45 years; diagnosis of schizophrenia according to DSM-IV criteria; PANSS ≥ 60;
1st episode; have not been treated with any antipsychotic drugs
Exclusion criteria: suicide risk; substance abuse/dependence; severe uncontrolled organic disease; contraindi-
cation to TMS (implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, metallic
hardware in the head or scalp, signs of increased intracranial pressure); pregnancy or lactating; estimated IQ
80; have a sibling or parent with epilepsy
N = 60
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Participants Men and women with first-episode schizophrenia (DSM-IV criteria)
Interventions 1. Active rTMS and sham risperidone: a. auditory hallucinations: LTPC rTMS, 1 Hz; b. negative symptoms:
LTPC rTMS, 10 Hz
2. Active risperidone and active rTMS (active comparator): same rTMS procedures + active risperidone
3. Sham rTMS and active risperidone (sham comparator)
Outcomes Primary outcomes: Mental state (PANSS); fMRI
Secondary outcomes:
Mental state: AHRS;
Depression: HAMD
Clinical global impression: CGI
Starting date August 2011
Contact information Yunchun Chen, Ph.D
phone: +086-13720582601
email: Yunchunchen@163.com
Shufang Feng, Ph.D
phone:+086-13227807801
email: fangshuan1984@yahoo.com.cn
Notes Study title updated at the NIH site
Estimated study completion date: December 2013
NCT01512290
Trial name or title Theta burst transcranial magnetic stimulation as treatment for auditory verbal hallucinations; a placebo-
controlled trial
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychosis
NOS; age 18+ years; frequent auditory verbal hallucinations (> once an hour)
Exclusion criteria: Metal objects in or around the head that cannot be removed; history of seizures; increased
intracranial pressure; history of eye trauma with a metal object or professional metal workers; coercively
treated; represented by a legal ward or under legal custody; pregnancy; changes in the prescribed medication
in a period of 2 weeks prior to participation
N = 60
Participants Men and women with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychosis NOS,
with frequent auditory hallucinations
Interventions 1. TMS: left temporoparietal theta burst transcranial magnetic stimulation (TBS); 5 pulses at 50 Hz repeated
at 5 Hz for 60 seconds with a total of 900 pulses per treatment; 10 treatments (5 days, 2 treatments/day)
2. Sham
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NCT01512290 (Continued)
Outcomes Primary outcomes:
Mental state (severity and frequency of hallucinations): AHAS; PSYRATS; PANSS (total hallucinations
subscore)
Secondary outcome:
Adverse events
Starting date March 2012
Contact information Anne Lotte Meijering
phone: +31887559046
e-mail: A.L.Meijering@hotmail.nl
Iris Sommer, Prof, dr.
phone: +3188755370
e-mail:I.Sommer@umcutrecht.nl
Notes Estimated study completion date: February 2014
NCT01523730
Trial name or title Effects of repetitive transcranial magnetic stimulation on cigarette smoking and cognitive function in smokers
with and without schizophrenia
Methods Randomised, double-blind placebo-control, cross-over assignment
Inclusion criteria:
1. For all participants: Full scale IQ ≥ 80 as determined by the Shipley-2; non-treatment-seeking smokers; a
score 5 on the FTND; smoking of ≥ 10 cigarettes/day; expired breath CO level > 10 ppm
2. For people with schizophrenia: DSM-IV criteria for schizophrenia or schizoaffective disorder; stable remis-
sion from positive symptoms of psychosis, psychiatric evaluation and a PANSS total score < 70; stable dose
of antipsychotic mediation(s) for ≥ 1 month
3. For healthy controls: not meet DSM-IV criteria for any current or past psychiatric disorder except for past
major depression if it has been in remission for a minimum of 1 year; not taking any psychotropic medications
General Exclusion Criteria: abuse or dependence of alcohol or illicit substances within the past 3 months;
use of nicotine replacement or tobacco products other than cigarettes; concomitant medical illness that may
compromise study participation or neurological illness (history of seizures or a first-degree relative with a
history of a seizure disorder); pregnancy; metallic implants
N = 50
Participants Men and women with schizophrenia and schizoaffective disorder, and healthy volunteers; age 18 - 55 years
Interventions 1. TMS: dorsolateral prefrontal cortex rTMS, 20 Hz at 90% resting motor threshold (25 stimulation trains
of 30 stimuli each with an inter-train interval of 30 sec), 2 weeks (twice daily, 2 days/week)
2. Sham: Same stimulation parameters and site as active condition but with a single-wing tilt rTMS coil
position producing somatic sensation and minimal brain effects
Participants will undergo 2 testing weeks (active and sham rTMS treatment), washout period ≥ 1 month
between the testing weeks
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NCT01523730 (Continued)
Outcomes Primary outcome:
Cigarette craving: TQSU
Secondary outcomes:
Cigarette withdrawal: MNWS
Expired breath carbon monoxide (CO) levels
Plasma nicotine/cotinine levels
Sustained attention and response inhibition: CPT-X
Working memory: N-back; EEG recording during performance of N-back task
Visuospatial working memory: SDR
Verbal learning and memory: HVLT-R
Smoking Topography
Spontaneous smoking
Starting date February 2012
Contact information Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Vicky C Wing, Ph.D.
phone: 416-5358501 ext 4882
e-mail: vicky wing@camh.net
Caroline E Wass, Ph.D
phone: 416-5358501 ext 6225
e.mail: Caroline Wass@camh.net
Notes Estimated study completion date: March 2014
NCT01551979
Trial name or title Therapeutic efficacy of cerebellar repetitive transcranial magnetic stimulation in patients with schizophrenia
Methods Randomised, double-blind, placebo-control, parallel assignment
Inclusion criteria: age 18 - 65 years; diagnosis of schizophrenia according to DSM-IV criteria
Exclusion Criteria: pre-existing or progressive neurological disorders; prior neurological procedures; previous
head injury; change in antipsychotic medication during the last 4 weeks; inpatient in a psychiatry clinic within
the last month; any other axis 1 diagnosis; unable to undergo a brainMRI; unstable medical condition; history
of seizures, diagnosis of epilepsy, history of abnormal EEG, or family history of treatment-resistant epilepsy;
possible pregnancy; metal in the brain, skull; medical devices (i.e.. cardiac pacemaker, deep brain stimulator,
medication infusion pump, cochlear implant, vagal nerve stimulator); substance abuse or dependence within
the past 6 months
N = 36
Participants Men and women with schizophrenia (DSM-IV criteria). Age: 18 - 65 years
Interventions 1. rTMS: High-frequency rTMS stimulation of the vermis (lobule VII) of the cerebellum intermittent theta
burst (iTBS) pattern (20 trains of 10 bursts given with 8 sec intervals) at 80% of active motor threshold. 600
pulses per session
2. Sham
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NCT01551979 (Continued)
Outcomes Primary outcomes:
Mental state: PANSS
Clinical improvement: CGI
Secondary outcomes:
Mood: POMS
Depression: CDSS
Subjective assessment of change: VAS
Starting date February 2012
Contact information Andrea Pousada-Casal, Ph.D.
Beth Israel Deaconess Medical Center, Boston USA
phone:617-724-1622
e-mail: apousada@partners.org
PI: Alvaro Pascual-Leone, M.D., Ph.D
Notes Estimated study completion date: November 2013
Vercammen 2009b
Trial name or title Mechanism and efficacy of low frequency rTMS treatment in schizophrenic patients with auditory halluci-
nations: an fMRI study
Methods Randomised, double-blind placebo-control, parallel assignment
Inclusion criteria: Inpatients and outpatients; meet diagnostic criteria for schizophrenia or schizoaffective
disorder; report frequent auditory hallucinations (≥ 1 time/day); meet the criteria for medication resistance
(persistent auditory hallucinations occurringduring treatment≥ 2 adequate trials of antipsychoticmedication)
Exclusion criteria: rTMS contraindications (e.g. a personal or family history of epileptic seizures, past neu-
rosurgical procedures, intracerebral or pacemaker implants, inner ear prosthesis or other metal prosthetics/
implants); neurological disorders; history of significant head trauma; severe behavioural disorders; current
substance abuse; pregnancy; active psychosis
N = 48
Participants Schizophrenia or schizoaffective disorder with auditory hallucinations
Interventions 1. TMS: bilateral rTMS, 1Hz at 90% of restingmotor threshold, 12 sessions of 20minutes, over 6 consecutive
working days
2. Placebo: Details not reported
Outcomes Primary:
Mental state (hallucinations): AHRS
Secondary:
Mood: PANAS;
Mental state: PANSS;
Participant’s beliefs about auditory hallucinations: (BAVQ)
Starting date September 1, 2006
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Vercammen 2009b (Continued)
Contact information Prof. Dr. A. Aleman
Department of Neuroscience
University of Groningen & University Medical Center
Groningen.
Nehterlands
Other contact information not provided.
Notes Estimated trial completion date: not reported on trial register website
NTR1813
AHRS: Auditory hallucination rating scale
BAVQ: Beliefs About Voices Questionnaire
BPRS: brief psychiatric rating scale
CDSS: Calgary Depression Rating Scale for Schizophrenia
CPT-X: Continuous performance test-X
DLPFC: dorsolateral prefrontal cortex
EEG: electro-encephalogram
fMRI: functional magnetic resonance imaging
FTND: Fagerström test for nicotine dependence
HAMD: Hamilton Depression Rating Scale
HVLT-R: Hopkins verbal learning test revised
iTBS: intermittent theta burst stimulation
LDLPFC: left dorsolateral prefrontal cortex
MNWS: Minnesota nicotine withdrawal scale
PANAS: Positive and Negative Affect SchedulePANSS: positive and negative symptoms scale
POMS: profile of mood states
PSYRATS: Psychotic symptom rating scale
rTMS: repetitive transcranial magnetic stimulation
SAPS: scale for the assessment of positive symptoms
SANS: scale for the assessment of negative symptoms
SDR: Spatial delayed response
SOFAS: social and occupational functioning assessment scale
SQLS: Self-report quality of life measure for people with schizophrenia
TQSU: Tiffany questionnaire for smoking urges
VAS: visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. TEMPOROPARIETAL TMS vs SHAM TMS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Clinical
improvement (CGI)
1 46 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 128.33]
2 Global state: 2. Average score for
clinical improvement (CGI,
high = poor)
7 224 Mean Difference (IV, Fixed, 95% CI) -0.50 [-0.76, -0.23]
3 Mental state: 1. General: a.
Clinical improvement (PANSS
> 30% reduction)
1 51 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.10, 10.27]
4 Mental state: 1. General: b.
Average total score (various
scales)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 BPRS (high = poor) 1 17 Mean Difference (IV, Fixed, 95% CI) -5.68 [-12.98, 1.62]
4.2 PANSS total (high = poor) 5 127 Mean Difference (IV, Fixed, 95% CI) -6.09 [-10.95, -1.22]
5 Mental state: 1. General:
c. Average general
psychopathology score (PANSS
general, high = poor)
4 87 Mean Difference (IV, Fixed, 95% CI) -2.34 [-5.26, 0.59]
6 Mental state: 2. Specific: a.
Average depression score
(various scales)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 HAMD (high = poor) 1 25 Mean Difference (IV, Fixed, 95% CI) -3.92 [-7.84, -0.00]
6.2 SDS (high = poor) 1 25 Mean Difference (IV, Fixed, 95% CI) -5.59 [-11.57, 0.39]
7 Mental state: 2. Specific: b.i.
Hallucinations - clinical
improvement (various scales)
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 AHRS >30% decrease in
symptoms
3 120 Risk Ratio (M-H, Fixed, 95% CI) 2.99 [1.12, 7.98]
7.2 HCS score ≤5 3 133 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [1.18, 4.35]
7.3 PANSS hallucination item
improvement ≥1 point
1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.43, 4.13]
7.4 PSYRATS > 30%
reduction
1 51 Risk Ratio (M-H, Fixed, 95% CI) 3.6 [0.20, 65.96]
8 Mental state: 2. Specific: b.ii.
Average hallucinations score
(various scales)
13 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 AHRS (high = poor) 9 327 Mean Difference (IV, Random, 95% CI) -2.11 [-4.38, 0.16]
8.2 AVH-related items
PSYRATS (high = poor)
2 624 Mean Difference (IV, Random, 95% CI) -0.51 [-3.38, 2.36]
8.3 HCS (high = poor) 3 162 Mean Difference (IV, Random, 95% CI) -1.64 [-2.80, -0.48]
8.4 PANSS hallucination item
(high = poor)
4 125 Mean Difference (IV, Random, 95% CI) -1.01 [-1.97, -0.04]
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9 Mental state: 2. Specific: c.
Average negative symptom
score (various scales)
8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 BPRS (high = poor) 1 17 Mean Difference (IV, Fixed, 95% CI) -3.06 [-7.15, 1.03]
9.2 PANSS (high = poor) 7 162 Mean Difference (IV, Fixed, 95% CI) -0.31 [-1.87, 1.25]
9.3 SANS (high = poor) 1 25 Mean Difference (IV, Fixed, 95% CI) -23.58 [-37.06, -10.
10]
10 Mental state: 2. Specific: d.i.
Positive symptoms - clinical
improvement (PANSS > 30%
reduction)
1 51 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.10, 10.27]
11 Mental state: 2. Specific: d.ii.
Average positive symptom
score (various scales)
13 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 BPRS (high = poor) 1 17 Mean Difference (IV, Fixed, 95% CI) 0.53 [-2.78, 3.84]
11.2 PANSS (high = poor) 11 333 Mean Difference (IV, Fixed, 95% CI) -2.14 [-3.15, -1.14]
11.3 SAPS (high = poor) 2 49 Mean Difference (IV, Fixed, 95% CI) -3.22 [-7.86, 1.42]
12 Adverse effects: 1. General: a.
Serious
2 130 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Adverse effects: 1. General: b.
Leaving the study early
8 320 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.46, 1.32]
14 Adverse effects: 2. Specific 11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 cardiovascular -
lightheaded/Dizziness
3 158 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.45, 5.75]
14.2 central nervous system -
tinnitus
1 83 Risk Ratio (M-H, Fixed, 95% CI) 3.63 [0.19, 67.82]
14.3 cognitive - concentration
problems
2 122 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.26, 9.73]
14.4 cognitive - mild memory
impairment/amnesia
2 89 Risk Ratio (M-H, Fixed, 95% CI) 2.90 [0.35, 24.18]
14.5 movement disorder - jaw
and facial contraction
2 70 Risk Ratio (M-H, Fixed, 95% CI) 8.32 [1.13, 61.17]
14.6 movement disorder -
restless legs
1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.07, 35.67]
14.7 psychiatric - worsening
hallucinations/audible
Thoughts
1 83 Risk Ratio (M-H, Fixed, 95% CI) 2.55 [0.31, 20.75]
14.8 others - earache 1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.07, 35.67]
14.9 others - headache 10 392 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [1.56, 4.50]
14.10 others - somatic
discomfort
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [0.65, 4.91]
14.11 others - tingling
sensation in the arm
1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.07, 35.67]
15 Quality of life: Average score
(Q-LES-Q, low = poor)
1 20 Mean Difference (IV, Fixed, 95% CI) -1.0 [-14.26, 12.26]
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Comparison 2. TEMPOROPARIETAL TMS vs STANDARD TREATMENT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: Clinical
improvement (CGI ≤ 2)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.91, 1.57]
2 Adverse effects: Leaving the
study early
2 140 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.08, 1.46]
Comparison 3. PREFRONTAL TMS vs SHAM TMS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: Average score
(various scales)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 CGI (high = poor) 1 31 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.15, 1.35]
1.2 CGI-S (high = poor) 1 32 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.63, 0.45]
1.3 GAF (low = poor) 1 32 Mean Difference (IV, Fixed, 95% CI) 3.43 [-5.22, 12.08]
1.4 SCL-90 GSI (high = poor) 1 22 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.66, 0.56]
2 Mental state: 1. General: a.
Clinical improvement (> 20%
decrease in total PANSS score)
1 22 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 0.98]
3 Mental state: 1. General: b.
Average total score (various
scales)
7 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 BPRS (high = poor) 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 PANSS (high = poor) 6 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Mental state: 1. General:
c. Average general
psychopathology score
(PANSS, high = poor)
6 Mean Difference (IV, Random, 95% CI) Subtotals only
5 Mental state: 2. Specific: a.
Average depression score
(various scales)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 HAMD-17 (high = poor) 1 43 Mean Difference (IV, Fixed, 95% CI) -2.40 [-3.88, -0.92]
5.2 HDRS (high = poor) 1 31 Mean Difference (IV, Fixed, 95% CI) 1.70 [-0.95, 4.35]
5.3 MADRS (high = poor) 1 22 Mean Difference (IV, Fixed, 95% CI) -4.36 [-7.05, -1.67]
5.4 SCL-90 DEP (high =
poor)
1 22 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.61, 0.63]
6 Mental state: 2. Specific: b.
Average hallucinations score
(PANSS, high = poor)
1 25 Mean Difference (IV, Fixed, 95% CI) -0.68 [-1.68, 0.32]
7 Mental state: 2. Specific: c. i.
Negative symptoms - clinical
improvement (> 20% decrease
in PANSS negative)
1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.04, 1.77]
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8 Mental state: 2. Specific: c. ii.
Average negative symptom
score (various scales)
13 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 PANSS (high = poor) 12 341 Mean Difference (IV, Random, 95% CI) -1.59 [-4.68, 1.50]
8.2 SANS (high = poor) 3 71 Mean Difference (IV, Random, 95% CI) -12.68 [-18.60, -6.
77]
9 Mental state: 2. Specific: d.
Average positive symptom
score (various scales)
10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 PANSS (high = poor) 10 279 Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.99, 0.33]
9.2 SAPS (high = poor) 1 22 Mean Difference (IV, Fixed, 95% CI) -0.27 [-2.61, 2.07]
10 Mental state: 2. Specific: e.
Average psychotism score
(SCL-90 PSY, high = poor)
1 22 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.48, 0.46]
11 Adverse effects: 1. General: a.
Adverse events (UKU)
1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Adverse effects: 1. General: b.
Leaving the study early
8 174 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.56, 2.50]
13 Adverse effects: 2. Specific: a.
Various
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 cognition - cognitive
difficulties
1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 movement disorder -
facial twitching
1 31 Risk Ratio (M-H, Fixed, 95% CI) 6.59 [0.37, 117.77]
13.3 movement disorder
- worsening of pre-existing
akathesia
1 31 Risk Ratio (M-H, Fixed, 95% CI) 4.71 [0.24, 90.69]
13.4 psychiatric - worsening
of pre-existing OCD
1 31 Risk Ratio (M-H, Fixed, 95% CI) 4.71 [0.24, 90.69]
13.5 other - headache 6 164 Risk Ratio (M-H, Fixed, 95% CI) 2.77 [1.22, 6.26]
13.6 other - TMS-related site
discomfort/pain
2 42 Risk Ratio (M-H, Fixed, 95% CI) 8.33 [1.68, 41.27]
14 Adverse effects: 2. Specific: b.
Average score (CSSES, high =
poor)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 cognitive complaints 1 17 Mean Difference (IV, Fixed, 95% CI) -0.6 [-2.69, 1.49]
14.2 subjective side effects 1 17 Mean Difference (IV, Fixed, 95% CI) -1.90 [-10.31, 6.51]
Comparison 4. PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: Clinical
improvement
1 27 Risk Ratio (M-H, Fixed, 95% CI) 4.06 [0.21, 77.37]
2 Mental state: 1. General: a.
Average overall mental state
score (PANSS total, high =
poor)
3 108 Mean Difference (IV, Fixed, 95% CI) -5.71 [-9.32, -2.10]
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3 Mental state: 1. General:
b. Average general
psychopathology score
(PANSS, high = poor)
3 108 Mean Difference (IV, Fixed, 95% CI) -2.47 [-4.21, -0.73]
4 Mental state: 2. Specific: a.
Average negative symptom
score (various scales)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 PANSS (high = poor) 3 108 Mean Difference (IV, Fixed, 95% CI) -2.67 [-4.25, -1.09]
4.2 SANS (high = poor) 1 27 Mean Difference (IV, Fixed, 95% CI) -11.55 [-21.90, -1.
20]
5 Mental state: 2. Specific: b.
Average positive symptom
score (PANSS, high = poor)
3 108 Mean Difference (IV, Fixed, 95% CI) -0.42 [-1.64, 0.80]
6 Cognitive state: Average score
(various measures)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 digit span test 1 39 Mean Difference (IV, Fixed, 95% CI) 2.10 [-0.23, 4.43]
6.2 verbal fluency test 1 39 Mean Difference (IV, Fixed, 95% CI) 2.10 [-2.87, 7.07]
7 Adverse effects: 1. Leaving the
study early
2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.07, 1.74]
8 Adverse effects: 2. Specific 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 headache 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.11, 2.70]
8.2 sleep disorder 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 6.11]
Comparison 5. SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs SHAM
TMS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: Clinical
improvement
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 including only people who
completed the studies
1 27 Risk Ratio (M-H, Fixed, 95% CI) 4.06 [0.21, 77.37]
1.2 Intention-to-treat analysis 1 30 Risk Ratio (M-H, Fixed, 95% CI) 4.41 [0.23, 84.79]
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Analysis 1.1. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 1 Global state: 1. Clinical
improvement (CGI).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 1 Global state: 1. Clinical improvement (CGI)
Study or subgroup Favours sham TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gao 2009a (1) 3/23 0/23 100.0 % 7.00 [ 0.38, 128.33 ]
Total (95% CI) 23 23 100.0 % 7.00 [ 0.38, 128.33 ]
Total events: 3 (Favours sham TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours sham TMS Favours TMS
(1) Markedly improved, response criteria not reported
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Analysis 1.2. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 2 Global state: 2. Average
score for clinical improvement (CGI, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 2 Global state: 2. Average score for clinical improvement (CGI, high = poor)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Jesus 2011 8 5 (1.06) 9 5.11 (1.05) 7.2 % -0.11 [ -1.12, 0.90 ]
Hoffman 2005 27 2.85 (0.85) 23 3.8 (0.88) 31.1 % -0.95 [ -1.43, -0.47 ]
Lee 2005 13 4.3 (0.85) 14 5 (1.11) 13.1 % -0.70 [ -1.44, 0.04 ]
NCT00308997 (1) 55 2.72 (1.15) 28 3.21 (1.35) 21.1 % -0.49 [ -1.08, 0.10 ]
Rosa 2007 6 2.67 (0.52) 5 2.4 (0.55) 17.8 % 0.27 [ -0.37, 0.91 ]
Rosenberg 2012 (2) 10 4 (1.6) 10 4.8 (0.9) 5.6 % -0.80 [ -1.94, 0.34 ]
Saba 2006a 8 3.38 (1.6) 8 3.38 (1.06) 4.1 % 0.0 [ -1.33, 1.33 ]
Total (95% CI) 127 97 100.0 % -0.50 [ -0.76, -0.23 ]
Heterogeneity: Chi2 = 10.63, df = 6 (P = 0.10); I2 =44%
Test for overall effect: Z = 3.61 (P = 0.00030)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours TMS Favours Sham TMS
(1) LOCF
(2) Deep TMS, data extracted from a graph
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Analysis 1.3. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 3 Mental state: 1.
General: a. Clinical improvement (PANSS > 30% reduction).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 3 Mental state: 1. General: a. Clinical improvement (PANSS > 30% reduction)
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blumberger 2012 (1) 2/34 1/17 100.0 % 1.00 [ 0.10, 10.27 ]
Total (95% CI) 34 17 100.0 % 1.00 [ 0.10, 10.27 ]
Total events: 2 (Temporoparietal TMS), 1 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Sham TMS Favours TMS
(1) Response criteria provided by the study
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Analysis 1.4. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 4 Mental state: 1.
General: b. Average total score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 4 Mental state: 1. General: b. Average total score (various scales)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BPRS (high = poor)
De Jesus 2011 8 23.88 (7.99) 9 29.56 (7.29) 100.0 % -5.68 [ -12.98, 1.62 ]
Subtotal (95% CI) 8 9 100.0 % -5.68 [ -12.98, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 PANSS total (high = poor)
Blumberger 2012 27 61.0022 (14.0203) 13 63.92 (17.66) 19.7 % -2.92 [ -13.88, 8.04 ]
Hao 2008 13 61.69 (13.91) 12 67.83 (12.13) 22.7 % -6.14 [ -16.35, 4.07 ]
Rosa 2007 6 83 (16.55) 5 85.75 (3.86) 12.7 % -2.75 [ -16.42, 10.92 ]
Saba 2006a 8 65.38 (19.73) 8 70.5 (15.25) 7.9 % -5.12 [ -22.40, 12.16 ]
Xu 2011 18 69.44 (15.35) 17 78.53 (7.75) 37.0 % -9.09 [ -17.08, -1.10 ]
Subtotal (95% CI) 72 55 100.0 % -6.09 [ -10.95, -1.22 ]
Heterogeneity: Chi2 = 1.10, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
-20 -10 0 10 20
Favours TMS Favours Sham TMS
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Analysis 1.5. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 5 Mental state: 1.
General: c. Average general psychopathology score (PANSS general, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 5 Mental state: 1. General: c. Average general psychopathology score (PANSS general, high = poor)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hao 2008 13 31.85 (5.57) 12 32.83 (6.37) 38.6 % -0.98 [ -5.69, 3.73 ]
Rosa 2007 6 45.2 (8.23) 5 44.75 (1.5) 19.0 % 0.45 [ -6.27, 7.17 ]
Saba 2006a 8 33.63 (10.64) 8 35.63 (6.68) 11.3 % -2.00 [ -10.71, 6.71 ]
Xu 2011 18 34.11 (9.82) 17 39.94 (5.5) 31.2 % -5.83 [ -11.07, -0.59 ]
Total (95% CI) 45 42 100.0 % -2.34 [ -5.26, 0.59 ]
Heterogeneity: Chi2 = 2.70, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours TMS Favours Sham TMS
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Analysis 1.6. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 6 Mental state: 2.
Specific: a. Average depression score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 6 Mental state: 2. Specific: a. Average depression score (various scales)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HAMD (high = poor)
Hao 2008 13 12 (3.27) 12 15.92 (6.17) 100.0 % -3.92 [ -7.84, 0.00 ]
Subtotal (95% CI) 13 12 100.0 % -3.92 [ -7.84, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 SDS (high = poor)
Hao 2008 13 37.08 (6.09) 12 42.67 (8.8) 100.0 % -5.59 [ -11.57, 0.39 ]
Subtotal (95% CI) 13 12 100.0 % -5.59 [ -11.57, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
-20 -10 0 10 20
Favours TMS Favours Sham TMS
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Analysis 1.7. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 7 Mental state: 2.
Specific: b.i. Hallucinations - clinical improvement (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 7 Mental state: 2. Specific: b.i. Hallucinations - clinical improvement (various scales)
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 AHRS >30% decrease in symptoms
Blumberger 2012 (1) 2/34 1/17 28.2 % 1.00 [ 0.10, 10.27 ]
Klirova 2010 (2) 9/20 0/20 10.6 % 19.00 [ 1.18, 305.88 ]
Vercammen 2009a (3) 6/21 2/8 61.2 % 1.14 [ 0.29, 4.53 ]
Subtotal (95% CI) 75 45 100.0 % 2.99 [ 1.12, 7.98 ]
Total events: 17 (Temporoparietal TMS), 3 (Sham TMS)
Heterogeneity: Chi2 = 4.42, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 2.19 (P = 0.029)
2 HCS score≤5
Blumberger 2012 (4) 3/34 1/17 13.5 % 1.50 [ 0.17, 13.36 ]
Fitzgerald 2005 (5) 8/17 4/15 42.9 % 1.76 [ 0.66, 4.70 ]
Hoffman 2005 (6) 14/27 4/23 43.6 % 2.98 [ 1.14, 7.80 ]
Subtotal (95% CI) 78 55 100.0 % 2.26 [ 1.18, 4.35 ]
Total events: 25 (Temporoparietal TMS), 9 (Sham TMS)
Heterogeneity: Chi2 = 0.70, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
3 PANSS hallucination item improvement≥1 point
Vercammen 2009a (7) 8/24 3/12 100.0 % 1.33 [ 0.43, 4.13 ]
Subtotal (95% CI) 24 12 100.0 % 1.33 [ 0.43, 4.13 ]
Total events: 8 (Temporoparietal TMS), 3 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
4 PSYRATS > 30% reduction
Blumberger 2012 (8) 3/34 0/17 100.0 % 3.60 [ 0.20, 65.96 ]
Subtotal (95% CI) 34 17 100.0 % 3.60 [ 0.20, 65.96 ]
Total events: 3 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
0.002 0.1 1 10 500
Favours Sham TMS Favours TMS
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(1) Response criteria not reported
(2) Response criteria provided by the study
(3) Response criteria provided by the study
(4) Response criteria provided by the study
(5) Response criteria not reported
(6) Response criteria provided by the study
(7) Response criteria provided by the study
(8) Response criteria provided by the study
Analysis 1.8. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 8 Mental state: 2.
Specific: b.ii. Average hallucinations score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 8 Mental state: 2. Specific: b.ii. Average hallucinations score (various scales)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 AHRS (high = poor)
Blumberger 2012 24 26.665 (7.6396) 12 24.92 (8.25) 9.5 % 1.74 [ -3.83, 7.32 ]
Brunelin 2006 14 14.1 (9.9) 10 20.5 (6.5) 7.8 % -6.40 [ -12.97, 0.17 ]
De Jesus 2011 8 27.13 (3.35) 9 25.44 (8.61) 8.6 % 1.69 [ -4.40, 7.78 ]
Gao 2009a 23 3.5 (1.5) 23 6.5 (2.1) 21.4 % -3.00 [ -4.05, -1.95 ]
Hoffman 2005 27 19.48 (7.76) 23 24.22 (6.93) 13.0 % -4.74 [ -8.81, -0.67 ]
NCT00308997 (1) 55 4.48 (6.9) 28 3 (6.21) 16.3 % 1.48 [ -1.46, 4.42 ]
Poulet 2005 (2) 5 -14.3 (8.97) 5 -1.6 (2.86) 5.6 % -12.70 [ -20.95, -4.45 ]
Rosenberg 2012 (3) 5 22.6 (6.2) 5 23 (5.8) 6.6 % -0.40 [ -7.84, 7.04 ]
Slotema 2011 37 22.6514 (6.8075) 14 24.1 (8.1) 11.2 % -1.45 [ -6.23, 3.33 ]
Subtotal (95% CI) 198 129 100.0 % -2.11 [ -4.38, 0.16 ]
Heterogeneity: Tau2 = 5.95; Chi2 = 20.85, df = 8 (P = 0.01); I2 =62%
Test for overall effect: Z = 1.83 (P = 0.068)
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Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 AVH-related items PSYRATS (high = poor)
Blumberger 2012 24 28.4983 (7.9823) 549 28.5 (12) 73.3 % 0.00 [ -3.35, 3.35 ]
Slotema 2011 37 23.4946 (9.3273) 14 25.4 (8.9) 26.7 % -1.91 [ -7.45, 3.64 ]
Subtotal (95% CI) 61 563 100.0 % -0.51 [ -3.38, 2.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
3 HCS (high = poor)
Fitzgerald 2005 (4) 17 -3.3 (4.1) 15 -1.9 (4.2) 14.6 % -1.40 [ -4.28, 1.48 ]
Hoffman 2005 (5) 26 5.8 (2.8) 21 8.7 (3.8) 28.8 % -2.90 [ -4.85, -0.95 ]
NCT00308997 (6) 55 6.45 (3.42) 28 7.51 (2.26) 56.6 % -1.06 [ -2.29, 0.17 ]
Subtotal (95% CI) 98 64 100.0 % -1.64 [ -2.80, -0.48 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.78 (P = 0.0054)
4 PANSS hallucination item (high = poor)
Fitzgerald 2005 17 4.35 (0.79) 15 4.8 (0.56) 29.5 % -0.45 [ -0.92, 0.02 ]
Gao 2010 21 2.5 (1.1) 21 4.8 (1.7) 25.2 % -2.30 [ -3.17, -1.43 ]
McIntosh 2004 8 4.5 (1.3) 8 4.5 (1.1) 21.5 % 0.0 [ -1.18, 1.18 ]
Xu 2011 18 3 (1.75) 17 4.24 (1.2) 23.8 % -1.24 [ -2.23, -0.25 ]
Subtotal (95% CI) 64 61 100.0 % -1.01 [ -1.97, -0.04 ]
Heterogeneity: Tau2 = 0.77; Chi2 = 16.13, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 2.05 (P = 0.041)
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Analysis 1.9. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 9 Mental state: 2.
Specific: c. Average negative symptom score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 9 Mental state: 2. Specific: c. Average negative symptom score (various scales)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BPRS (high = poor)
De Jesus 2011 8 9.5 (3.81) 9 12.56 (4.79) 100.0 % -3.06 [ -7.15, 1.03 ]
Subtotal (95% CI) 8 9 100.0 % -3.06 [ -7.15, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 PANSS (high = poor)
Fitzgerald 2005 17 15.94 (5.9) 15 15.13 (3.46) 22.2 % 0.81 [ -2.50, 4.12 ]
Hao 2008 13 16.54 (6.12) 12 19.83 (7.85) 7.9 % -3.29 [ -8.84, 2.26 ]
Lee 2005 13 21.23 (7.8) 14 20.29 (5.38) 9.4 % 0.94 [ -4.15, 6.03 ]
McIntosh 2004 8 17.5 (6) 8 17.5 (5.6) 7.5 % 0.0 [ -5.69, 5.69 ]
Rosa 2007 6 18 (4.8) 5 18.75 (0.5) 16.3 % -0.75 [ -4.62, 3.12 ]
Saba 2006a 8 17.87 (5.23) 8 18.88 (5.41) 8.9 % -1.01 [ -6.22, 4.20 ]
Xu 2011 18 18.5 (5.51) 17 18.88 (3.18) 27.7 % -0.38 [ -3.34, 2.58 ]
Subtotal (95% CI) 83 79 100.0 % -0.31 [ -1.87, 1.25 ]
Heterogeneity: Chi2 = 1.91, df = 6 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
3 SANS (high = poor)
Hao 2008 13 24 (11.18) 12 47.58 (21.27) 100.0 % -23.58 [ -37.06, -10.10 ]
Subtotal (95% CI) 13 12 100.0 % -23.58 [ -37.06, -10.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.43 (P = 0.00061)
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Analysis 1.10. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 10 Mental state: 2.
Specific: d.i. Positive symptoms - clinical improvement (PANSS > 30% reduction).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 10 Mental state: 2. Specific: d.i. Positive symptoms - clinical improvement (PANSS > 30% reduction)
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blumberger 2012 (1) 2/34 1/17 100.0 % 1.00 [ 0.10, 10.27 ]
Total (95% CI) 34 17 100.0 % 1.00 [ 0.10, 10.27 ]
Total events: 2 (Temporoparietal TMS), 1 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 11 Mental state: 2.
Specific: d.ii. Average positive symptom score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 11 Mental state: 2. Specific: d.ii. Average positive symptom score (various scales)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BPRS (high = poor)
De Jesus 2011 8 9.75 (4.16) 9 9.22 (2.48) 100.0 % 0.53 [ -2.78, 3.84 ]
Subtotal (95% CI) 8 9 100.0 % 0.53 [ -2.78, 3.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
2 PANSS (high = poor)
Blumberger 2012 27 15.6626 (3.8029) 13 17.08 (4.55) 12.3 % -1.42 [ -4.28, 1.44 ]
Fitzgerald 2005 17 17.41 (4.06) 15 20.87 (4.49) 11.3 % -3.46 [ -6.44, -0.48 ]
Hao 2008 13 13.31 (4.09) 12 15.17 (4.8) 8.2 % -1.86 [ -5.37, 1.65 ]
Hoffman 2005 27 14.29 (3.95) 23 16.48 (4.94) 16.0 % -2.19 [ -4.70, 0.32 ]
Klirova 2010 20 16.05 (6.6823) 10 22.6 (6.41) 4.1 % -6.55 [ -11.49, -1.61 ]
Lee 2005 13 23.07 (7.26) 14 21.64 (4.81) 4.6 % 1.43 [ -3.25, 6.11 ]
McIntosh 2004 8 15.9 (4.6) 8 18.9 (6.4) 3.4 % -3.00 [ -8.46, 2.46 ]
Rosa 2007 6 19.8 (5.63) 5 22.25 (3.5) 3.4 % -2.45 [ -7.90, 3.00 ]
Saba 2006a 8 16.38 (6.26) 8 17.25 (4.59) 3.5 % -0.87 [ -6.25, 4.51 ]
Slotema 2011 37 14.7703 (4.8503) 14 15.9 (3.5) 17.3 % -1.13 [ -3.54, 1.28 ]
Xu 2011 18 16.83 (3.65) 17 19.71 (3.9) 16.0 % -2.88 [ -5.39, -0.37 ]
Subtotal (95% CI) 194 139 100.0 % -2.14 [ -3.15, -1.14 ]
Heterogeneity: Chi2 = 7.66, df = 10 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 4.19 (P = 0.000028)
3 SAPS (high = poor)
Brunelin 2006 14 49.1 (22.7) 10 58.3 (25.9) 5.4 % -9.20 [ -29.18, 10.78 ]
Hao 2008 13 9.62 (5.95) 12 12.5 (6.19) 94.6 % -2.88 [ -7.65, 1.89 ]
Subtotal (95% CI) 27 22 100.0 % -3.22 [ -7.86, 1.42 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
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Analysis 1.12. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1.
General: a. Serious.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 12 Adverse effects: 1. General: a. Serious
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT00308997 0/55 0/28 Not estimable
Vercammen 2009a 0/24 0/23 Not estimable
Total (95% CI) 79 51 Not estimable
Total events: 0 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 1.
General: b. Leaving the study early.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 13 Adverse effects: 1. General: b. Leaving the study early
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Blumberger 2012 7/17 4/17 17.2 % 1.75 [ 0.63, 4.89 ]
Fitzgerald 2005 0/17 2/16 11.1 % 0.19 [ 0.01, 3.66 ]
Hoffman 2005 2/27 2/23 9.3 % 0.85 [ 0.13, 5.58 ]
Lee 2005 0/8 0/8 Not estimable
Liu 2008 1/12 1/11 4.5 % 0.92 [ 0.06, 12.95 ]
NCT00308997 1/56 1/28 5.7 % 0.50 [ 0.03, 7.70 ]
Rosenberg 2012 (1) 4/9 4/9 17.2 % 1.00 [ 0.36, 2.81 ]
Slotema 2011 5/42 6/20 35.0 % 0.40 [ 0.14, 1.15 ]
Total (95% CI) 188 132 100.0 % 0.78 [ 0.46, 1.32 ]
Total events: 20 (Temporoparietal TMS), 20 (Sham TMS)
Heterogeneity: Chi2 = 5.15, df = 6 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2.
Specific.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 14 Adverse effects: 2. Specific
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 cardiovascular - lightheaded/Dizziness
Lee 2005 2/25 2/14 66.1 % 0.56 [ 0.09, 3.55 ]
NCT00308997 5/55 0/28 17.0 % 5.70 [ 0.33, 99.48 ]
Vercammen 2009a 1/24 0/12 17.0 % 1.56 [ 0.07, 35.67 ]
Subtotal (95% CI) 104 54 100.0 % 1.60 [ 0.45, 5.75 ]
Total events: 8 (Temporoparietal TMS), 2 (Sham TMS)
Heterogeneity: Chi2 = 2.00, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 central nervous system - tinnitus
NCT00308997 3/55 0/28 100.0 % 3.63 [ 0.19, 67.82 ]
Subtotal (95% CI) 55 28 100.0 % 3.63 [ 0.19, 67.82 ]
Total events: 3 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
3 cognitive - concentration problems
Lee 2005 1/25 0/14 32.4 % 1.73 [ 0.08, 39.86 ]
NCT00308997 3/55 1/28 67.6 % 1.53 [ 0.17, 14.02 ]
Subtotal (95% CI) 80 42 100.0 % 1.59 [ 0.26, 9.73 ]
Total events: 4 (Temporoparietal TMS), 1 (Sham TMS)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
4 cognitive - mild memory impairment/amnesia
Hoffman 2005 2/27 0/23 45.9 % 4.29 [ 0.22, 84.97 ]
Lee 2005 (1) 1/25 0/14 54.1 % 1.73 [ 0.08, 39.86 ]
Subtotal (95% CI) 52 37 100.0 % 2.90 [ 0.35, 24.18 ]
Total events: 3 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
5 movement disorder - jaw and facial contraction
Blumberger 2012 (2) 4/17 0/17 43.2 % 9.00 [ 0.52, 155.24 ]
Vercammen 2009a 7/24 0/12 56.8 % 7.80 [ 0.48, 126.13 ]
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Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 41 29 100.0 % 8.32 [ 1.13, 61.17 ]
Total events: 11 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
6 movement disorder - restless legs
Vercammen 2009a 1/24 0/12 100.0 % 1.56 [ 0.07, 35.67 ]
Subtotal (95% CI) 24 12 100.0 % 1.56 [ 0.07, 35.67 ]
Total events: 1 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
7 psychiatric - worsening hallucinations/audible Thoughts
NCT00308997 5/55 1/28 100.0 % 2.55 [ 0.31, 20.75 ]
Subtotal (95% CI) 55 28 100.0 % 2.55 [ 0.31, 20.75 ]
Total events: 5 (Temporoparietal TMS), 1 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
8 others - earache
Vercammen 2009a 1/24 0/12 100.0 % 1.56 [ 0.07, 35.67 ]
Subtotal (95% CI) 24 12 100.0 % 1.56 [ 0.07, 35.67 ]
Total events: 1 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
9 others - headache
Blumberger 2012 4/17 2/17 11.6 % 2.00 [ 0.42, 9.50 ]
De Jesus 2011 2/8 0/9 2.7 % 5.56 [ 0.31, 100.94 ]
Gao 2009a 6/23 1/23 5.8 % 6.00 [ 0.78, 45.99 ]
Gao 2010 6/21 1/21 5.8 % 6.00 [ 0.79, 45.63 ]
Lee 2005 5/25 2/14 14.8 % 1.40 [ 0.31, 6.30 ]
Liu 2008 1/12 1/11 6.0 % 0.92 [ 0.06, 12.95 ]
NCT00308997 12/55 4/28 30.7 % 1.53 [ 0.54, 4.30 ]
Rosa 2007 1/6 0/5 3.1 % 2.57 [ 0.13, 52.12 ]
Vercammen 2009a 8/24 1/12 7.7 % 4.00 [ 0.56, 28.40 ]
Yu 2010 8/31 2/30 11.8 % 3.87 [ 0.89, 16.77 ]
Subtotal (95% CI) 222 170 100.0 % 2.65 [ 1.56, 4.50 ]
Total events: 53 (Temporoparietal TMS), 14 (Sham TMS)
Heterogeneity: Chi2 = 4.44, df = 9 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00030)
10 others - somatic discomfort
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Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
NCT00308997 14/55 4/28 100.0 % 1.78 [ 0.65, 4.91 ]
Subtotal (95% CI) 55 28 100.0 % 1.78 [ 0.65, 4.91 ]
Total events: 14 (Temporoparietal TMS), 4 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
11 others - tingling sensation in the arm
Vercammen 2009a 1/24 0/12 100.0 % 1.56 [ 0.07, 35.67 ]
Subtotal (95% CI) 24 12 100.0 % 1.56 [ 0.07, 35.67 ]
Total events: 1 (Temporoparietal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
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Analysis 1.15. Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 15 Quality of life:
Average score (Q-LES-Q, low = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 1 TEMPOROPARIETAL TMS vs SHAM TMS
Outcome: 15 Quality of life: Average score (Q-LES-Q, low = poor)
Study or subgroup
Temporoparietal
TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rosenberg 2012 (1) 10 52 (13) 10 53 (17) 100.0 % -1.00 [ -14.26, 12.26 ]
Total (95% CI) 10 10 100.0 % -1.00 [ -14.26, 12.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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(1) Deep TMS, data extracted from a graph
Analysis 2.1. Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 1 Global
state: Clinical improvement (CGI ≤ 2).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT
Outcome: 1 Global state: Clinical improvement (CGI ≤ 2)
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Liu 2011 (1) 37/50 31/50 100.0 % 1.19 [ 0.91, 1.57 ]
Total (95% CI) 50 50 100.0 % 1.19 [ 0.91, 1.57 ]
Total events: 37 (Temporoparietal TMS), 31 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 2 Adverse
effects: Leaving the study early.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT
Outcome: 2 Adverse effects: Leaving the study early
Study or subgroup
Temporoparietal
TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bagati 2009 2/20 6/20 100.0 % 0.33 [ 0.08, 1.46 ]
Liu 2011 0/50 0/50 Not estimable
Total (95% CI) 70 70 100.0 % 0.33 [ 0.08, 1.46 ]
Total events: 2 (Temporoparietal TMS), 6 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 1 Global state: Average score
(various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 1 Global state: Average score (various scales)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CGI (high = poor)
Klein 1999 (1) 16 4.6 (1.3) 15 4 (0.8) 100.0 % 0.60 [ -0.15, 1.35 ]
Subtotal (95% CI) 16 15 100.0 % 0.60 [ -0.15, 1.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
2 CGI-S (high = poor)
Guse 2013 18 4.29 (0.77) 14 4.38 (0.77) 100.0 % -0.09 [ -0.63, 0.45 ]
Subtotal (95% CI) 18 14 100.0 % -0.09 [ -0.63, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
3 GAF (low = poor)
Guse 2013 18 61.29 (12.34) 14 57.86 (12.43) 100.0 % 3.43 [ -5.22, 12.08 ]
Subtotal (95% CI) 18 14 100.0 % 3.43 [ -5.22, 12.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
4 SCL-90 GSI (high = poor)
Holi 2004 11 0.73 (0.56) 11 0.78 (0.86) 100.0 % -0.05 [ -0.66, 0.56 ]
Subtotal (95% CI) 11 11 100.0 % -0.05 [ -0.66, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 3.2. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 2 Mental state: 1. General: a.
Clinical improvement (> 20% decrease in total PANSS score).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 2 Mental state: 1. General: a. Clinical improvement (> 20% decrease in total PANSS score)
Study or subgroup Prefrontal TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Holi 2004 (1) 1/11 7/11 100.0 % 0.14 [ 0.02, 0.98 ]
Total (95% CI) 11 11 100.0 % 0.14 [ 0.02, 0.98 ]
Total events: 1 (Prefrontal TMS), 7 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Sham TMS Favours Prefrontal TMS
(1) Response criteria provided by the study
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Analysis 3.3. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: b.
Average total score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 3 Mental state: 1. General: b. Average total score (various scales)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS (high = poor)
Klein 1999 (1) 16 29.9 (13.7) 15 26.8 (4.5) 3.10 [ -3.99, 10.19 ]
2 PANSS (high = poor)
Fitzgerald 2008 (2) 10 65.4 (11) 10 58.4 (7.6) 7.00 [ -1.29, 15.29 ]
Gao 2009b 21 40.1 (5.4) 22 39.4 (4.2) 0.70 [ -2.20, 3.60 ]
Prikryl 2007 11 45.82 (8.51) 11 57 (10.26) -11.18 [ -19.06, -3.30 ]
Ren 2010 (3) 12 63.69 (14.16) 13 69.08 (17.71) -5.39 [ -17.91, 7.13 ]
Ren 2011 12 62 (12.01) 11 67.56 (15.99) -5.56 [ -17.20, 6.08 ]
Zheng 2012 38 60.1 (13.0291) 17 67.7 (11.7) -7.60 [ -14.53, -0.67 ]
-50 -25 0 25 50
Favours Prefrontal TMS Favours Sham TMS
(1) Right prefrontal, low frequency (1Hz)
(2) LOCF
(3) Low frequency (1 Hz)
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Analysis 3.4. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: c.
Average general psychopathology score (PANSS, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 4 Mental state: 1. General: c. Average general psychopathology score (PANSS, high = poor)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gao 2009b 21 20.3 (2.7) 22 19.1 (2.8) 1.20 [ -0.44, 2.84 ]
Klein 1999 (1) 16 29.8 (10.7) 15 24 (7) 5.80 [ -0.53, 12.13 ]
Prikryl 2007 11 23 (3.44) 11 28.64 (4.5) -5.64 [ -8.99, -2.29 ]
Ren 2010 (2) 12 33.31 (8.79) 13 36.08 (8.65) -2.77 [ -9.61, 4.07 ]
Ren 2011 12 33.36 (10.41) 11 35 (8.26) -1.64 [ -9.29, 6.01 ]
Zheng 2012 38 26.45 (5.7878) 17 31.1 (3.9) -4.65 [ -7.26, -2.04 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
-10 -5 0 5 10
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149Transcranial magnetic stimulation (TMS) for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.5. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 5 Mental state: 2. Specific: a.
Average depression score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 5 Mental state: 2. Specific: a. Average depression score (various scales)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HAMD-17 (high = poor)
Gao 2009b 21 11.7 (2.1) 22 14.1 (2.8) 100.0 % -2.40 [ -3.88, -0.92 ]
Subtotal (95% CI) 21 22 100.0 % -2.40 [ -3.88, -0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
2 HDRS (high = poor)
Klein 1999 (1) 16 8.6 (3.5) 15 6.9 (4) 100.0 % 1.70 [ -0.95, 4.35 ]
Subtotal (95% CI) 16 15 100.0 % 1.70 [ -0.95, 4.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 MADRS (high = poor)
Prikryl 2007 11 4.64 (3.61) 11 9 (2.76) 100.0 % -4.36 [ -7.05, -1.67 ]
Subtotal (95% CI) 11 11 100.0 % -4.36 [ -7.05, -1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
4 SCL-90 DEP (high = poor)
Holi 2004 11 0.83 (0.69) 11 0.82 (0.79) 100.0 % 0.01 [ -0.61, 0.63 ]
Subtotal (95% CI) 11 11 100.0 % 0.01 [ -0.61, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
-10 -5 0 5 10
Favours Prefrontal TMS Favours Sham TMS
(1) Right prefrontal, low frequency (1Hz)
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Analysis 3.6. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: b.
Average hallucinations score (PANSS, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 6 Mental state: 2. Specific: b. Average hallucinations score (PANSS, high = poor)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ren 2010 (1) 12 3.15 (1.28) 13 3.83 (1.27) 100.0 % -0.68 [ -1.68, 0.32 ]
Total (95% CI) 12 13 100.0 % -0.68 [ -1.68, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Prefrontal TMS Favours Sham TMS
(1) Low frequency (1 Hz)
Analysis 3.7. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: c. i.
Negative symptoms - clinical improvement (> 20% decrease in PANSS negative).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 7 Mental state: 2. Specific: c. i. Negative symptoms - clinical improvement (> 20% decrease in PANSS negative)
Study or subgroup Prefrontal TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Novak 2006 (1) 1/8 4/8 100.0 % 0.25 [ 0.04, 1.77 ]
Total (95% CI) 8 8 100.0 % 0.25 [ 0.04, 1.77 ]
Total events: 1 (Prefrontal TMS), 4 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Sham TMS Favours Prefrontal TMS
(1) Response criteria provided by the study
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Analysis 3.8. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: c. ii.
Average negative symptom score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 8 Mental state: 2. Specific: c. ii. Average negative symptom score (various scales)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PANSS (high = poor)
Barr 2013 13 14 (6.08) 12 14.17 (4.84) 8.3 % -0.17 [ -4.46, 4.12 ]
Fitzgerald 2008 (1) 10 15.5 (3.1) 10 17.9 (5.5) 8.6 % -2.40 [ -6.31, 1.51 ]
Gao 2009b 21 10.5 (1.9) 22 19.1 (2.8) 9.7 % -8.60 [ -10.02, -7.18 ]
Gao 2009c 21 25.5 (4.1) 21 34.8 (4.7) 9.2 % -9.30 [ -11.97, -6.63 ]
Holi 2004 11 27.5 (10.9) 11 25.2 (5.8) 6.4 % 2.30 [ -5.00, 9.60 ]
Klein 1999 (2) 16 17.6 (6.8) 15 15.5 (5) 8.4 % 2.10 [ -2.08, 6.28 ]
Mogg 2005 8 28.5 (3.6) 9 27.8 (3.1) 9.0 % 0.70 [ -2.51, 3.91 ]
Novak 2006 8 18.6 (6) 8 16.9 (5.6) 7.4 % 1.70 [ -3.99, 7.39 ]
Prikryl 2007 11 15 (4.82) 11 20.18 (5.83) 8.2 % -5.18 [ -9.65, -0.71 ]
Ren 2010 (3) 12 16.15 (3.24) 13 13.5 (5.25) 8.9 % 2.65 [ -0.74, 6.04 ]
Ren 2011 12 19.27 (8.82) 11 19.44 (7.52) 6.8 % -0.17 [ -6.85, 6.51 ]
Zheng 2012 38 22.75 (5.2002) 17 22.6 (5.5) 9.0 % 0.15 [ -2.94, 3.24 ]
Subtotal (95% CI) 181 160 100.0 % -1.59 [ -4.68, 1.50 ]
Heterogeneity: Tau2 = 25.01; Chi2 = 104.24, df = 11 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.01 (P = 0.31)
2 SANS (high = poor)
Fitzgerald 2008 (4) 10 38.8 (11) 10 53.7 (8.3) 39.5 % -14.90 [ -23.44, -6.36 ]
Prikryl 2007 11 31.91 (14.78) 11 52.18 (21.24) 14.0 % -20.27 [ -35.56, -4.98 ]
Schneider 2008 (5) 15 42.2 (12.12) 14 50.7 (8.99) 46.4 % -8.50 [ -16.23, -0.77 ]
Subtotal (95% CI) 36 35 100.0 % -12.68 [ -18.60, -6.77 ]
Heterogeneity: Tau2 = 4.06; Chi2 = 2.32, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 4.20 (P = 0.000027)
-20 -10 0 10 20
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Analysis 3.9. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: d.
Average positive symptom score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 9 Mental state: 2. Specific: d. Average positive symptom score (various scales)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 PANSS (high = poor)
Barr 2013 13 13 (4.26) 12 13.22 (4.21) 3.9 % -0.22 [ -3.54, 3.10 ]
Gao 2009b 21 9.3 (1.3) 22 9.4 (1.9) 46.3 % -0.10 [ -1.07, 0.87 ]
Holi 2004 11 20 (9.1) 11 19.1 (7.4) 0.9 % 0.90 [ -6.03, 7.83 ]
Klein 1999 (1) 16 12.4 (5.5) 15 10.9 (5.4) 3.0 % 1.50 [ -2.34, 5.34 ]
Mogg 2005 8 20.9 (3.7) 9 20 (2.5) 4.7 % 0.90 [ -2.14, 3.94 ]
Novak 2006 8 13.5 (4.7) 8 10.1 (3) 2.9 % 3.40 [ -0.46, 7.26 ]
Prikryl 2007 11 7.82 (1.33) 11 8.36 (1.75) 25.8 % -0.54 [ -1.84, 0.76 ]
Ren 2010 (2) 12 13.69 (4.5) 13 17.08 (4.56) 3.4 % -3.39 [ -6.94, 0.16 ]
Ren 2011 12 9.91 (3.51) 11 13.11 (5.42) 3.1 % -3.20 [ -6.97, 0.57 ]
Zheng 2012 38 10.9 (4.2143) 17 12.8 (4.9) 6.0 % -1.90 [ -4.59, 0.79 ]
Subtotal (95% CI) 150 129 100.0 % -0.33 [ -0.99, 0.33 ]
Heterogeneity: Chi2 = 11.91, df = 9 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.98 (P = 0.33)
2 SAPS (high = poor)
Prikryl 2007 11 1.73 (2.87) 11 2 (2.72) 100.0 % -0.27 [ -2.61, 2.07 ]
Subtotal (95% CI) 11 11 100.0 % -0.27 [ -2.61, 2.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
-10 -5 0 5 10
Favours Prefrontal TMS Favours Sham TMS
(1) Right prefrontal, low frequency (1Hz)
(2) Low frequency (1 Hz)
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Analysis 3.10. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: e.
Average psychotism score (SCL-90 PSY, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 10 Mental state: 2. Specific: e. Average psychotism score (SCL-90 PSY, high = poor)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Holi 2004 11 0.5 (0.6) 11 0.51 (0.53) 100.0 % -0.01 [ -0.48, 0.46 ]
Total (95% CI) 11 11 100.0 % -0.01 [ -0.48, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 11 Adverse effects: 1. General:
a. Adverse events (UKU).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 11 Adverse effects: 1. General: a. Adverse events (UKU)
Study or subgroup Prefrontal TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cordes 2010 (1) 0/20 0/15 Not estimable
Total (95% CI) 20 15 Not estimable
Total events: 0 (Prefrontal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Prefrontal TMS Favours Sham TMS
(1) No adverse events other than mild headaches
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Analysis 3.12. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General:
b. Leaving the study early.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 12 Adverse effects: 1. General: b. Leaving the study early
Study or subgroup Prefrontal TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fitzgerald 2008 2/10 3/10 29.2 % 0.67 [ 0.14, 3.17 ]
Holi 2004 1/11 1/11 9.7 % 1.00 [ 0.07, 14.05 ]
Klein 1999 (1) 5/18 5/17 50.1 % 0.94 [ 0.33, 2.69 ]
Mogg 2005 0/8 0/9 Not estimable
Novak 2006 1/9 0/8 5.1 % 2.70 [ 0.13, 58.24 ]
Ren 2010 (2) 0/12 0/13 Not estimable
Ren 2011 0/12 0/11 Not estimable
Wing 2012 3/9 0/6 5.7 % 4.90 [ 0.30, 80.69 ]
Total (95% CI) 89 85 100.0 % 1.19 [ 0.56, 2.50 ]
Total events: 12 (Prefrontal TMS), 9 (Sham TMS)
Heterogeneity: Chi2 = 1.98, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Prefrontal TMS Favours Sham TMS
(1) Right prefrontal, low frequency (1Hz)
(2) Low frequency (1 Hz)
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Analysis 3.13. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 2. Specific:
a. Various.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 13 Adverse effects: 2. Specific: a. Various
Study or subgroup Prefrontal TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 cognition - cognitive difficulties
Klein 1999 (1) 0/16 0/15 Not estimable
Subtotal (95% CI) 16 15 Not estimable
Total events: 0 (Prefrontal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 movement disorder - facial twitching
Klein 1999 (2) 3/16 0/15 100.0 % 6.59 [ 0.37, 117.77 ]
Subtotal (95% CI) 16 15 100.0 % 6.59 [ 0.37, 117.77 ]
Total events: 3 (Prefrontal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 movement disorder - worsening of pre-existing akathesia
Klein 1999 (3) 2/16 0/15 100.0 % 4.71 [ 0.24, 90.69 ]
Subtotal (95% CI) 16 15 100.0 % 4.71 [ 0.24, 90.69 ]
Total events: 2 (Prefrontal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
4 psychiatric - worsening of pre-existing OCD
Klein 1999 (4) 2/16 0/15 100.0 % 4.71 [ 0.24, 90.69 ]
Subtotal (95% CI) 16 15 100.0 % 4.71 [ 0.24, 90.69 ]
Total events: 2 (Prefrontal TMS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
5 other - headache
Fitzgerald 2008 0/10 1/10 21.7 % 0.33 [ 0.02, 7.32 ]
Gao 2009b 7/21 2/22 28.3 % 3.67 [ 0.86, 15.68 ]
Holi 2004 3/11 0/11 7.2 % 7.00 [ 0.40, 121.39 ]
Klein 1999 (5) 2/16 0/15 7.5 % 4.71 [ 0.24, 90.69 ]
Ren 2010 (6) 3/12 2/13 27.8 % 1.63 [ 0.33, 8.11 ]
Ren 2011 2/12 0/11 7.5 % 4.62 [ 0.25, 86.72 ]
0.002 0.1 1 10 500
Favours Prefrontal TMS Favours Sham TMS
(Continued . . . )
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(. . . Continued)
Study or subgroup Prefrontal TMS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 82 82 100.0 % 2.77 [ 1.22, 6.26 ]
Total events: 17 (Prefrontal TMS), 5 (Sham TMS)
Heterogeneity: Chi2 = 3.01, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
6 other - TMS-related site discomfort/pain
Fitzgerald 2008 (7) 4/10 1/10 66.7 % 4.00 [ 0.54, 29.80 ]
Holi 2004 (8) 8/11 0/11 33.3 % 17.00 [ 1.10, 262.66 ]
Subtotal (95% CI) 21 21 100.0 % 8.33 [ 1.68, 41.27 ]
Total events: 12 (Prefrontal TMS), 1 (Sham TMS)
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0094)
0.002 0.1 1 10 500
Favours Prefrontal TMS Favours Sham TMS
(1) Right prefrontal, low frequency (1Hz)
(2) Right prefrontal, low frequency (1Hz)
(3) Right prefrontal, low frequency (1Hz)
(4) Right prefrontal, low frequency (1Hz)
(5) Right prefrontal, low frequency (1Hz)
(6) Low frequency (1 Hz)
(7) Discomfort
(8) Pain
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Analysis 3.14. Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific:
b. Average score (CSSES, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 3 PREFRONTAL TMS vs SHAM TMS
Outcome: 14 Adverse effects: 2. Specific: b. Average score (CSSES, high = poor)
Study or subgroup Prefrontal TMS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 cognitive complaints
Mogg 2005 8 1.8 (2.1) 9 2.4 (2.3) 100.0 % -0.60 [ -2.69, 1.49 ]
Subtotal (95% CI) 8 9 100.0 % -0.60 [ -2.69, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
2 subjective side effects
Mogg 2005 8 7.5 (9.2) 9 9.4 (8.4) 100.0 % -1.90 [ -10.31, 6.51 ]
Subtotal (95% CI) 8 9 100.0 % -1.90 [ -10.31, 6.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
-100 -50 0 50 100
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Analysis 4.1. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
1 Global state: Clinical improvement.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 1 Global state: Clinical improvement
Study or subgroup Prefrontal TBS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zhang 2010 (1) 2/15 0/12 100.0 % 4.06 [ 0.21, 77.37 ]
Total (95% CI) 15 12 100.0 % 4.06 [ 0.21, 77.37 ]
Total events: 2 (Prefrontal TBS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Sham TMS Favours Prefrontal TBS
(1) TBS (50 Hz)
Analysis 4.2. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
2 Mental state: 1. General: a. Average overall mental state score (PANSS total, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 2 Mental state: 1. General: a. Average overall mental state score (PANSS total, high = poor)
Study or subgroup Prefrontal TBS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 2011 23 62.39 (9.42) 19 67.58 (7.14) 52.0 % -5.19 [ -10.20, -0.18 ]
Zhang 2010 15 61.53 (9.96) 12 68.42 (9.12) 25.1 % -6.89 [ -14.10, 0.32 ]
Zheng 2012 19 62.1 (12.3) 20 67.7 (11.7) 23.0 % -5.60 [ -13.14, 1.94 ]
Total (95% CI) 57 51 100.0 % -5.71 [ -9.32, -2.10 ]
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.10 (P = 0.0020)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 4.3. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
3 Mental state: 1. General: b. Average general psychopathology score (PANSS, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 3 Mental state: 1. General: b. Average general psychopathology score (PANSS, high = poor)
Study or subgroup Prefrontal TBS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 2011 23 28.61 (4.59) 19 30.53 (3.84) 46.7 % -1.92 [ -4.47, 0.63 ]
Zhang 2010 15 28.8 (5.25) 12 31.58 (3.87) 25.6 % -2.78 [ -6.22, 0.66 ]
Zheng 2012 19 28 (6.3) 20 31.1 (3.9) 27.7 % -3.10 [ -6.41, 0.21 ]
Total (95% CI) 57 51 100.0 % -2.47 [ -4.21, -0.73 ]
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Prefrontal TBS Favours Sham TMS
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Analysis 4.4. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
4 Mental state: 2. Specific: a. Average negative symptom score (various scales).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 4 Mental state: 2. Specific: a. Average negative symptom score (various scales)
Study or subgroup Prefrontal TBS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 PANSS (high = poor)
Chen 2011 23 22.22 (4.63) 19 24.95 (2.84) 48.1 % -2.73 [ -5.01, -0.45 ]
Zhang 2010 15 21 (4.19) 12 24.58 (3.92) 26.6 % -3.58 [ -6.65, -0.51 ]
Zheng 2012 19 21 (4.5) 20 22.6 (5.5) 25.3 % -1.60 [ -4.75, 1.55 ]
Subtotal (95% CI) 57 51 100.0 % -2.67 [ -4.25, -1.09 ]
Heterogeneity: Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 3.31 (P = 0.00095)
2 SANS (high = poor)
Zhang 2010 15 45.2 (13.15) 12 56.75 (14) 100.0 % -11.55 [ -21.90, -1.20 ]
Subtotal (95% CI) 15 12 100.0 % -11.55 [ -21.90, -1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
-20 -10 0 10 20
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Analysis 4.5. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
5 Mental state: 2. Specific: b. Average positive symptom score (PANSS, high = poor).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 5 Mental state: 2. Specific: b. Average positive symptom score (PANSS, high = poor)
Study or subgroup Prefrontal TBS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chen 2011 23 11.57 (2.71) 19 12.11 (2.79) 53.0 % -0.54 [ -2.21, 1.13 ]
Zhang 2010 15 11.73 (2.6) 12 12.25 (2.93) 33.2 % -0.52 [ -2.64, 1.60 ]
Zheng 2012 19 13.1 (5.6) 20 12.8 (4.8) 13.8 % 0.30 [ -2.98, 3.58 ]
Total (95% CI) 57 51 100.0 % -0.42 [ -1.64, 0.80 ]
Heterogeneity: Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 4.6. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
6 Cognitive state: Average score (various measures).
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 6 Cognitive state: Average score (various measures)
Study or subgroup Prefrontal TBS Sham TMS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 digit span test
Zheng 2012 19 11.6 (3.4) 20 9.5 (4) 100.0 % 2.10 [ -0.23, 4.43 ]
Subtotal (95% CI) 19 20 100.0 % 2.10 [ -0.23, 4.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
2 verbal fluency test
Zheng 2012 19 26.6 (9) 20 24.5 (6.6) 100.0 % 2.10 [ -2.87, 7.07 ]
Subtotal (95% CI) 19 20 100.0 % 2.10 [ -2.87, 7.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
-10 -5 0 5 10
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Analysis 4.7. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
7 Adverse effects: 1. Leaving the study early.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 7 Adverse effects: 1. Leaving the study early
Study or subgroup Prefrontal TBS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chen 2011 1/24 3/22 59.5 % 0.31 [ 0.03, 2.72 ]
Zhang 2010 1/16 2/14 40.5 % 0.44 [ 0.04, 4.32 ]
Total (95% CI) 40 36 100.0 % 0.36 [ 0.07, 1.74 ]
Total events: 2 (Prefrontal TBS), 5 (Sham TMS)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome
8 Adverse effects: 2. Specific.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 8 Adverse effects: 2. Specific
Study or subgroup Prefrontal TBS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 headache
Zhang 2010 2/15 3/12 100.0 % 0.53 [ 0.11, 2.70 ]
Subtotal (95% CI) 15 12 100.0 % 0.53 [ 0.11, 2.70 ]
Total events: 2 (Prefrontal TBS), 3 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 sleep disorder
Zhang 2010 0/15 1/12 100.0 % 0.27 [ 0.01, 6.11 ]
Subtotal (95% CI) 15 12 100.0 % 0.27 [ 0.01, 6.11 ]
Total events: 0 (Prefrontal TBS), 1 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
0.01 0.1 1 10 100
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Analysis 5.1. Comparison 5 SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION
TMS vs SHAM TMS, Outcome 1 Global state: Clinical improvement.
Review: Transcranial magnetic stimulation (TMS) for schizophrenia
Comparison: 5 SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS
Outcome: 1 Global state: Clinical improvement
Study or subgroup Prefrontal TBS Sham TMS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 including only people who completed the studies
Zhang 2010 (1) 2/15 0/12 100.0 % 4.06 [ 0.21, 77.37 ]
Subtotal (95% CI) 15 12 100.0 % 4.06 [ 0.21, 77.37 ]
Total events: 2 (Prefrontal TBS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
2 Intention-to-treat analysis
Zhang 2010 (2) 2/16 0/14 100.0 % 4.41 [ 0.23, 84.79 ]
Subtotal (95% CI) 16 14 100.0 % 4.41 [ 0.23, 84.79 ]
Total events: 2 (Prefrontal TBS), 0 (Sham TMS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours Sham TMS Favours Prefrontal TBS
(1) TBS (50Hz)
(2) TBS (50Hz)
A D D I T I O N A L T A B L E S
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Contact details
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Table 2. Skewed data - Temporoparietal TMS vs Sham TMS
Study Outcome TMS Mean TMS SD TMS N Sham TMS Mean Sham TMS SD Sham TMS N
De Jesus 2011 Mental
state: specific
- BPRS de-
pressive factor
(high = poor)
2.25 2.18 8 3.56 3.24 9
Men-
tal state: spe-
cific - BPRS
excitement
factor (high =
poor)
1.25 1.28 8 3.89 4.79 9
Poulet 2005 Mental state:
Specific - posi-
tive symptoms
(SAPS, high =
poor)
51.2 13.5 5 47.8 25.2 5
Mental state:
Specific - hal-
lucina-
tions (AHRS,
high = poor)
14.6 12.1 5 20.8 3.4 5
Rosenberg
2012
Mental state:
Specific - posi-
tive symptoms
(SAPS, high =
poor)
26 20 10 37 16 10
Men-
tal state: Spe-
cific - nega-
tive symptoms
(SANS, high =
poor)
32 27 10 39 23 10
Xu 2011 Cogni-
tive state:CPT
false items
1.94 2.04 18 1.41 2.12 17
Cogni-
tive state:CPT
missed items
6.28 4.5 18 7.59 6.68 17
AHRS - Auditory Hallucination Rating Scale
BPRS - Brief Psychiatric Rating Scale
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CPT - Continuous Performance Test
SANS - Scale for Assessment of Negative Symptoms
SAPS - Scale for the Assessment of Positive Symptoms
Table 3. Cognitive outcomes - Temporoparietal TMS vs Sham TMS
Outcome Change
/ endpoint
data
Study TMS Sham TMS Mean difference [95% CI]
Mean SD N Mean SD N
Animal
naming
Change Hoffman
2005
-0.77 4.41 26 0.9 4.17 21 -1.67 [-4.13 to 0.79]
CPT re-
action time
(ms)
Endpoint Xu 2011 926.22 126.2 18 959 109.35 17 -32.78 [-110.89 to 45.33]
Con-
trolled oral
word asso-
ciation
Change Hoffman
2005
2.57 7.07 26 2.53 0.91 21 0.04 [-2.71 to 2.79]
CVLT 1
score
Change Hoffman
2005
0.88 6.61 26 -0.19 1.69 21 1.07 [-1.57 to 3.71]
CVLT B
score
Change Hoffman
2005
0.15 1.76 26 0.48 3.1 21 -0.33 [-1.82 to 1.16]
CVLT
Long-de-
lay free re-
call
Change Hoffman
2005
-1.69 2.28 26 -1.48 3.1 21 -0.21 [-1.80 to 1.38]
CVLT
Recog-
nition dis-
crimina-
tive ability
Change Hoffman
2005
-0.007 0.08 26 -0.014 0.088 21 0.01 [-0.04 to 0.06]
CVLT
Short-de-
lay free re-
call
Change Hoffman
2005
-0.92 2.15 26 -0.71 3 21 -0.21 [-1.74 to 1.32]
CVLT1-5
Total score
Change Hoffman
2005
-3.42 7.08 26 -3.14 8.21 21 -0.28 [-4.72 to 4.16]
Digit recall
(distrac-
tion)
Change Hoffman
2005
0.61 3.93 26 -0.9 4.77 21 1.51 [-1.03 to 4.05]
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Table 3. Cognitive outcomes - Temporoparietal TMS vs Sham TMS (Continued)
Digit recall
(non-dis-
traction)
Change Hoffman
2005
-0.12 4.66 26 1.19 4.08 21 -1.31 [-3.81 to 1.19]
Digit sym-
bol
Change Hoffman
2005
3.15 7.76 26 2.95 7.72 21 0.20 [-4.25 to 4.65]
Grooved
pegboard,
dominant
Change Hoffman
2005
4.65 15.1 26 5.57 48.8 21 -0.92 [-22.58 to 20.74]
Grooved
pegboard,
nondomi-
nant
Change Hoffman
2005
6.46 15.5 26 12 31.5 21 -5.54 [-20.27 to 9.19]
Tempo-
ral orienta-
tion
Change Hoffman
2005
-0.154 1.82 26 -0.35 2.39 21 0.20 [-1.04 to 1.43]
Trail Mak-
ing A
Change Hoffman
2005
2.58 12.6 26 -0.42 8.23 21 3.00 [-2.99 to 8.99]
Trail Mak-
ing B
Change Hoffman
2005
19.5 48.3 26 25.3 50.4 21 -5.80 [-34.25 to 22.65]
WCST
completed
categories
Endpoint Xu 2011 2.17 2.23 18 2.82 2.32 17 -0.65 [-2.16 to 0.86]
WCST
completed
categories
Endpoint Liu 2008 5.3 1 11 4.5 1.4 10 0.80 [-0.25 to 1.85]
WCST
conceptu-
alisation
level
Endpoint Xu 2011 61 24.13 18 64.12 24.93 17 -3.12 [-19.39 to 13.15]
WCSTCR Endpoint Liu 2008 54 9 11 49 11 10 5.00 [-3.65 to 13.65]
WCST
FM
Endpoint Liu 2008 13.6 7.3 11 9.8 11.2 10 3.80 [-4.37 to 11.97]
WCST
NPE
Endpoint Liu 2008 17.2 7.6 11 20.9 5.6 10 -3.70 [-9.38 to 1.98]
WCST
PCLR
Endpoint Liu 2008 60.5 19.2 11 45.9 18.6 10 14.60 [-1.58 to 30.78]
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Table 3. Cognitive outcomes - Temporoparietal TMS vs Sham TMS (Continued)
WCST PE Endpoint Liu 2008 45.3 23.6 11 50.8 22.3 10 -5.50 [-25.14 to 14.14]
WCST
PNPE
Endpoint Liu 2008 31.3 13.8 11 32.4 14.5 10 -1.10 [-13.24 to 11.04]
WCST
PPE
Endpoint Liu 2008 68.7 13.8 11 67.6 14.6 10 1.10 [-11.08 to 13.28]
WCST PR Endpoint Liu 2008 41 13.3 11 34.2 15 10 6.80 [-5.37 to 18.97]
WCST Ra Endpoint Xu 2011 122.67 15.18 18 126.06 5.02 17 -3.39 [-10.80 to 4.02]
WCST Re Endpoint Xu 2011 56.11 22.99 18 53.88 16.14 17 2.23 [-10.87 to 15.33]
WCST Rp Endpoint Xu 2011 45.72 20.18 18 60.12 19.23 17 -14.40 [-27.46 to -1.34]
WCST TA Endpoint Liu 2008 117 18 11 121 10 10 -4.00 [-16.31 to 8.31]
WCST
TCFC
Endpoint Liu 2008 21.7 14 11 29.0 13.4 10 -7.30 [-19.02 to 4.42]
WCST TE Endpoint Liu 2008 63 24 11 72 20 10 -9.00 [-27.84 to 9.84]
WCST
time (sec)
Endpoint Liu 2008 405 174 11 411 177 10 -6.00 [-156.36 to 144.36]
WCST se-
lective er-
ror rate
(%)
Endpoint Liu 2008 51.6 15.3 11 58.4 12.3 10 -6.80 [-18.63 to 5.03]
WCST
correct
thinking
time (sec)
Endpoint Liu 2008 172 67 11 160 96 10 12.00 [-59.47 to 83.47]
WCST er-
ror think-
ing time
(sec)
Endpoint Liu 2008 233 128 11 251 100 10 -18.00 [-115.79 to 79.79]
WRAT-R Change Hoffman
2005
0.19 2.54 26 0.33 2.81 21 6.80 [-5.37 to 18.97]
CPT - Continuous performance test
CVLT - California verbal learning test
WCST - Wisconsin card sorting test
WRAT-R - wide range achievement test - reading
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Table 4. Skewed data - Temporoparietal TMS vs standard treatment
Study Outcome TMS Mean TMS SD TMS N Sham TMS Mean Sham TMS SD Sham TMS N
Bagati 2009 Mental state:
Specific - hal-
lucinations
(AHRS, high =
poor)
6.7 8.64 20 27.95 7.51 20
AHRS - Auditory Hallucination Rating Scale
Table 5. Skewed data - Prefrontal TMS vs Sham TMS
Study Outcome TMS Mean TMS SD TMS N Sham TMS Mean Sham TMS SD Sham TMS N
Barr 2013 Men-
tal state: Spe-
cific - nega-
tive symptoms
(PANSS, high
= poor)
26.15 13.45 13 31.42 13.19 12
Men-
tal state: Spe-
cific - depres-
sive symptoms
(CDS, high =
poor )
2.38 2.06 13 1.67 1.92 12
Fitzgerald
2008
Mental
state: Specific -
positive symp-
toms (PANSS,
high = poor)
(LOCF)
10.8 7.0 10 7.3 2.9 10
Mental
state: Depres-
sion (CDRS,
high = poor)
(LOCF)
7.2 5.9 10 3.5 3.8 10
CDRS - Calgary depression rating scale
CDS - Calgary depression scale
PANSS - positive and negative symptoms scale
LOCF - last observation carried forward
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Table 6. Cognitive outcomes - Prefrontal TMS vs Sham TMS
Outcome Change /
endpoint
Study TMS Sham TMS Mean difference [95% CI]
Mean SD N Mean SD N
AVLT (low
= poor)
Endpoint Novak
2006
45.6 6.8 8 44.9 8 8 0.70 [-6.58 to 7.98]
COWAT
(within
24 hours of
TMS)
Endpoint Mogg
2005
11.6 5.3 8 10.9 5.0 9 0.70 [-4.22 to 5.62]
COWAT
(2
weeks after
TMS)
Endpoint Mogg
2005
14.2 5.7 8 9.1 2.7 9 5.10 [0.77 to 9.43]
Digit span
test
Endpoint Zheng
2012
10.5 3.5763 38 9.5 4 17 1.00 [-15.70 to 17.70]
Grooved
pegboard
(seconds
to comple-
tion)
(within
24 hours of
TMS)
Endpoint Mogg
2005
117.1 32.0 8 108.6 41.2 9 8.50 [-26.37 to 43.37]
Grooved
pegboard
(seconds to
com-
pletion) (2
weeks after
TMS)
Endpoint Mogg
2005
109 29.5 8 98.5 16 9 10.50 [-12.46 to 33.46]
HVLT-
de-
layed recall
(within
24 hours of
TMS)
Endpoint Mogg
2005
4.4 2.3 8 4.4 1.1 9 0.00 [-1.75 to 1.75]
HVLT-
delayed re-
call (2
weeks after
TMS)
Endpoint Mogg
2005
5.4 2.7 8 3.3 1.0 9 2.10 [0.12 to 4.08]
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Table 6. Cognitive outcomes - Prefrontal TMS vs Sham TMS (Continued)
HVLT-
imme-
diate recall
(within
24 hours of
TMS)
Endpoint Mogg
2005
6.3 2.0 8 5.6 1.1 9 0.70 [-0.86 to 2.26]
HVLT-
immedi-
ate recall (2
weeks after
TMS)
Endpoint Mogg
2005
7.4 2.8 8 5 0.8 9 2.40 [0.39 to 4.41]
Stroop test
(within
24 hours of
TMS)
Endpoint Mogg
2005
77.4 20.3 8 51.4 14.9 9 26.00 [8.89 to 43.11]
Stroop test
(2
weeks after
TMS)
Endpoint Mogg
2005
88.2 12.3 8 60.8 6.4 9 27.40 [17.91 to 36.89]
Trail mak-
ing test A
Change Guse 2013 0.64 15.08 14 -11.92 29.27 12 12.56 [-5.79 to 30.91]
Trail mak-
ing test B
Change Guse 2013 -0.54 28.41 13 -5.64 20.31 11 5.10 [-14.46 to 24.66]
Ver-
bal fluency
test (high =
poor)
Endpoint Zheng
2012
24.2 9.2542 38 24.5 6.6 17 -0.30 [-4.60 to 4.00]
WCST
categories
Change Guse 2013 1.58 22.2 12 -0.27 1.95 11 1.85 [-10.76 to 14.46]
WCST
categories
for partici-
pants with
WCST
categories
pre < me-
dian (= 4)
Change Guse 2013 3.33 2.58 6 0.4 2.07 5 2.93 [0.18 to 5.68]
WCST
persevera-
Change Guse 2013 -9 11.65 12 -19.18 27.76 11 10.18 [-7.50 to 27.86]
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Table 6. Cognitive outcomes - Prefrontal TMS vs Sham TMS (Continued)
tive
answers
WCST
persever-
ative mis-
takes
Change Guse 2013 -8.17 9.81 12 -11.27 17.51 11 3.10 [-8.64 to 14.84]
AVTL - auditory verbal learning test
COWAT - controlled oral word association test
HVLT - Hopkins verbal learning test
WCST - Wisconsin card sorting test
A P P E N D I C E S
Appendix 1. Outcome scales
1. Global functioning
1.1 Clinical Global Impression Scale - CGI (Guy 1976), in De Jesus 2011; Gao 2009a; Guse 2013; Hoffman 2005; Klein 1999;
Lee 2005; Liu 2011; NCT00308997; Rosenberg 2012; Saba 2006a. A rating scale which measures severity of illness and clinical
improvement based on a seven-point scoring system. A low score indicates overall improvement and reduced illness severity.
1.2 Global Assessment of Functioning - GAF (APA 1987) in Guse 2013.
This scale measures the level of psychological, social, and occupational functioning of psychiatric patients. Possible scores range from
1 to 90. High scores indicate better functioning.
2. Mental State
2.1 Positive and Negative Syndrome Scale - PANSS (Kay 1986), in most (27) of the studies.
A measure of schizophrenia with three subscales, which include severity of general psychopathology, positive symptoms, and negative
symptoms. The scale is scored from 30 to 210, with each item rated on a seven-point scale ranging from absent (1) to severe (7). Higher
scores indicate more severe symptoms.
2.2 Auditory Hallucinations Rating Scale - AHRS (Hoffman 2005), in Blumberger 2012; Brunelin 2006; De Jesus 2011; Gao 2009a;
Hoffman 2005; Klirova 2010; NCT00308997; Poulet 2005; Rosenberg 2012; Slotema 2011; Vercammen 2009a.
A descriptive measure of the specific characteristics of auditory hallucinations. The scale consists of seven items, which include frequency,
reality, loudness, number of voices, length, attentional salience, and distress level. Higher scores indicate more severe symptoms.
2.3 Scale for Assessment of Negative Symptoms - SANS (Andreasen 1983), in Fitzgerald 2008; Hao 2008; Prikryl 2007; Schneider
2008; Zhang 2010.
An instrument to measure change of clinical outcomes in the negative symptoms of schizophrenia. A six-point rating system is used,
ranging from absent (0) to severe (5) on measures of alogia, affective blunting, avolition apathy, anhedonia-associality, and attention
impairment. Higher scores indicate greater severity of symptoms.
2.4 Scale for Assessment of Positive Symptoms - SAPS (Andreasen 1984), in Brunelin 2006; Hao 2008; Prikryl 2007.
A rating tool designed to measure change of clinical outcomes in the positive symptoms of schizophrenia. Severity is rated from
questionable (0) to severe (5). Symptoms are divided into four main categories of hallucinations, delusions, bizarre behaviour and
positive formal thought disorder. Higher scores indicate greater severity of symptoms.
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2.5 Brief Psychiatric Rating Scale - BPRS (Overall 1962), in De Jesus 2011; Klein 1999.
A clinical instrument which is used to quantify the severity of various psychiatric symptoms. The scale consists of 18 items, each of
which is rated on a seven-point scale from not present (1) to extremely severe (7). Scores range from 18 to 126, with higher scores
indicating greater severity.
2.6 Hamilton Rating Scale for Depression - HDRS/HAMD (Hamilton 1967), in Gao 2009b; Hao 2008; Klein 1999.
A depression rating scale for use in people who have already been diagnosed with a depressive disorder. Scores are based on the
interviewer’s assessment of 17 items which include depressed mood, suicide, work, loss of interest, agitation, general somatic symptoms,
and loss of insight. Higher scores indicate greater severity of depression.
2.7 Psychotic Symptoms Rating Scale - PSYRATS (Haddock 1999), in Blumberger 2012; Slotema 2011.
This consists of two scales, which assess delusional beliefs and auditory hallucinations. There are 11 items in the auditory hallucinations
scale, including frequency, duration, level of distress, controllability, loudness, location and beliefs about origin of voices. The delusional
beliefs scale has six items, including preoccupation, intensity of distress, conviction and disruption. Each item is rated on a ve-point
scale with higher scores indicating greater severity.
2.8 Hallucination Change Scale - HCS (Hoffman 1999) in Blumberger 2012; Fitzgerald 2005; Hoffman 2005; NCT00308997.
This scale consists of a single rating from 0 (no voices) to 20 (greatest severity) of hallucination severity. At baseline, the rating is set to
10 with each patient providing an individual description of the severity of his/her voices.
2.9 Self-rating Depression Scale - SDS (Zung 1965) in Hao 2008.
This is a short self-administered survey to quantify the depressed status of a patient. There are 20 items on the scale that rate the
four common characteristics of depression: the pervasive effect, the physiological equivalents, other disturbances, and psychomotor
activities. A higher score indicates more severe depression.
2.10 Symptom Checklist - SCL-90 (Derogatis 1973) in Holi 2004.
This self-report questionnaire helps evaluate a broad range of psychological problems and symptoms of psychopathology. The test
helps measure nine primary symptom dimensions (somatisation, obsessive-compulsive, interpersonal sensitivity, depression, anxiety,
hostility, phobic anxiety, paranoid ideation, psychoticism and a category of “additional items”) and is designed to provide an overview
of a patient’s symptoms and their intensity at a specific point in time.The Global Severity Index (GSI) can be used as a summary of the
test and is designed to measure overall psychological distress. High scores indicate more severe symptoms.
2.11 Montgomery-Asberg Depression Rating Scale - MADRS (Montgomery 1979) in Prikryl 2007.
This scale was developed using a 65-item psychopathology scale to identify the 17 most commonly occurring symptoms in primary
depressive illness. The maximum score is 30, and a higher score indicates more severe psychopathology.
3. Cognitive State
3.1 Auditory Verbal Learning Test - AVLT (Rey 1964, Rosenberg 1984, Geffen 1994) in Novak 2006.
A tool used to assess competence in various memory domains, which include immediate memory span, recognition, retroactive and
proactive interference. The test involves the verbal presentation of 15 words which must be remembered in subsequent consecutive
learning trials. Higher scores indicate better memory performance.
4. Adverse effects
4.1 Columbia ECT Subjective Side Effects Schedule - CSSES (Sackeim 1987) in Mogg 2005.
A 32-item schedule administered after electroconvulsive therapy to assess subjective side effects reflecting physical complaints, perceived
cognitive impairment, and mood-related side effects. A high score indicates more severe side effects.
4.2 Udvalg for Kliniske Undersøgelser Side Effect Rating Scale - UKU (Lingjaerde 1987) in Cordes 2010.
A comprehensive, clinician-rated scale, designed to assess the side effects in people treated with psychotropic medications. The UKU
consists of 48 questions. Zero indicates normal; one indicates mild symptoms; two indicates moderate symptoms; and three indicates
severe symptoms.
5. Quality of Life
5.1 Q-LES-Q (Endicott 1993) in Rosenberg 2012.
This is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and
satisfaction experienced by subjects in various areas of daily functioning. A low score indicates poor satisfaction.
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Nadine Dougall - read abstracts, study selection, quality assessment for studies from the 2006 and 2008 searches, wrote to authors
with missing data queries, data extraction, data entry into RevMan, wrote the protocol, edited and updated the review to Version 5 of
RevMan, and edited the final review to incorporate peer-reviewer comments.
Lisa McDermott - converted the protocol to RevMan 5, conducted additional data entry, updated the quality assessments, and helped
write the review.
Karla Soares-Weiser and Nicola Maayan - screened studies, quality assessment, data extraction and results for studies included from the
2013 search, ’Summary of findings’ tables, and edited the review to incorporate the findings from the 2013 search.
Andrew McIntosh - read abstracts, study selection, quality assessment for studies from 2006 and 2008 searches, wrote to authors with
missing data queries, data extraction, data entry into RevMan, and co-wrote the protocol.
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• Gordon Small Charitable Trust for Research in Old Age Psychiatry, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Three new review authors were added to the review (LM, NM, KSW) and one (KPE) was withdrawn.
The protocol was prepared in RevMan 4 with the review converted to RevMan 5 format. There is no substantive difference in the text
itself between the protocol and review. However the text was reconfigured to fit under the RevMan 5 sub-headings.
We have updated the sections on Selection of studies, Contributions of authors and Acknowledgements.
’Risk of bias’ tables and ’Summary of findings’ tables: These were introduced as standard for Cochrane reviews after this protocol
was published, see Data extraction and management and Assessment of risk of bias in included studies for the methods used.
Types of outcome measures: The outcome measures published in the protocol were classified into seven categories and made no
distinction between primary and secondary outcome measures; primary outcomes were determined by measures of Global state and all
other categories were designated secondary outcomes.
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We have added ’Quality of life’ as an outcome.
We had planned in the protocol to divide outcomes into immediate (within two hours), short-term (greater than two hours and up
to 24 hours) and medium-term (greater than 24 hours and up to two weeks). However, the majority of studies reported only that
outcomes were measured after treatment and did not specify exactly how long after treatment, and so we did not classify the data this
way.
Measures of treatment effect:For statistically significant results we had planned to calculate the number needed to treat for an additional
beneficial outcome/harmful outcome statistic (NNTB/H), and its 95% confidence interval (CI) using Visual Rx (www.nntonline.net/),
taking account of the event rate in the control group. This, however, has been superseded by the ’Summary of findings’ tables and
calculations therein, and hence we did not estimate this statistic.
Had there been cluster-randomised trials in which clustering was not accounted for in primary studies, we would have presented data
in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will
seek to contact first authors of studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and to adjust for this
by using accepted methods (Gulliford 1999). Where clustering had been incorporated into the analysis of primary studies, we would
have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient [Design effect
= 1 + (m - 1) * ICC] (Donner 2002). If the ICC is not reported we will assume it to be 0.1 (Ukoumunne 1999).
If cluster studies had appropriately analysed their data, taking into account ICCs and relevant data documented in the report, synthesis
with other studies would have been possible using the generic inverse variance technique.
Standard deviations:Where there are missing measures of variance for continuous data but an exact standard error (SE) and confidence
interval are available for group means, and either the P value or t value are available for differences in means, we will calculate them
according to the rules described in the Cochrane Handbook (Higgins 2011). When only the standard error is reported, standard
deviations (SDs) can be calculated by the formula SD = SE *
√
(n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook (Higgins
2011b) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, and ranges or other statistics.
If these formulae do not apply, we will calculate SDs according to a validated imputation method which is based on the SDs of the
other included studies (Furukawa 2006). Some of these imputation strategies can introduce error. The alternative would be to exclude
a given study’s outcome and thus to lose information. We will nevertheless examine the validity of the imputations in a sensitivity
analysis excluding imputed values.
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